

Curriculum Vitae

Nicholas Bodor, Ph.D., D.Sc., D.Sc., h.c. (multi)

Graduate Research Professor Emeritus (active)
Executive Director, Center for Drug Discovery
College of Pharmacy



NICHOLAS BODOR

Dr. Nicholas Bodor is a Graduate Research Professor Emeritus (active) at the University of Florida College of Pharmacy, Gainesville. He joined the university in 1979 as Professor and Chairman of the Medicinal Chemistry Department, and was promoted to Graduate Research Professor in 1983. He is the Executive Director of the college's Center for Drug Discovery, founded by him in 1986. During his tenure at the University of Florida, Dr. Bodor has supervised the training of more than 50 doctoral students and over 100 postdoctoral level research associates and fellows. In February 2000, he took a leave of absence from his academic posts at the University of Florida in order to accept a position as Senior Vice President of Basic Research and Drug Discovery at the IVAX Corporation. Dr. Bodor then served as Chief Scientific Officer of the IVAX Corporation, Managing Director of the IVAX Drug Research Institute, Budapest, Hungary, as well as President of the IVAX Research Institute until October 2005.

Dr. Bodor's main research interests include design of drugs with improved therapeutic index, design of new chemical delivery systems, computer-assisted drug design, drug transport and metabolism, and theoretical and mechanistic organic chemistry. He has published more than 520 research articles, has over 240 patents, and is on the editorial boards of several international scientific journals. An internationally recognized leader in drug discovery, design and delivery, he has introduced revolutionary, general, comprehensive drug design and drug targeting concepts known as *retrometabolic drug design* approaches. These concepts strategically combine chemical and enzymatic (metabolic) processes to achieve drug targeting and to produce safe drugs and safe environmental chemicals. The two major classes of the retrometabolic drug design concepts contain "*chemical drug targeting systems*" (CDS) and the "*soft drugs*" (SD). Each of these large classes contains various subclasses, based on the different design rules. The design concepts incorporated in the soft drug approaches were used by Dr. Bodor to develop a *general and comprehensive* program, including a *computerized expert system* which can be used to design all potential and possible metabolites and the corresponding safe active soft drugs or chemical delivery systems. The soft steroid Loteprednol Etabonate, designed by Dr. Bodor, is on the market in the U.S. and other countries. Other drugs designed by him using the retrometabolic concepts are in advanced clinical development. The progress in these various related fields is reviewed biennially at an international series of symposia Dr. Bodor has founded and organizes entitled, *The Retrometabolism Based Drug Design and Targeting Conference*. The ninth meeting of this series is scheduled for May 2013 in Orlando; in addition to Florida, venues of the previous eight conferences have included Japan, Hungary and Austria.

Dr. Bodor received his B.S./M.S. degree in Organic Chemistry in 1959 at Bolyai University in Transylvania, and his Ph.D. degree in 1965 from the University of Babes-Bolyai, Cluj and the Romanian National Academy of Sciences. He was a Group Leader at the Pharmacochemical Research Institute in Romania until 1968, when he was offered an R. A. Welch Fellowship at the University of Texas in Austin, where he worked in the field of theoretical organic chemistry with Dr. Michael J. S. Dewar, the first Robert A. Welch Research Chair. In 1972 he became a Senior Research Scientist at ALZA Laboratories in Lawrence, Kansas, which later became INTERx Research Corporation, where he was Director of Research, as well as an Adjunct Professor at the University of Kansas until 1978.

Among his many honors, Dr. Bodor is an elected Fellow of the Academy of Pharmaceutical Sciences, American Association of Pharmaceutical Scientists, American Association for the Advancement of Science, and American College of Clinical Pharmacology. He is also an Honorary Member of the Hungarian Chemical Society and the Panhellenic Society of Pharmacists. Among other honors, Dr. Bodor has been named "The 1984 Florida Scientist of the Year" and received the first AAPS Research Achievement Award in Medicinal and Natural Product Chemistry in 1988, as well as the APhA Research Achievement Award in Pharmaceutical and Medicinal Chemistry in 1989. In 1994 he was named the first recipient of the Nagai Foundation Tokyo International Fellowship. He was named by the American Chemical Society as the 1996 recipient of the Leo Friend Award in recognition of his article entitled, "Design of Biologically Safer Chemicals," published in *Chemtech*, October 1995. He is the first College of Pharmacy faculty member to receive a Professorial Excellence Award, given by the University of Florida in 1996. The AACP selected

Dr. Bodor as the recipient of the 1997 Volwiler Research Achievement Award. In April 2000, he was named the V. Ravi Chandran Professor in Drug Design and Targeting of the UF College of Pharmacy, the first recipient of this endowed professorship. In February 2002, he was elected a Fellow of the World Innovation Foundation. An honorary Doctor of Science degree was conferred upon Dr. Bodor by the University of Florida in 2005. In 2007, the American Association of Pharmaceutical Scientists awarded Dr. Bodor with the Distinguished Pharmaceutical Scientist Award. Dr. Bodor was inducted into the [American Chemical Society's Hall of Fame](#), Medicinal Chemistry Division in August 2012.

In addition to the awards above, Dr. Bodor has received the highest levels of recognition from his home country of Hungary for his scientific achievements and leadership of the Budapest-based Institute for Drug Research. In 1989 he received an honorary Doctor of Science degree from the Technical University of Budapest, and then was awarded the Doctor Honoris Causa degree from the Medical University of Debrecen in 1990. In 1995 he was elected to the Hungarian National Academy of Sciences. Ferenc Madl, President of Hungary, awarded Dr. Bodor the Gold Cross of Merit of the Hungarian Republic in 2004. In 2010 he received the prestigious Fabinyi Prize of the Hungarian Chemical Society, which is given to scientists living outside Hungary whose outstanding scientific accomplishment have contributed to the reputation of the HCS. In August 2010 at the national celebration of Hungary's over 1000 years statehood and its canonized first king, St. Stephen, Dr. Bodor was awarded at the Hungarian Parliament, the Commander's Cross of the Order of Merit of the Hungarian Republic, a prestigious award of civil merit.

Dr. Bodor and his wife Sheryl call Miami their primary residence. He founded Bodor Laboratories, Inc. in 2006, and works there with his son Erik and daughter Nicole (who hold PhD/MBA and PhD degrees, respectively, in the relevant fields) to further develop his drug design strategies to the marketplace. His oldest son Miklós (an MD, PhD) is Chairman of the Clinical Pharmacology Department at the Medical University in Debrecen, Hungary.

CURRICULUM VITAE

NICHOLAS BODOR

Date of Birth: February 1, 1939

Address: 10225 Collins Avenue, Apt. 1002/1004
Bal Harbour, FL 33154

Telephone: (305) 868-8250 (residence)
(352) 392-3417 (office – University of Florida)

Married To: Sheryl Lee Bodor

Children: Nicole, Erik

Education: Diploma in Science (B.S., M.S., Organic Chemistry) with special honors; straight A's throughout the five years, Bolyai University, Cluj, Romania, 1959

Doctor in Chemistry
Babes-Bolyai University, and Supreme Council of Scientific Titles of the Romanian National Academy of Science, 1965

R.A. Welch Postdoctoral Fellow
University of Texas at Austin, 1968-1969; 1970-1972

Employment Positions:

Present: Founder and CEO
Bodor Laboratories, Inc.
Miami, FL, 33137; 2006 - present

Executive Director
Center for Drug Discovery
College of Pharmacy, P.O. Box 100497
J. Hillis Miller Health Center
University of Florida, Gainesville, FL, 32610, 1990-present

Graduate Research Professor Emeritus (active), 2003-present
Department of Pharmaceutics
College of Pharmacy
University of Florida, Gainesville, FL 32610

Affiliate Graduate Research Professor
Department of Ophthalmology
College of Medicine
J. Hillis Miller Health Center
University of Florida, Gainesville, FL, 32610, 1991-present

Affiliate Professor
Department of Chemistry
College of Liberal Arts & Sciences
University of Florida, Gainesville, FL, 32610, 1990-present

Former:

Chief Scientific Officer
IVAX Corporation
4400 Biscayne Blvd.
Miami, Florida 33137
(2003-2005)

Managing Director
IVAX Drug Research Institute, Ltd.
47-49 Berline Street, H-1045
Budapest, HUNGARY
(1999-2005)

President
IVAX Research Institute, Inc.
4400 Biscayne Blvd.
Miami, Florida 33137
(2002-2005)

Senior Vice President
Basic Research and Drug Discovery
IVAX Research, Inc.
4400 Biscayne Blvd.
Miami, Florida 33137
(2000-2005)

Graduate Research Professor
Departments of Medicinal Chemistry (1983-2003) and
Pharmaceutics (1991-2003)
College of Pharmacy
University of Florida, Gainesville, FL, 32610

V Ravi Chandran PhD Professor in Drug Design and Targeting
College of Pharmacy
University of Florida, Gainesville, FL, 32610
2000-2003

Vice President and Director, Pharmatec, Inc.
Alachua, FL, 32615, 1983-1992

Director
Center for Drug Design and Delivery
Box J-497, J. Hillis Miller Health Center
University of Florida, Gainesville, FL, 32610, 1986-1990

Chairman
Department of Medicinal Chemistry
College of Pharmacy
J. Hillis Miller Health Center
University of Florida, Gainesville, FL, 32610, 1989-1990

Professor (1979-1983) and Chairman (1979-1984)
Department of Medicinal Chemistry
J. Hillis Miller Health Center
University of Florida, Gainesville, FL, 32610

Associate Director of Medicinal Chemistry
INTERx Research Corporation, Lawrence, KS, 1973-1979

Adjunct Professor of Pharmaceutical Chemistry
University of Kansas, Lawrence, KS, 1978-1980

Adjunct Professor of Medicinal Chemistry
University of Kansas, Lawrence, KS, 1974-1978

Senior Research Scientist
ALZA Corporation, Lawrence, KS, 1972-1973

R.A. Welch Postdoctoral Fellow, 1968-1969; 1970-1972
University of Texas at Austin, TX

Principal Investigator and Group Leader
Chemical-Pharmaceutical Research Institute
Cluj, Romania, 1961-1968; 1969-1970

Research Investigator and Group Leader
"1 September" Factory, Satu Mare, Romania, 1959-1961

Honors, Fellowships:

National Scholarship for Outstanding Achievement, 1954-1959

Various honors and awards for undergraduate research

Diploma of Honor (straight A's for five years)

R.A. Welch Fellowship (two occasions, 1968-1969; 1970-1972)

The Nagai Foundation Tokyo Fellowship 1994

Listed in:

Who's Who in America

Who's Who in Science and Technology

Who's Who in Frontiers of Science

Who's Who in Technology Today

Who's Who Worldwide (Platinum Edition)

Ki Kicsoda (Who's Who Worldwide--Hungarian Edition)

American Scientist

Elected to:

Fellow, Academy of Pharmaceutical Research and Science, 1983

Fellow, American Association of Pharmaceutical Scientists, 1986

Fellow, American Association for the Advancement of Science,
1989

Honorary Member, Hungarian Chemical Society, 1988

Honorary Member, Panhellenic Association of Pharmacists, 1989

Fellow, American College of Clinical Pharmacology, 1991

Hungarian Academy of Sciences, 1995

Elected Member, Dermatology Advisory Board, Glaxo Wellcome,
1997

Fellow, the World Innovation Foundation, 2002

Name Lectureships:

Hoechst-Rousell Lectureship in Chemistry, Somerville, NJ, 1983;
Hoshi University Diploma, Tokyo, Japan, 1983; Bombay College
of Pharmacy Silver Medal, Bombay, India, 1984; Nichols
Distinguished Symposium, American Chemical Society, Tarrytown,
NY, 1986; Sigma Xi Lectureship, 1987; The Högyes Lecture,
Semmelweis Univ. of Medicine, Budapest, Hungary, 2000.

Awards:

University of Florida Graduate Research Professor in 1983

"The 1984 Florida Scientist of the Year"

AAPS Research Achievement Award (the first) in Medicinal and Natural Product Chemistry, 1988

APhA Research Achievement Award in Pharmaceutical and Medicinal Chemistry, 1989

University of Florida Research Achievement Award, 1990

Doctor Honoris Causa, Technical University of Budapest, Hungary, 1989

Doctor Honoris Causa, Medical University of Debrecen, Hungary, 1990

University of Florida Research Achievement Award, 1991

Leo Friend Award, American Chemical Society, 1996

Professorial Excellence Program Award, Univ. of FL, 1996

Volwiler Research Achievement Award, AACP, 1997

Gold Cross of Merit of the Hungarian Republic, awarded by Ferenc Madl, President of Hungary, on March 31, 2004

Honorary Doctor of Science Degree, University of Florida, 2005

Distinguished Pharmaceutical Scientist Award, AAPS, 2007

Fabinyi Prize, awarded by the Hungarian Chemical Society, 2010

Commander's Cross of the Order of Merit of the Hungarian Republic, presented at the Hungarian Parliament during the August 2010 national celebration of over 1,000 years of statehood and its Canonized first king, St. Stephen

Inducted to the American Chemical Society Hall of Fame Medicinal Chemistry Division in 2012

Other:

Visiting Professor, Assiut University, Assiut, Egypt, 1984

Visiting Professor, Hoshi University, Tokyo, Japan, 1995

Principal Investigator of numerous National Institutes of Health research grant awards

Member, Board of Trustees, ARKAT-USA

Chairman, Policy Committee of the Florida Center for Heterocyclic Compounds

Consultant, advisor, or Board of Directors member for numerous major pharmaceutical companies (Schering-Plough, ALCHEM Laboratories, ONO Pharmaceutical Co., Otsuka Pharmaceutical Co., Xenon Vision, Inc., Helene Curtis, Inc., etc.)

Invited speaker of over 400 international and national symposia and special lectures

Editorial Boards:

AAPS Journal

Burger's Medicinal Chemistry, 6th Edition

Drug Design & Discovery

Pharmaceutical Research

Advanced Drug Delivery Reviews

Pharmaceutical Science Communications

Magyar Kemiai Folyoirat

Journal of Ocular Pharmacology and Therapeutics

Current Medicinal Chemistry

Pharmacy and Pharmacology Communications

Current Drugs

Journal of Pharmacy and Pharmacology

STP Pharma Sciences

Journal of Pharmacology & Clinical Toxicology

American Journal of Drug Delivery

Expert Opinion on Drug Delivery

Open Medicinal Chemistry Journal

Languages:

Fluent in: English, Hungarian, and Romanian

Read and Write: French, Russian, and German

Publications:

520

Patents:

250

Memberships:

American Chemical Society
American Pharmaceutical Association
Academy of Pharmaceutical Sciences
American Association of Colleges of Pharmacy
American Association of Pharmaceutical Scientists
American Association for the Advancement of Science
American Epilepsy Society
Association for Ocular Pharmacology and Therapeutics
New York Academy of Sciences
International Union of Pure and Applied Chemistry
Sigma Xi
Controlled Release Society
American College of Clinical Pharmacology
International Scientific Advisory Panel of Oxford Molecular
Group, PLC
Worldwide Hungarian Medical Academy
Hungarian National Academy of Sciences
International Council of Scientific Unions

**Graduate and Postdoctoral
Supervision:**

Has supervised more than 50 doctoral students and 100
postdoctoral research associates/fellows

NICHOLAS BODOR, Ph.D., D.Sc., D.Sc., h.c. (multi)
PATENTS ISSUED

1. N. Bodor, L. Fey, M. Kircz and F. Hodosan, "Synthesis of the Deoxycorticosterone Acetate (DCA)," Rom. Pat. 48,094, January 11, 1967.
2. N. Bodor and D. Rotaru, "Synthesis of 4-Chlorotestosterone Acetate," Rom. Pat. 48,624, January 31, 1967.
3. O. Mantsch, N. Bodor and A. Becanu, "Synthesis of the 6- α -Methyl- β -acetoxy Progesterone (Provera)," Rom. Pat., February 2, 1967; Fr. Pat. 1,547,748, November 29, 1968.
4. N. Bodor and E. Silaghi, "Synthesis of the Chloramphenicol Palmitate," Rom. Pat. 51,893, March 26, 1969.
5. N. Bodor and O. Mantsch, "Synthesis of 5 β -Androstan-3 α , 6 α -diol-17-one from 16,20-Oxido-3 α ,6 α ,20-triacetoxy-pregnane," Reg. Rom Pat. 65,038, November 20, 1970.
6. O. Mantsch and N. Bodor, "Synthesis of the 17- α -Acetoxy-progesterone from Pregnane-3 α ,6 α -diol-20-one," Rom. Pat. 65-309, November 20, 1970.
7. O. Mantsch, N. Bodor, F. Hodosan, N. Serban, I. Jude and A. Balogh, "Synthesis of 3-(5 α -Andostan-3 α -6 α ,17 β -triol-17 α -yl)-Propiolic Acid," Reg. Rom. Pat., 65,309, November 20, 1970.
8. F. Hodosan, N. Serban, A. Balogh, I. Jude, O. Mantsch and N. Bodor, "Novel Process for 3 β ,17 β -Dihydroxy-5-Androstene-17 α -Propynoic Acid," Rom. Pat. 64,146/1970; U.S. Pat. 3,734,938, May 22, 1973.
9. N. Bodor, "Pro-Drug Forms of Digoxin," U.S. Pat. 3,884,905, May 20, 1975.
10. N. Bodor and J. Kaminski, "1,4-Dichloro-2,2,5,5-Tetrasubstituted-3,6-Piperazinediones," U.S. Pat. 3,891,649, June 24, 1975.
11. N. Bodor, K. Sloan and A. Hussain, "Novel, Transient Pro-Drug Forms of L-DOPA," U.S. Pat. 3,891,696, July 29, 1975.
12. N. Bodor and J. Kaminski, "3-Chloro-Tetrahydro-1,3-Oxazines or Oxazolidines," U.S. Pat. 3,897,425, July 29, 1975.
13. T. Higuchi, N. Bodor and E. Shek, "Novel Pro-Drug Derivatives of Pyridinium Aldoxime Type Cholinesterase Reactivators and Process for Preparing Same," U.S. Pat. 3,929,813, December 30, 1975.

14. N. Bodor and J. Kaminski, "3-Chloro-2-Oxazolidinones," U.S. Pat. 3,931,213, January 6, 1976.
15. T. Higuchi, N. Bodor and Y. Kuo, "Useful Pro-Drug Forms of Theophylline," U.S. Pat. 3,935,196, January 27, 1976.
16. N. Bodor and J. Kaminski, "3-Chloro-Tetrahydro-1,3-Oxazines or Oxazolines Spiro Substituted," U.S. Pat. 3,936,466, February 3, 1976.
17. N. Bodor, K. Sloan and A. Hussain, "Novel, Transient Pro-Drug Forms of L-DOPA Useful in the Treatment of Parkinson's Disease," U.S. Pat. 3,939,253, February 17, 1976.
18. N. Bodor and J. Kaminski, "Method for Inhibiting Bacterial Growth with Certain Selected 3-Chloro-Tetrahydro-1,3-Oxazines or Oxazolidines," U.S. Pat. 3,954,985, May 4, 1976.
19. N. Bodor and K. Sloan, "Certain Transient Pro-Drug Forms of Phenylbutazone," U.S. Pat. 3,957,803, May 18, 1976.
20. T. Higuchi, N. Bodor and E. Shek, "Novel Pro-Drug Derivatives of Pyridinium Aldoxime Type Cholinesterase Reactivators and Method of Using Same," U.S. Pat. 3,962,447, June 8, 1976.
21. N. Bodor and S. Yuan, "Novel Synthesis of Optically Active M-Acyloxy- α -[(Methylamino)Methyl]Benzyl Alcohols, the Pharmaceutically Acceptable Acid Addition Salts Thereof and Intermediate Useful in the Preparation Thereof," U.S. Pat. 3,966,749, June 29, 1976.
22. J. Kaminski and N. Bodor, "N-Chloro-Amino Acid Derivatives Activity," U.S. Pat. 3,966,796, June 29, 1976.
23. N. Bodor, "Soft Quaternary Surface Active Agents Exhibiting Antibacterial Activity," U.S. Pat. 3,989,711, November 2, 1976.
24. N. Bodor, "1-Hydrocarbonoyloxymethyl-3-carbamoyl or 3-Carboethoxy-Pyridinium Salts," U.S. Pat. 3,998,815, December 21, 1976.
25. N. Bodor, K. Sloan and A. Hussain, "Novel, Transient Pro-Drug Forms of L-DOPA," U.S. Pat. 3,998,799, December 21, 1976.
26. N. Bodor, K. Sloan and Y. Kuo, "Method for Synthesizing Certain Selected Pro-Drug Forms of Theophylline," U.S. Pat. 4,000,132, December 28, 1976.

27. J. Kaminski and N. Bodor, "Method of Inhibiting Bacterial Growth with Certain Selected 3-Chloro-2-Oxazolidinones," U.S. Pat. 4,000,393, December 28, 1976.
28. T. Higuchi, N. Bodor and Y. Kuo, "Useful Prodrug Forms of Theophylline," U.S. Pat. 4,002,756, January 11, 1977.
29. N. Bodor and J. Kaminski, "Brominating and Oxidizing Agent and Method of Using Same," U.S. Pat. 4,009,178, February 22, 1977.
30. N. Bodor and J. Kaminski, "Method of Arresting Bacterial Growth with Certain Selected Dichloro-2,2,5,5-Tetrasubstituted-3,6-Piperazinediones," U.S. Pat. 4,018,925, April 19, 1977.
31. N. Bodor, "Pro-Drug Forms of Digoxin and Method of Preparing and Using Same," U.S. Pat. 4,021,546, May 3, 1977.
32. N. Bodor and S. Yuan, "Novel Intermediates Useful in the Synthesis of Optically Active M-Acyloxy- α -[(Methylamino)Methyl]Benzyl Alcohols," U.S. Pat. 4,028,368, June 7, 1977.
33. N. Bodor, K. Sloan and A. Hussain, "Novel, Transient Prodrug Forms of L-DOPA," U.S. Pat. 4,035,507, July 12, 1977.
34. N. Bodor and S. Yuan, "Novel Synthesis for Preparing the Hydrochloride Salt of Selected Catecholamine Derivatives," U.S. Pat. 4,035,405, July 12, 1977.
35. N. Bodor and K. Sloan, "Novel Transient Acyl Derivatives of Phenylbutazone," U.S. Pat. 4,036,845, July 19, 1977.
36. J. Kaminski and N. Bodor, "Certain Chloroamino Esters of Pyridine Carboxylates and Derivatives Thereof," U.S. Pat. 4,036,843, July 19, 1977.
37. J. Kaminski and N. Bodor, "N-Chloro-Amino Acid Derivatives Exhibiting Antibacterial Activity," U.S. Pat. 4,045,578, August 30, 1977.
38. N. Bodor, "Labile Quaternary Ammonium Salts Useful in Binding Bile Acids in Warm-blooded Animals," U.S. Pat. 4,046,899, September 6, 1977.
39. N. Bodor and J. Kaminski, "3-Chloro-1,3-Oxazines or Oxazolidines as Antibacterial Agents," U.S. Pat. 4,049,818, September 20, 1977.
40. N. Bodor, "Selected Quaternary Ammonium Salts of Pilacarpine Useful in Reducing Intraocular Pressure in Warm-blooded Animals," U.S. Pat. 4,061,722, December 6, 1977.

41. N. Bodor and K. Sloan, "Treating Psoriasis with Transient Prodrug Forms of Xanthine Derivatives," U.S. Pat. 4,061,753, December 6, 1977.
42. N. Bodor, K. Sloan and A. Hussain, "N-Nicotinoyl-3,4-dinicotinoyloxy-L-phenylalanine and Derivatives, Pharmaceutical Compositions and Methods Containing Same," U.S. Pat. 4,065,566, December 27, 1977.
43. N. Bodor and K. Sloan, "Pro-drugs for the Improved Delivery of Certain Selected Anti-inflammatory Steroids," U.S. Pat. 4,069,322, January 17, 1978.
44. T. Higuchi, N. Bodor and Y. Kuo, "Stable Prodrug Forms of Theophylline," U.S. Pat. 4,085,214, April 18, 1978.
45. N. Bodor and S. Yuan, "Novel Optically Active M-Acyloxy- α [(Methylamino)-Methyl]Benzyl Alcohols and the Pharmaceutically Acceptable Acid Addition Salts Thereof," U.S. Pat. 4,088,783, May 9, 1978.
46. J. Kaminski and N. Bodor, "Novel Soft N-Chloroamino Alcohol Derivatives Exhibiting Antibacterial Activity," U.S. Pat. 4,092,420, May 30, 1978.
47. N. Bodor, "Method for Reducing Intraocular Pressure in Warm-blooded Animals," U.S. Pat. 4,094,983, June 13, 1978.
48. N. Bodor and K. Sloan, "Antibacterial Novel Soft N-Chloroamino Alcohol Derivatives," U.S. Pat. 4,115,588, September 19, 1978.
49. N. Bodor and K. Sloan, "Transient Pro-drug Forms of Phenylbutazone," U.S. Pat. 4,117,232, September 26, 1978.
50. N. Bodor, "Labile Quaternary Ammonium Salts Useful in Binding Bile Acids in Warm-blooded Animals," U.S. Pat. 4,120,959, October 17, 1978.
51. J. Kaminski and N. Bodor, "Novel Soft N-Chloroamino Alcohol Derivatives Exhibiting Antibacterial Activity," U.S. Pat. 4,132,805, January 2, 1979.
52. N. Bodor and K. Sloan, "1,2-Diphenyl,5-Ditrifluoroacetyloxy-4-Butyl-5-Hydroxy-3-Pyrazoline," U.S. Pat. 4,139,709, February 13, 1979.
53. N. Bodor, "Labile Quaternary Ammonium Salts Useful in Binding Bile Acids in Warm-blooded Animals," U.S. Pat. 4,140,796, February 20, 1979.
54. N. Bodor, "Sympathomimetic Amines Exhibiting Anti-hemorrhoidal Activity," U.S. Pat. 4,145,441, March 20, 1979.

55. N. Bodor and T. Higuchi, "Nonbitter Tasting Potassium Product for Oral Administration to Warm-blooded Animals and Method for Preparing Same," U.S. Pat. 4,154,824, May 15, 1979.
56. N. Bodor and S. Yuan, "Intermediates Useful in the Synthesis of Optically Active M-Acyloxy- α [(Methylamino)Methyl]Benzyl Alcohols," U.S. Pat. 4,158,005, June 12, 1979.
57. N. Bodor, "Novel 'Soft' Anticholinergic Agents Exhibiting Anti-secretory Activity," U.K. Appln. GB2010270A, published June 27, 1979.
58. N. Bodor, "Labile Non-Heterocyclic Quaternary Ammonium Salts/Esters as Transient Derivatives," U.S. Pat. 4,160,099, July 3, 1979.
59. N. Bodor and K. Sloan, "Novel Transient Pro-Drug Forms of Phenylbutazone and Oxyphenbutazone in Compositions and Methods of Use," U.S. Pat. 4,169,147, September 25, 1979.
60. J. Kaminski and N. Bodor, "Antibacterially Active N-Chloroamino Ester Derivatives of Alkyl Carboxylates," U.S. Pat. 4,171,452, October 16, 1979.
61. N. Bodor and S. Yuan, "Intermediates Useful in the Preparation of Optically and Therapeutically Active m-Acyloxy- α -(Methyl-Amino)Methyl Benzyl Alcohols," U.S. Pat. 4,174,450, November 13, 1979.
62. N. Bodor and J. Zupan, "Esters of Cromoglycates," U.S. Pat. 4,189,571, February 19, 1980.
63. N. Bodor, "Soft Quaternary Surface Active Agents and Method of Using Same," U.S. Pat. 4,204,065, May 20, 1980.
64. Bodor and K. Sloan, "Anti-acne and Anti-seborrhea Prodrug Derivatives of Progesterone," U.S. Pat. 4,213,978, July 22, 1980.
65. N. Bodor and K. Sloan, "Esteramide Prodrugs of Anti-inflammatory Corticosteroids," U.S. Pat. 4,221,787, September 9, 1980.
66. N. Bodor and K. Sloan, "Thiazolidine Prodrugs for the Improved Delivery of Antiinflammatory Corticosteroids," U.S. Pat. 4,239,757, December 16, 1980.
67. J. Epstein and N. Bodor, "Novel Pyridinium Aldoximes Having Micellar Characteristics," U.S. Pat. 4,263,305, April 21, 1981.
68. N. Bodor and L. Freiberg, "Salts of Erythromycin A Esters," U.S. Pat. 4,264,765, April 28, 1981.

69. N. Bodor, K. Sloan and S. Pogany, "Novel Prodrugs of Biologically Active Agents Containing Mercapto Groups, Process for Preparing and Therapeutically Effective Composition Containing the Same," Eur. Pat. 81,102,940.4, May 14, 1981.
70. N. Bodor and K. Sloan, "Prodrugs for Improved Bioavailability of Certain Δ^4 Keto-Steroidal Sex Hormones," U.S. Pat. 4,268,441, May 19, 1981.
71. N. Bodor and S. Yuan, "Process for Preparing d, 1-m,p-dipivalylepinephrine Hydrochloride and Hydrochloride Salts of Related Sympathomimetically-active Catecholamines Using Cesium Chloride Reactant," Canadian Pat. 1,102,336, June 2, 1981.
72. N. Bodor and K. Sloan, "Novel, Transient Pro-drug Forms of Xanthine Derivatives and Their Use as Topical Anti-inflammatory Agents," U.S. Patent 4,275,064, June 23, 1981.
73. N. Bodor and K. Sloan, "Prodrugs for the Improved Delivery of Halogen-Containing Glucocorticosteroids," U.S. Pat. 4,279,900, July 21, 1981.
74. N. Bodor, "Soft Steroids Having Anti-inflammatory Activity," Belg. BE889,563 (Cl. CO7J) November 3, 1981.
75. N. Bodor, K. Sloan and S. Pogany, "Novel Derivatives of Bio-affecting Phenolic Compounds and Pharmaceutical Composition Containing Them," Eur. Pat. 81,106,277.7, December 2, 1981.
76. N. Bodor, K. Sloan and S. Pogany, "Novel Dopa/Dopamine Prodrugs," U.S. Pat. 4,311,706, January 19, 1982.
77. N. Bodor, "Soft Quaternary Surface Active Agents," U.S. Pat. 4,313,889, February 2, 1982.
78. N. Bodor, K. Sloan and S. Pogany, "Novel Sympathomimetic Amine Prodrugs," U.S. Pat. 4,313,956, February 2, 1982.
79. N. Bodor, K. Sloan and S. Pogany, "Novel Inotropic Prodrugs," U.S. Pat. 4,340,603, July 20, 1982.
80. N. Bodor and L. Freiberg, "Salts of Erythromycin A Esters," Canadian Pat. 1,144,543, April 12, 1983.
81. N. Bodor and K. Sloan, "Prodrugs for Improved Bioavailability of Certain Δ^4 Ketosteroidal Sex Hormones," Canadian Pat. 1,148,533, June 21, 1983.

82. N. Bodor, K. Sloan and S. Pogany, "Prodrugs of 6-Mercaptopurine and 6-Mercaptopurine Ribosides and Therapeutic Compositions and Methods Employing Them," U.S. Pat. 4,443,435, April 17, 1984.
83. N. Bodor, "Soft Steroids Having Anti-Inflammatory Activity," Canadian Pat. 1,174,667, September 18, 1984.
84. N. Bodor, "Brain Specific Drug Delivery," U.S. Pat. 4,479,932, October 30, 1984.
85. N. Bodor, "4,5 α Epoxy-morphinan-6-Spiro-2'-(4'-Carboxy, 1',3'-Thiazolidine) Derivatives," U.S. Pat. 4,496,570, January 29, 1985.
86. N. Bodor, "Brain-Specific Drug Delivery," U.S. Pat. 4,540,564, September 10, 1985.
87. N. Bodor, K. Sloan and S. Pogany, "Novel Derivatives of Bio-affecting Phenolic Compounds and Pharmaceutical Composition Containing Them," European Pat. 0046270, May 21, 1986.
88. N. Bodor, "Methods for Inducing Mydriasis in Animals," U.S., Pat. 4,594,356, June 10, 1986.
89. N. Bodor, K. Sloan and S. Pogany, "Novel Prodrugs of Biologically Active Agents Containing Mercapto Groups, Process for Preparing and Therapeutically Effective Composition Containing the Same," Eur. Pat. 0038541, August 13, 1986.
90. N. Bodor, K. Estes and J. Simpkins, "Method and Compositions for Weight Control," U.S. Pat. 4,617,298, October 14, 1986.
91. N. Bodor, "Testicular-Specific Drug Delivery," U.S. Pat. 4,622,218, November 11, 1986.
92. N. Bodor, "4,5 α Epoxy-morphinan-6-Spiro-2'-(4'-Carboxy, 1',3'-Thiazolidine) Derivatives," Canadian Pat. 1,218,990, March 10, 1987
93. N. Bodor and Y. Oshiro, "Certain 3-Pyridiniumesters of Mono- or Di-Lower Alkyl Carbamates Having Anticholinesterase Activity," U.S. Pat. 4,661,502, April 28, 1987.
94. N. Bodor, "Orally Active Heparin Salts Containing Multivalent Cationic Units," U.S. Pat. 4,703,042, October 27, 1987.
95. N. Bodor, "Soft Steroids Having Anti-Inflammatory Activity," U.S. Pat. 4,710,495,
96. N. Bodor, "Brain-Specific Dopaminergic Activity Involving Dihydropyridine Carboxamides, Dihydroquinoline and Isoquinoline Carboxamides," U.S. Pat. 4,727,079, February 23, 1988.

97. N. Bodor, "Labile Quaternary Ammonium Salts as Prodrugs," U.S. Pat. 4,727,151, February 23, 1988.
98. N. Bodor and Y. Ohshiro, "Anticholinesterase Pyridine Derivatives," European Pat. 122376 (GB, FR, DE), June 29, 1988.
99. N. Bodor, "Novel 4,5-g(a) Epoxymorphinan-6-Spiro-2'-(4'-Carboxy, 1',3'-Thiazolidine) Derivatives," Eur. Pat. 0144341, July 6, 1988.
100. N. Bodor and T. Loftsson, "Percutaneous Penetration Enhancer of Oleic Acid and 2-Ethyl-1,3-Hexanediol," U.S. Pat. 4,764,381, August 16, 1988.
101. N. Bodor, "Brain-Specific Analogues of Centrally Acting Amines," U.S. Pat. 4,771,059, September 13, 1988.
102. P. Stacpoole and N. Bodor, "Certain Inositol-Nicotinate Ester Derivatives and Polyionic Complexes Therefore Useful for Treating Diabetes Mellitus, Hyperlipidemia and Lactic Acidosis," U.S. Pat. 4,801,597, January 31, 1989.
103. N. Bodor, "Orally Active Heparin Multiplets," Eur. Pat. 0189427, February 8, 1989.
104. N. Bodor, "Brain Specific Drug Delivery," U.S. Pat. 4,824,850, April 25, 1989.
105. N. Bodor, "Physiological Means of Enhancing Transdermal Delivery of Drugs," U.S. Pat. 4,824,676, April 25, 1989.
106. N. Bodor, "Novel Redox Carriers for Brain-Specific Drug Delivery," U.S. Pat. 4,829,070, May 9, 1989.
107. N. Bodor, "Soft β -Adrenergic Blocking Agents," U.S. Pat. 4,829,086, May 9, 1989.
108. T. Loftsson and N. Bodor, "Sulfur-Substituted Phenylacetamides," U.S. Pat. 4,859,707, August 22, 1989.
109. W. Anderson, N. Bodor and J. Simpkins, "Method for Treating Male Sexual Dysfunction," U.S. Pat. 4,863,911, September 5, 1989.
110. N. Bodor, "Brain-Specific Delivery of Dopamine Utilizing Dihydropyridine/Pyridinium Salt-Type Redox Carriers," U.S. Pat. 4,880,816, November 14, 1989.
111. N. Bodor, "Brain-Specific Drug Delivery," U.S. Pat. 4,880,921, November 14, 1989.
112. N. Bodor and T. Loftsson, "Percutaneous Penetration Enhancer of Oleic Acid and 2-Ethyl-

- 1,3-Hexanediol," U.S. Pat. 4,885,174, December 5, 1989.
113. N. Bodor, "Amino Acids Containing Dihydropyridine Ring Systems for Site-Specific Delivery of Peptides to the Brain," U.S. Pat. 4,888,427, December 19, 1989.
 114. N. Bodor, "Brain-Specific Analogues of Centrally Acting Amines," Eur. Pat. 0174342, December 20, 1989.
 115. N. Bodor and T. Loftsson, "Composition and Method for Enhancing Permeability of Topical Drugs," U.S. Pat. 4,892,737, January 9, 1990.
 116. N. Bodor, "Pharmaceutical Composition for Parenteral Administration," Japan Pat. 2009825, January 12, 1990.
 117. N. Bodor, "Brain-Specific Drug Delivery of Steroid Sex Hormones Cleaved from Pyridinium Carboxylates and Dihydro-Pyridine Carboxylate Precursors," U.S. Pat. 4,900,837, February 13, 1990.
 118. N. Bodor, "Radiopharmaceuticals and Chelating Agents Useful in their Preparation," Canadian Pat. 1,266,864, March 20, 1990.
 119. N. Bodor, "Compounds for Site-Enhanced Delivery of Radionuclides and Uses Thereof," Canadian Pat. 1,267,899, April 17, 1990.
 120. N. Bodor, "Brain Specific Analogues of Centrally Acting Amines," U.S. Pat. 4,933,438, June 12, 1990.
 121. N. Bodor, "Soft α (b)-Adrenergic Blocking Agents," Eur. Pat. 0174956, August 16, 1990.
 122. N. Bodor, "Compounds for Site-Enhanced Delivery of Radionuclides and Uses Thereof," U.S. Pat. 4,963,688, October 16, 1990.
 123. N. Bodor, "Novel Radiopharmaceuticals and Chelating Agents Useful in Their Preparation," U.S. Pat. 4,963,682, October 16, 1990.
 124. N. Bodor, "Pharmaceutical Formulations for Parenteral Use," U.S. Pat. 4,983,586, January 8, 1991.
 125. N. Bodor and T. Loftsson, "Percutaneous Penetration Enhancer of Oleic Acid and 2-Ethyl-1,3-Hexanediol," U.S. Pat. 4,983,396, January 8, 1991.
 126. J. Houdeshell, N. Bodor and M. Brewster, "Low Allergic Steroid Type Anesthetic/Hypnotic Agent," Japan Pat. 3011018, January 18, 1991.

127. N. Bodor, "Soft Steroids Having Anti-Inflammatory Activity," U.S. Pat. 4,996,335, February 26, 1991.
128. N. Bodor, "Improvements in Redox Systems for Brain-Targeted Drug Delivery," U.S. Pat. 5,002,935, March 26, 1991.
129. N. Bodor, "Physiological Means of Enhancing Transdermal Delivery of Drugs," U.S. Pat. 5,008,111, April 16, 1991.
130. N. Bodor, "Brain-Specific Drug Delivery," U.S. Pat. 5,008,257, April 16, 1991.
131. N. Bodor, "Redox Systems for Brain-Targeted Drug Delivery," U.S. Pat. 5,017,566, May 1, 1991.
132. N. Bodor, "Labile Ketone Derivative of 3-Substituted-1-Alkylamino-2-Propranolols and Their Use as Beta-Adrenergic Blockers," U.S. Pat. 5,017,618, May 21, 1991.
133. N. Bodor, "Physiological Means of Enhancing Transdermal Delivery of Drugs," Eur. Pat. 0198034, June 12, 1991.
134. N. Bodor, "Pharmaceutical Formulations for Parenteral Use," U.S. Pat. 5,024,998, June 18, 1991.
135. N. Bodor, "Labile Ketone Derivative of 3-Substituted-1-Alkylamino-2-Propranolols and Their Use as β -Adrenergic Blockers," U.S. Pat. 609,788, September 2, 1991.
136. K. Rand, N. Bodor and W. Brey, "NMR-Assayable Ligand-Labelled Trifluorothymidine Containing Composition and Method for Diagnosis of HSV Infection," U.S. Pat. 5,053,215, October 1, 1991.
137. N. Bodor, "Quaternary Pyridinium Salts," U.S. Pat. 5,079,366, January 7, 1992.
138. N. Bodor, "Brain-Specific Analogues of Centrally Acting Amines," U.S. Pat. 5,082,853, January 21, 1992.
139. N. Houdeshell, N. Bodor and M. Brewster, "Hypoallergenic Steroidal Anesthetic-Hypnotic Compositions," South African Pat. 90/3992, January 29, 1992.
140. N. Bodor, "Redox Carriers for Brain-Specific Drug Delivery," U.S. Pat. 5,087,618, February 11, 1992.

141. W. Anderson, N. Bodor and J. Simpkins, "Method for Treating Male Sexual Dysfunction," Can. Pat. 1,300,020, May 5, 1992.
142. N. Bodor, "Pharmaceutical Formulations for Parenteral Use," Australian Pat. 618995, June 1, 1992.
143. N. Bodor, "Redox Systems for Brain-Targeted Drug Delivery," Australian Pat. 619788, June 22, 1992.
144. N. Bodor, "Soft Beta-Adrenergic Blocking Agents," U.S. Pat. 5,135,926, August 4, 1992.
145. N. Bodor, "Novel Radiopharmaceuticals and Chelating Agents Useful in Their Preparation," U.S. Pat. 5,136,038, August 4, 1992.
146. N. Bodor, "Compounds for Site-Enhanced Delivery of Radionuclides and Uses Thereof," U.S. Pat. 5,155,227, October 13, 1992.
147. W. Anderson, N. Bodor and J. Simpkins, "Method for Treating Male Sexual Dysfunction," Eur. Pat. 0256668, November 4, 1992.
148. N. Bodor, "Targeted Drug Delivery Via Phosphonate Derivatives," U.S. Pat. 5,177,064, January 5, 1993.
149. N. Bodor, "Brain-Specific Drug Delivery," U.S. Pat. 5,187,158, February 16, 1993.
150. N. Bodor, "Labile Ketone Derivatives of 3-Substituted 1-Alkylamino-2-Propanols and Their Use as β -Adrenergic Blockers," Nor. Pat. 171,312, February 24, 1993.
151. R. Hammer and N. Bodor, "Anticholinergic Compounds, Pharmaceutical Compositions and Method of Treatment," Eur. Pat. 0238982, March 10, 1993.
152. N. Bodor and T. Loftsson, "Transdermal Delivery System," Eur. Pat. 0250542, March 17, 1993.
153. N. Bodor, "Soft Beta-Adrenergic Blocking Agents," U.S. Pat. 5,202,347, April 13, 1993.
154. N. Bodor, "Pharmaceutical Formulations for Parenteral Use," Eur. Pat. 0335545, June 9, 1993.
155. N. Bodor, "Soft Steroids Having Anti-Inflammatory Activity," Eur. Pat. 0334853, June 9, 1993.
156. R. Hammer and N. Bodor, "Anticholinergic Compounds, Compositions and Methods of

- Treatment," U.S. Pat. 5,223,528, June 29, 1993.
157. N. Bodor, "Method of Improving Oral Bioavailability of Carbamazepine," U.S. Pat. 5,231,089, July 27, 1993.
 158. N. Bodor, "Redox Amino Acids and Peptides Containing Them," Eur. Pat. 0293071, September 1, 1993.
 159. R. Hammer and N. Bodor, "Anticholinergic Compounds, Compositions and Methods of Treatment," U.S. Pat. 5,258,388, November 2, 1993.
 160. J.Houdeshell, N. Bodor and M. Brewster, "Hypoallergenic Steroidal Anesthetic/Hypnotic Compositions," Eur. Pat. 0399716, January 26, 1994.
 161. N. Bodor, "Brain Specific Drug Delivery," Can. Pat. 1,327,566, March 8, 1994.
 162. N. Bodor, "Brain Specific Analogues of Centrally Acting Amines," U.S. Pat. 5,296,483, March 22, 1994.
 163. N. Bodor and R. Hammer, "Anticholinergic Compounds, Pharmaceutical Compositions and Method of Treatment," Canadian Pat. 1,328,106, March 29, 1994.
 164. N. Bodor, "Brain-Enhanced Delivery of Neuroactive Peptides by Sequential Metabolism," PCT WO 94/06450, March 31, 1994.
 165. N. Bodor, "3-Substituted-1-Alkylamino-2-Propanol as Beta-Adrenergic Effect Blocking Medicine," Japan Pat. 6122624, May 6, 1994.
 166. N. Bodor, "Labile Ketone Derivatives of 3-Substituted-1-Alkylamino-2-Propanols and Their Use as Beta-Adrenergic Blockers," Eur. Pat. 0283147, May 11, 1994.
 167. N. Bodor, "Soft Beta-Adrenergic Blocking Agents," U.S. Pat. 5,334,601, August 2, 1994.
 168. N. Bodor, "Redox Systems for Brain-Targeted Drug Delivery," Canadian Pat. 1,331,564, August 23, 1994.
 169. N. Bodor, "Pharmaceutical Formulations for Parenteral Use," Irish Pat. No. 62095, December 5, 1994.
 170. N. Bodor, "Redox Amino Acids and Peptides Containing Them," Irish Pat. No. 62072, December 5, 1994.
 171. N. Bodor, "Labile Ketone Derivatives of 3-Substituted-1-Alkylamino-2-Propanols and Their Use as Beta-Adrenergic Blockers," Irish Pat. 62828, February 14, 1995.

172. N. Bodor, "Redox Carriers for Brain-Specific Drug Delivery," U.S. Pat. 5,389,623, February 14, 1995.
173. N. Bodor, "Labile Ketone Derivatives of 3-Substituted-1-Alkylamino-2-Propanols and Their Use as β -Adrenergic Blockers," Can. Patent 1,335,286, April 18, 1995.
174. N. Bodor, "Targeted Drug Delivery Via Phosphonate Derivatives," U.S. Pat. 5,413,996, May 9, 1995.
175. R. Hammer and N. Bodor, "Anticholinergic Compounds, Compositions and Methods of Treatment," U.S. Pat., 5,418,244, May 23, 1995.
176. N. Bodor, "Pharmaceutical Formulations for Parenteral Use," Canadian Pat. 1,336,498, August 1, 1995.
177. N. Bodor, "Brain-Specific Drug Delivery," Eur. Pat. 0110955, August 23, 1995.
178. N. Bodor, "Mitigation of Beta-Adrenergic Blocking Agent," Japan Pat. 7238017, September 12, 1995.
179. N. Bodor, "Soft Beta-Adrenergic Blocking Agents," U.S. Pat. 5,482,961, January 9, 1996.
180. N. Bodor, "Brain-Specific Drug Delivery," U.S. Pat. 5,525,727, June 11, 1996.
181. N. Bodor, "Soft Beta-Adrenergic Blocking Agents" U.S. Pat. 5,576,332, November 19, 1996.
182. R. Hammer and N. Bodor, "Anticholinergic Compounds, Compositions and Methods of Treatment," U.S. Pat., 5,610,188, March 11, 1997.
183. N. Bodor, "Targeted Drug Delivery via Phosphonate Derivatives," United Kingdom Pat. 0539493, March 26, 1997.
184. N. Bodor, "Targeted Drug Delivery via Phosphonate Derivatives," Eur. Pat. 0539493; Ger. Pat P69125377; Austria Pat. E150759; March 26, 1997.
185. N. Bodor, "Brain-Specific Drug Delivery," Singapore, Pat. 9790597-0, March 29, 1997.
186. N. Bodor, "Pharmaceutical Formulations for Parenteral Use," Singapore, Pat. 9790596-2, March 29, 1997.
187. N. Bodor, "Targeted Drug Delivery via Phosphonate Derivatives," U.S. Pat. 5,618,803, April 8, 1997.

188. R. Hammer and N. Bodor, "Anticholinergic Compounds, Pharmaceutical Compositions and Methods of Treatment," U.S. Pat., 5,618,826, April 8, 1997.
189. N. Bodor, "Brain-Enhanced Delivery of Neuroactive Peptides by Sequential Metabolism," U.S. Pat., 5,624,894, April 29, 1997.
190. N. Bodor, "Pharmaceutical Formulations for Parenteral Use," Japan Pat. 2643426, May 2, 1997.
191. W. Anderson, N. Bodor and J. Simpkins, "Method for Treating Male Sexual Dysfunction," Japan Pat., 2646568, May 9, 1997.
192. R. Hammer and N. Bodor, "Anticholinergic Compounds, Pharmaceutical Compositions and Methods of Treatment," U.S. Pat., 5,637,601, June 10, 1997.
193. N. Bodor, "Redox Amino Acids and Peptides Containing Them," U.S. Pat., 5,639,885, June 17, 1997.
194. R. Hammer and N. Bodor, "Anticholinergic Compounds, Pharmaceutical Compositions and Methods of Treatment," Japan Pat. 2672311, July 11, 1997.
195. N. Bodor, "Redox Systems for Brain-Targeted Drug Delivery," Austria Pat. E164855; European Pat. 0327766; Germany P3856160; April 8, 1998.
196. N. Bodor, "Pharmaceutical Formulations for Parenteral Use," Eur. Pat. 0335545, September 23, 1998.
197. N. Bodor, "Brain-Enhanced Delivery of Neuroactive Peptides by Sequential Metabolism," European Pat. 0661986, June 9, 1999.
198. N. Bodor, "Androstene Derivatives," U.S. Pat. 5,981,517, November 9, 1999.
199. N. Bodor, "Androstene Derivatives," Eur. Pat. 0902789, January 23, 2002.
200. N. Bodor and M. Grant, "Compounds and Method for the Prevention and Treatment of Diabetic Retinopathy," U.S. Pat. 6,440,933, August 27, 2002.
201. N. Bodor, "Inactive Metabolite Approach to Soft Drug Design," U.S. Pat. 6,610,675, August 26, 2003.
202. N. Bodor, "Transmucosal Dosage Forms for Brain-Targeted Steroid Chemical Delivery Systems," WO 2005011617, February 10, 2005.

203. N. Bodor, "Methods for the Treatment of Male and Female Sexual Dysfunction," WO 2005011618, February 10, 2005.
204. N. Bodor and M. Grant, "Compounds and Method for the Prevention and Treatment of Diabetic Retinopathy," U.S. Pat. 6,943,145, September 13, 2005.
205. N. Bodor and M. Grant, "Compounds and Method for the Prevention and Treatment of Diabetic Retinopathy," U.S. Patent 7,115,566, October 3, 2006.
206. N. Bodor, "Soft Anticholinergic Esters," Australian Pat. 2006315657 B2, November 13, 2006.
207. N. Bodor, "Cladribine Formulations for Improved Oral and Transmucosal Delivery," U.S. Pub. 2007/0065492 A1, March 22, 2007.
208. N. Bodor "Enhancement of Activity and/or Duration of Action of Selected Anti-inflammatory Steroids for Topical or Other Local Application" European Pat. 1,658,083, August 8, 2007.
209. N. Bodor, "Enhancement of Activity and/or Duration of Action of Selected Anti-Inflammatory Steroids for Topical or Other Local Application," Mexican Pat. 255693, March 27, 2008.
210. J. Kuszmann, I. Kurucz, G. Medgyes and N. Bodor, "Polysulfated Glycosides and Salts Thereof," European Pat. 1778709, May 28, 2008.
211. N. Bodor, "Soft Anticholinergic Esters," U.S. Pat. 7,399,861, July 15, 2008.
212. N. Bodor, "Soft Anticholinergic Zwitterions," U.S. Pat. 7,417,147, August 26, 2008.
213. N. Bodor, "Enhancement of Activity and/or Duration of Action of Selected Anti-inflammatory Steroids for Topical or Other Local Applications," U.S. Pat. 7,419,971, September 2, 2008.
214. N. Bodor "Combination of Anti-inflammatory Steroids Having Transporter-Enhanced Corticosteroid Activity" European Pub. 2,026,818, February 25, 2009.
215. N. Bodor, "A Saturated Cladribine-Cyclodextrin Complex Formulated into a Solid Oral Dosage Form" India Pat. 231,220, March 3, 2009.
216. N. Bodor, "Soft Anticholinergic Zwitterions," U.S. Pat. 7,538,219, May 26, 2009.
217. N. Bodor, "Enhancement of Activity and/or Duration of Action of Soft Anti-inflammatory

- Steroids for Topical or Other Local Applications,” U.S. Pat. 7,560,448, July 14, 2009.
218. N. Bodor, “Soft Anticholinergic Esters,” U.S. Pat. 7,576,210, August 18, 2009.
 219. N. Bodor, “Enhancement of Activity and/or Duration of Action of Selected Anti-inflammatory Steroids for Topical or Other Local Applications,” European Pat. 1,653,974, January 6, 2010.
 220. N. Bodor “Cladribine Formulations for Improved Oral and Transmucosal Delivery” Australia Pat. 2004226435, March 4, 2010.
 221. N. Bodor, “Transporter Enhanced Corticosteroid Activity,” U.S. Pat. 7,687,484, March 30, 2010.
 222. N. Bodor, “Transporter-Enhanced Corticosteroid Activity and Methods and Compositions for Treating Dry Eye,” U.S. Pat. 7,691,811, April 6, 2010.
 223. N. Bodor and Y. Dandiker, “Oral Formulations of Cladribine,” European Pat. 1608344, August 4, 2010.
 224. N. Bodor, “Enhancement of Activity and/or Duration of Action of Selected Anti-inflammatory Steroids for Topical or Other Local Applications,” U.S. Pat. 7,776,846, August 17, 2010.
 225. N. Bodor, “Combination of Anti-Inflammatory Steroids Having Transporter-Enhanced Corticosteroid Activity,” European Pat. 2026818, December 22, 2010.
 226. N. Bodor and Y. Dandiker, “Oral Formulations of Cladribine,” U.S. Pat. 7,888,328, February 15, 2011.
 227. J. Kuszmann, I. Kurucz, G. Medgyes and N. Bodor, “Polysulfated Glycosides and Salts Thereof,” U.S. Pat. 7,902,158, March 8, 2011.
 228. N. Bodor, “Enhancement of Activity and/or Duration of Action of Soft Anti-Inflammatory Steroids for Topical or Other Local Application,” U.S. Pat. 7,923,441, April 12, 2011.
 229. N. Bodor and Y. Dandiker, “Oral Formulations of Cladribine,” Canadian Pat. 2,520,523, October 11, 2011.
 230. N. Bodor, “Soft Anticholinergic Esters,” European Pat. 1948596, October 19, 2011.
 231. N. Bodor, “Soft Anticholinergic Zwitterions,” European Pat. 1957451, October 19, 2011.
 232. N. Bodor, “Soft Anticholinergic Zwitterions,” U.S. Pat. 8,071,639, December 6, 2011.

233. N. Bodor, "Enhancement of Activity and/or Duration of Action of Soft Anti-Inflammatory Steroids for Topical or Other Local Application," Japan Pat. 4893305, January 6, 2012.
234. N. Bodor, "Soft Anticholinergic Esters," Australian Patent 2006315657, March 15, 2012.
235. N. Bodor, "Soft Anticholinergic Esters," U.S. Pat. 8,147,809, April 3, 2012.
236. J. Kuzsmann, I. Kurucz, G. Medgyes and N. Bodor, "Polysulfated Glycosides and Salts Thereof," Canadian Pat. 2,576,131, April 24, 2012.
237. N. Bodor, "Enhancement of Activity and/or Duration of Action of Soft Anti-inflammatory Steroids for Topical or Other Local Application," Canadian Pat. 2,558,944, May 9, 2012.
238. N. Bodor, "Enhancement of Activity and/or Duration of Action of Selected Anti-Inflammatory Steroids," Canadian Pat. 2,558,941, May 15, 2012.
239. N. Bodor, "Cladribine Formulations for Improved Oral and Transmucosal Delivery," Canadian Patent 2,520,522, May 29, 2012.
240. N. Bodor and Y. Dandiker, "Oral Formulations of Cladribine," European Pat. 2272503, March 20, 2013.
241. N. Bodor, "Soft Anticholinergic Esters," Japan Pat. 5257073, May 2, 2013.
242. N. Bodor and Y. Dandiker, "Oral Formulations of Cladribine," Japan Pat. 5256611, May 2, 2013.
243. N. Bodor and Y. Dandiker, "Oral Formulations of Cladribine," Australian Pat. 2010214777, May 16, 2013.
244. N. Bodor, "Combination of Anti-Inflammatory Steroids Having Transporter-Enhanced Corticosteroid Activity," Japan Pat. 5278313, May 31, 2013.
245. N. Bodor, "Soft Anticholinergic Esters," Canadian Pat. 2,627,982, September 10, 2013.
246. N. Bodor, "Soft Anticholinergic Zwitterions," US Patent 8,568,699, October 29, 2013.
247. N. Bodor, "Cladribine Formulations for Improved Oral and Transmucosal Delivery," US Patent 8,623,408, January 7, 2014.
248. N. Bodor, "Soft Anticholinergic Esters," US Patent 8,628,759 B2, January 14, 2014.

249. N. Bodor, P. Buchwald, et. al., "Therapeutic Hybrid Implantable Devices," US Patent 8,702,684, April 22, 2014.
250. N. Bodor and Y. Dandiker, "Oral Formulations of Cladribine," US Patent 8,785,415, July 22, 2014.
251. N. Bodor, "Treatment of Eyelid Dermatitis," US Patent 8,835,410, September 16, 2014.

Approximately 25 patents are pending as of September 2014.

INVITED LECTURES GIVEN BY NICHOLAS BODOR

March, 1978 - June, 1989

Location	Date	Institution
Lake Ozark, MO	3/78	11th Higuchi Research Seminar
JAPAN:		
Osaka	5/78	Otsuka Pharmaceutical Co.
Osaka	5/78	Kanebo, Ltd.
Tokyo	5/78	Sankyo
Aberdeen Proving Ground, MD	6/78	Edgewood Arsenal
Chicago, IL	11/78	Abbott Laboratories
Kalamazoo, MI	1/79	Upjohn Company
Lake Ozark, MO	3/79	Ayerst Laboratory
Honolulu, HI	4/1-6/79	ACS/CSJ Symposium Computer Assisted Drug Design
Palo Alto, Ca	4/79	Syntex Research
Raleigh, NC	6/79	Decontamination of Chemical Agents ARO Special Meeting
Philadelphia, PA	11/79	McNeil Laboratories
ENGLAND:		
London	11/79	Chemical Society- Royal Society
London	11/79	University of London
Portsmouth	11/79	American Cyanamid
Birmingham	11/79	University of Birmingham
Bloomfield, NJ	2/80	Schering-Plough

Curriculum Vitae--Presentations
Nicholas Bodor

Lake, Ozark, MO	3/80	13th Higuchi Research Seminar
Skokie, IL	4/80	G.D. Searle
Skokie, IL	4/80	APhA National Meeting
Las Vegas, NV	8/24-29/80	ACS Symposium, "Soft Drugs: Strategies for Design of Safer Drugs"
	8/80	Gordon Conference Research Conference on Medicinal Chemistry
Reston, VA	11/3-15/80	ARO Conference on Defense Against Chemical Agents, "Acceleration of Deactivation of Chemical Agents"
Ann Arbor, MI	12/8/80	University of Michigan, "The Soft Drug Approach: Strategies for the Design of Safer Drugs"
	12/9/80	Warner Lambert, "The Soft Drug Approach: Strategies for the Design of Safer Drugs"
Washington, DC	2/23/81	National Institute for Aging, "Soft Drugs"
Lake Ozark, MO	3/15-18/81	14th Higuchi Research Seminar
Atlanta, GA	4/12-17/81	FASEB Symposium on Drug Carrier Systems, "The Prodrug Approach to Controlled Delivery"

Curriculum Vitae--Presentations
Nicholas Bodor

New London, NH	8/3-7/81	Gordon Research Conference on Medicinal Chemistry
Noordwijkerhout, THE NETHERLANDS	8/25-28/81	IUPAC-IUPHAR Symposium, "Strategy in Drug Research"
Indianapolis, IN	10/20/21/81	Lilly Research Company
Montpellier, FRANCE	11/27-28/81	Clin Midy Research Center Symposium, "Drug Metabolism and Drug Design: Quo Vadis?"
JAPAN:		
Osaka	12/6-14/81	Otsuka Pharmaceutical Co.
Kyoto	12/7/81	Kyoto University
Painesville, OH	1/10-11/82	Diamond Shamrock
Clifton, NJ	1/25/82	American Cyanamid Company
Hillside, NJ	2/15-16/82	Bristol Myers
Boston, MA	2/22/82	Gillette Company
Lake Ozark, MO	3/15-17/82	15th Higuchi Research Seminar
Painesville, Oh	3/29/82	Diamond Shamrock
Groton, Ct	3/31/82	Pfizer Company

Curriculum Vitae--Presentations
Nicholas Bodor

Aberdeen Proving Ground, MD	4/1/82	Edgewood Arsenal
Austin, TX	5/6/82	University of Texas
College Station, TX	5/7/82	Texas A&M University
Chicago, IL	5/25/82	Abbott Laboratories, "Brain-Specific Delivery of Drugs"
JAPAN:		
Osaka	12/82	Fujisawa Pharmaceutical Co.
Hiroshima	12/82	Umezawa Research Institute, "Brain-Specific Delivery of Drugs"
Kyoto	12/82	University of Kyoto, "Soft Drugs"
Lake Ozark, Mo	3/13/-16/83	16th Higuchi Research Seminar
Skokie, IL	4/25/83	G.D. Searle
San Francisco, CA at San	5/6/83	University of California Francisco
Somerville, NJ	9/29/83	Hoechst-Roussel
Gainesville, FL	10/19/83	University of Florida Frontiers of Science, "Strategies to Design Safe Drugs"

Curriculum Vitae--Presentations
Nicholas Bodor

JAPAN:	10/25-11/15/83	
Tokyo		Sankyo, Ltd.
Tokyo		Hoshi University, Special Lecture
Tokyo		Snow Brand Milk Products
Tokyo		Toyo Jozo Co., Ltd.
Osaka		Takeda Chemical Industries, Ltd.
Osaka		Fujisawa Pharmaceutical Co.
Osaka		Tanabe Co., Ltd.
Osaka		Sumitomo Company
Osaka		Otsuka Pharmaceutical Co.
Osaka		Yoshitomi Company
Hiroshima		Hiroshima University, Key Lecture at Drug Design and Metabolism Symposium
Kyoto		Ono Pharmaceuticals
Kyoto		Kyoto University-- Japanese Pharmaceutical Association
Takata		Wakunaga Pharmaceutical Co.
Boston, MA	12/7/83	New England Nuclear
Detroit, MI	12/8/83	Warner Lambert
Gainesville, FL	12/14/83	University of Florida Endocrinology Seminar
Chicago, Il	12/19/83	Smith Labs
Assiut, EGYPT	1/84	University of Assiut, Lecture Series

Curriculum Vitae--Presentations
Nicholas Bodor

Milan, ITALY	1/84	Recordati Pharmaceutica e Chimica
Basel, SWITZERLAND	1/84	Sandoz, Inc.
INDIA:		
Bombay	1/28/84	Bombay College of Pharmacy, International Symposium Celebrating 25th Anniversary
New Delhi	2/1/84	Indian Pharmaceutical Association Satellite Seminar on Advances in Drug Delivery Systems
JAPAN:		
Osaka	2/84	Ono Pharmaceuticals
Osaka	2/84	Yoshitomi Company
Osaka	2/84	Fujisawa Pharmaceutical Co.
Lake Ozark, Mo	3/11-14/84	17th Higuchi Research Seminar
Arlington, VA	4/19/84	NIH Special Study Section on "Boronate, Redox and Related Compounds as Vital Reagents"
Boston, MA	5/15/84	American Chemical Society, NE Section, Invited Lecture
Miami, FL	7/26/84	Key Pharmaceuticals

Curriculum Vitae--Presentations
Nicholas Bodor

New London, NH	7/30-8/3/84	Gordon Conference on Medicinal Chemistry
Philadelphia, PA	8/26-31/84	American Chemical Society Symposium on Drug Design and Discovery
Gainesville, FL	9/27/84	University of Florida Department of Chemistry
Philadelphia, PA	10/28-31/84	American Pharmaceutical Association Academy of Pharmaceutical Sciences Symposium on Theory and Application of Bioreversible Carriers to Drug Design
West Chester, PA	11/1/84	SmithKline and Beckman Corporation
Gainesville, FL	11/9/84	Engineering Advisory Council
Austin, TX	2/21-22/85	University of Texas
Lake Ozark, Mo	3/10-13/85	18th Higuchi Research Seminar

Curriculum Vitae--Presentations
Nicholas Bodor

JAPAN:

Tokyo	3/18/85	Tokyo University- Pharmaceutical Society of Japan (Divisional)
Tsukuba	3/19/85	Eisai Company
Osaka	3/20/85	Takeda Pharmaceutical Co.
Osaka	3/21/85	Sumitomo Pharmaceutical Co.
Hiroshima	3/22/85	Hiroshima University- Pharmaceutical Society of Japan (Divisional)
Osaka	3/23/85	Ono Pharmaceuticals
Tokushima	3/25/85	Otsuka Pharmaceutical Co.
Kyoto	3/26/85	Biwako Research Institute
Osaka	3/27/85	Nihon Medi-Physics
Anaheim, CA	4/21-25/85	FASEB
Cincinnati, OH	5/7/85	Proctor & Gamble
Raleigh-Durham, NC	5/8/85	Burroughs-Wellcome
Magnolia, AR	5/30/85	Medicinal Chemistry Symposium
Budapest, HUNGARY	6/10/85	National Academy of Science
Milan, ITALY	6/20/85	Recordati Industria Chimica e Farmaceutica S.P.A.
Geneva, SWITZERLAND	6/24/85	Arcopharma

Curriculum Vitae--Presentations
Nicholas Bodor

London, ENGLAND	7/4/85	The Institute of Cancer Research and London University College Hospital
Plymouth, NH	7/22-25/85	Gordon Conference on Drug Metabolism
Philadelphia, PA	9/16/85	McNeil Pharmaceutical Co.
Kingsport, TN	9/17/85	Eastman Chemical Co.
Belfast, IRELAND	9/25/85	Queen's University of Belfast, Symposium on Prodrugs, Biochemical Society
Reykjavik, ICELAND	9/27/85	University of Iceland
Copenhagen, DENMARK	9/30/85	Lunbeck A/C
Helsingborg, SWEDEN	10/1/85	Leo Pharmaceuticals
London, ENGLAND	10/3/85	University College Hospital
Kalamazoo, MI	11/7/85	Upjohn Company
Rochester, NY	12/3/85	Eastman Kodak Company
Lake Ozark, MO	3/9-12/86	19th Higuch Research Seminar
Tarrytown, NY	4/4/86	ACS Nichols Distinguished Symposium
Edgewood, MD	5/19/86	Edgewood Arsenal Conference

Curriculum Vitae--Presentations
Nicholas Bodor

Baltimore, MD	5/20/86	Nova Pharmaceutical Co.
Chapel Hill, NC	6/15-19/86	ACS Medicinal Chemistry Symposium
Budapest, HUNGARY	7/29-8/13/86	Conference on the Role of Hungarians in Science and Technology in the World; National Academy of Science of Hungary; Central Research Institute for Drug Research;
Budapest, Hungary		Chinoin Pharmaceutical Co.
Castres Cedex, FRANCE	9/12/86	Pierre Fabre Research Center
West Berlin, GERMANY	9/14-18/86	IXth International Symposium on Medicinal Chemistry
Helsingborg, SWEDEN	9/19/86	Leo Pharmaceutical Co.

Curriculum Vitae--Presentations
Nicholas Bodor

JAPAN:

Tokushima	9/29-30/86	Otsuka Research Institute
Hiroshima	10/1/86	Hiroshima University
Osaka	10/2/86	Takeda Chemical Industries
	10/3/86	Sumitomo Pharmaceutical Co.
Kyoto	10/4/86	Kyoto University
Tokyo	10/6/86	Hoshi University and Kanto Division of Japanese Pharmaceutical Society
	10/7/86	Tokyo University
	10/7/86	Snow Brand Milk Industries
Tsukuba	10/8/86	Eisai Company
	10/8/86	Tsukuba Research Institute
Osaka	10/9/86	Fujisawa Pharmaceutical Co.
Osaka	10/10/86	Ono Pharmaceutical Co.
Washington, DC	11/2-6/86	American Association Pharmaceutical Scientists
Edgewood, MD	11/18-21/86	Edgewood Arsenal Conference
New York, NY	1/12-015/87	New York Academy of Sciences
Gainesville, FL	2/10/87	Sigma Xi, "Concepts to Design Safer Drugs"

Curriculum Vitae--Presentations
Nicholas Bodor

Lake Ozark, MO	3/14-18/87	20th Higuchi Research Seminar
Washington, DC	3/30-4/3/87	FASEB
Milan, ITALY	4/2/87	Recordati Industria Chimica e Farmaceutica S.P.A.
Paris, FRANCE	4/3/87	Delagrang, Inc.
Budapest, HUNGARY	4/3-13/87	Institute for Drug Research and Hungarian Academy of Sciences
Bloomfield, NJ	4/20-21/87	Schering Corporation
Frankfurt, GERMANY	5/20-23/87	Hoechst AG and Cassella Riedel Pharma GmbH
Boston, MA	6/4-7/87	American Association of Pharmaceutical Scientists
Madison, NJ	6/7-12/87	Residential School in Medicinal Chemistry of Drew University
Washington, DC	6/23-25/87	NIH Special Study Section
New York, NY	7/29/87	Pfizer
New London, NH	8/3-7/87	Gordon Conference on Medicinal Chemistry

Curriculum Vitae--Presentations
Nicholas Bodor

JAPAN:

Takasaki	9/21/87	Upjohn
Tokyo	9/22/87	Eisai
Osaka	9/24/87	Takeda
Osaka	9/25/87	Ono
Hiroshima	9/26/87	Hiroshima University
Osaka	9/28/87	Osaka University
Tokushima	9/29/87	Otsuka

EUROPE:

Budapest, Hungary	10/17/87	Chinoin
Munich, Germany	10/22/87	Cyanamid
Frankfurt, Germany	10/22/87	Hoechst
Frankfurt, Germany	10/23/87	Merck
London, England	10/26/87	May & Baker
Edgewood, MD	11/17-20/87	1987 Scientific Conference on Chemical Defense Research
Honolulu, HI	12/2-7/87	JUC PHARM SCI '87
Raleigh, NC	12/10/87	Burroughs-Wellcome and Glaxco
Beaverton, Or	12/17/87	Tektronix
Chicago, IL	2/3-4/88	Hayes & Griffith
New York, NY	2/7-9/88	Pfizer
Austin, TX	2/25-27/88	Dewar Symposium
Lake Ozark, MO	3/12-16/88	Higuchi Research Seminar
Lexington, KY	3/16-18/88	University of Kentucky

Curriculum Vitae--Presentations
Nicholas Bodor

CALIFORNIA:

Palo Alto	4/26/88	Syntex
Palo Alto	4/27/88	Alza
San Francisco	4/28/88	Genentech

Gainesville, FL	5/6/88	College of Pharmacy Dev. Adv. Board
-----------------	--------	--

ISRAEL:

Jerusalem	5/29-6/4/88	International Conference on Pharmaceutical Science, "Structure- Pharmacokinetic Relationships"
-----------	-------------	---

Philadelphia, PA	6/22/88	HGP, Inc.
------------------	---------	-----------

Newark, NJ	7/14/88	Johnson & Johnson
------------	---------	-------------------

HUNGARY:

Budapest	8/12-19/88	Xth International Symp. on Medicinal Chemistry
----------	------------	---

Debrecen	8/19-26/88	
----------	------------	--

JAPAN:

Tokyo	10/7-13/88	
-------	------------	--

Tokushima	10/14/88	
-----------	----------	--

INDIA:

Newark, NJ	10/24-25/88	Johnson & Johnson
------------	-------------	-------------------

Orlando, FL	10/30-11/3/88	AAPS
-------------	---------------	------

Curriculum Vitae--Presentations
Nicholas Bodor

Miami, FL	1/27/89	Schering-Plough Corporation
Lake Ozark, MO	3/12-15/89	22nd Higuchi Research Seminar
Anaheim, CA	4/8-11/89	APhA Annual Meeting
GREECE:		
Thessaloniki	5/11-16/89	Aristotelian University Postgraduate Seminar on Medicinal Chemistry
JAPAN:		
Osaka	5/29-5/30/89	Ono
Tokushima	5/31-6/1/89	Otsuka Pharmaceutical Co., Ltd.
Tokyo	6/2/89	Upjohn

INVITED LECTURES GIVEN BY NICHOLAS BODOR

July 1, 1989-Present

Location	Date	Conference or Institution	Title
HUNGARY:			
Budapest	8/12-19/89	Xth International Symposium on Medicinal Chemistry	
Budapest	8/21-25/89	The Role of Hungarians in the Scientific & Technological Progress of the World	"Recent Advances in the Design of Safer Drugs"
Bethesda, MD	9/14-15/89	APhA End-of-Summer Symposium	"Chemically Designed Targeted Drug Delivery System"
Morgantown, WV	9/20-21/89	Department of Chemistry Symposium	"Site-Specific Chemical Delivery Systems"
Atlanta, GA	10/22-26/89	American Association of Pharmaceutical Scientists	"Concepts in the Design of Safer Drugs"
Phoenix, AZ	11/3-7/89	Preuss Foundation Seminar	"Role of the BBB in the Therapy of Brain Tumors"
JAPAN:			
Kyoto	11/23/89	ONO Pharmaceutical Co., Ltd.	"Site-Specific Drug Delivery"
Osaka	11/24/89	Otsuka Pharmaceutical Co., Ltd.	"Soft Drugs"
Tokyo	11/27/89	Japan Tobacco Company	"Novel Strategies in Drug Design"
London, ENGLAND	12/1/89	IBC Conference on Recent Advances in Site-Specific Chemical Delivery Systems	"Role of Prodrugs and Soft Drugs in Drug Delivery and Targeting Systems"

Curriculum Vitae--Presentations
 Nicholas Bodor

Debrecen, HUNGARY	12/4/89	Medical University of Debrecen	"Redox Delivery Systems of Drugs to the Brain"
Maui, HI	12/11-15/89	American College of Neuro- psychopharmacology	"Clinical Utilization of Redox Drug Combinations"
Memphis, TN	2/12-14/90	College of Pharmacy University of Tennessee	"Novel Strategies to Design Safer Drugs"
Cleveland, OH	2/15-16/90	College of Pharmacy Case Western Reserve University	"Site-Specific Chemical Delivery Systems"
Reno, NV	2/25-28/90	AAPS Western Regional Meeting	"Brain-Specific Delivery of Peptides and Related
Palo Alto, CA	3/1/90	Syntex	"Novel Strategies in Drug Design and Delivery"
Lake Ozark, MO	3/10-14/90	Higuchi Research Seminar	"Delivery of Peptides to the Brain"
Bath, ENGLAND	3/31-4/8/90	The Biochemical Society	"Design Strategies for Safer Drugs"
Amsterdam, THE NETHER- LANDS	7/1-6/90	XIth International Congress of Pharmacology	"Drug Targeting by Site- Specific Chemical Drug Delivery Systems"
JAPAN:			
Tokyo	7/16-18/90	Fifth Japanese-American Con- ference on Pharmacokinetics and Biopharmaceutics	"Novel Site-Specific Chemical Drug Delivery Systems"
Kyoto	7/18-19/90	ONO Pharmaceutical Co.	"Brain Delivery of Peptides"

Curriculum Vitae--Presentations
Nicholas Bodor

Tokushima	7/22-23/90	Otsuka Pharmaceutical Co.	"Brain Delivery of Neuropeptides and Related Compounds"
Osaka	7/25-26/90	Fujisawa Pharmaceutical Co.	"Delivery of Peptides to the Brain"
Tokyo	7/26/90	Nihon Medi-Physics	"Technetium Chelates"
HUNGARY:			
Debrecen	8/22/90 Society	Hungarian Pharmaceutical	"Recent Advances in the Design of Safer Drugs"
Budapest	8/23/90	Federation of European Biochemical Societies Systems"	"Recent Advances in Site-Specific Chemical Delivery
Las Vegas, NV	11/4-8/90	AAPS Annual Meeting	"Pharmacological Evaluation of Alprenolone Oxime--A New Potential Antiglaucoma Agent"
Gainesville, FL	2/6/91	Division of Cardiovascular Medicine, UF College of Medicine	Roundtable discussion on: "A New Site-Specific Endovascular Drug Delivery Catheter System"
Charleston, SC	4/4/91	AAPS Regional Meeting	"Topical Drug Targeting by Chemical Delivery Systems and Soft Drugs"
JAPAN:			
Osaka	4/9/91	Takeda Chemical Industries, Inc.	"Recent Advances in Chemical-Enzymatic Targeting of Drugs"
Osaka	4/10/91	Otsuka Pharmaceutical Co., Ltd.	

Curriculum Vitae--Presentations

Nicholas Bodor

Osaka	4/11-12/91	ONO Minase Research Institute	
Tokyo	4/15/91	Eisai Tsukuba Research Laboratories	
Tokyo	4/16/91	Japan Tobacco Company	"Novel Soft Drugs"
KOREA:			
Suwon	4/18/91	Ajou University	"Design of Soft Drugs"
Suwon	4/19/91	Korean Drug Delivery Symposium	"Brain-Specific Drug Delivery"
Suwon	4/22/91	Korea Research Institute of Chemical Technology	"Design of Soft Drugs"
Dallas, TX	5/6/91	Alcon Laboratories, Inc.	"Enzymes in the Eye"
Gainesville, FL	5/10/91	Florida School on Applied Molecular Orbital Theory	"Molecular Orbitals and Drug Design"
Jamaica, NY	5/21/91	St. John's University College of Pharmacy and Health Related Professions	"Chemical-Enzymatic Drug Targeting"
San Diego, CA	6/6/91	Gensia Pharmaceutical Co.	"Metabolism-Based Drug Design"
La Jolla, CA	6/7/91	Agouron Pharmaceutical Co.	"Rational Design of Drugs Based on Metabolic Considerations"
Amsterdam, THE NETHERLANDS	7/8-13/91	Controlled Release Society Symposium	"Chemical Delivery Systems for Brain Targeting of Drugs"
Basel, SWITZERLAND	7/12/91	F. Hoffmann-La Roche AG	"Strategies to Design Safer Drugs"

Curriculum Vitae--Presentations
 Nicholas Bodor

Tampa, FL	7/24/91	Bausch & Lomb, Inc.	
Budapest, HUNGARY	8/17-22/91	33rd IUPAC Congress	"Drug Discovery by Retrometabolism-- Concepts and Applications"
East Bruns- wick, NJ	9/30-10/1/91	Technology Management Group Conference on "Pharmaceutical Markets in Imaging Agents and Related Products	"Targeted Chemicals for Imaging (Brain and Heart)"
Atlanta, GA	10/13-16/91	American College of Clinical Pharmacology Meeting	"Topical Drug Targeting by Chemical Delivery and Soft Drugs"
Gainesville, FL	10/30/91	College of Pharmacy Honors Seminar Course in Pharmaceutical Research	"Metabolism-Based Drug Design"
JAPAN:	11/23-30/91		
Kyoto	11/26-28/91	ONO Pharmaceuticals	
Itami	11/28/91	Senju Pharmaceutical Company	"Drug Design Based on Retrometabolism Concepts"
Osaka	11/29/91	Otsuka	
London, ENGLAND	12/6/91	IBC Conference--Drug Delivery III	"Drug Targeting by Chemical Delivery and Soft Drugs"
Gainesville, FL	1/22-24/92	Short Course on Surface Science in Pharmaceutical Technology	"Drug Targeting by Chemical Delivery and Soft Drugs"
King of Prussia, PA	2/8-12/92	CAChe Scientific Conference	"Chemistry by Design"
Baltimore, MD	3/26-27/92	Johns Hopkins Oncology Center	"Novel Methods of Drug Design"

Curriculum Vitae--Presentations
 Nicholas Bodor

JAPAN: 5/14-22/92

Tokushima	5/15/92	Otsuka Pharmaceutical Co.	"Recent Advances in Retrometabolic Drug Design"
Osaka	5/18/92	Japan Tobacco Company	
Itami	5/19/92	Senju Research Company	
Kyoto	5/20/92	ONO Pharmaceutical Company	

ISRAEL:

Jerusalem,	5/24-29/92	Second Jerusalem Conference on Pharmaceutical Sciences and Clinical Pharmacology	"Chemical-Enzymatic Approaches to Drug Targeting: Retrometabolism Concepts"
Rehovot	5/25/92	Pharmos, Ltd.	
Budapest,	6/1-4/92	Hungarian Academy of Sciences	"Recent Results in HUNGARY Retrometabolic Drug Design"
Tarrytown, NY	6/8-10/92	Conference on Topical Glucocorticoids with Increased Benefit/Risk Ratio	"Chemical Variability of Glucocorticoid Molecules: Application of the Soft Drug Concept to Topical Anti-inflammatory Agents"
Washington, DC	7/22-24/92	NIH/Drug Discovery Groups for Alzheimer's Disease	"Brain Targeting of Peptides"
Miami, FL	8/12/92	IVAX	"Novel Soft Drugs"
Madrid, SPAIN	9/10/92	12th World Computer Congress (Presentor: Dr. Alan Harget)	"Computer Aided Drug Design: A Neural Network Approach"
Washington, DC	9/15-17/92	American College of Clinical Pharmacology	"Development of New Corticosteroids"

Curriculum Vitae--Presentations

Nicholas Bodor

Gainesville, FL	9/18,21, 23/92	Frontiers of Human Knowledge (University-Wide Honors Course)	"Drug Design and Discovery Based on Retrometabolism Concepts"
Leiden, THE NETHER- LANDS	10/9-11/92	Symposium on Drug Transport to the Brain: Concepts and Strategies	"The Application of Chemical Delivery Systems for Brain Targeting of Drugs"
Rehovot, ISRAEL	10/13-14/92	Pharmos Corporation	"Phosphate and Phosphonate Delivery Systems"
Gainesville, FL	10/26, 28/92	Faculty Honors Course University of Florida	"In Search of Magic Bullets"
San Antonio, TX	11/15-19/92	AAPS	"Brain Targeting of Peptides"
Fort Worth, TX	11/19-20/92	Alcon	"Chemical Delivery Systems for the Eye"
Chicago, IL	12/1/92	Helene Curtis, Inc	"Novel Soft Anticholinergic Compounds"
Miami, FL	2/20-22/93	IVAX	"Soft Drugs for the Treatment of Asthma"
Raleigh,	2/24/93	Cato Research, Ltd. Treatment of Colitis"	"Soft Steroids for the NC
Amelia Island, FL	3/5-8/93	Pharmos	"Soft Ophthalmic Drugs"
Garden City, NY	4/20-21/93	35th Annual Pharmacy Congress	"Application of Retrometabolic Approaches for Design of Novel Ophthalmic Drugs"
Washington,	6/5-8/93	Patent Office System"	"Novel Anionic Delivery DC

Curriculum Vitae--Presentations
Nicholas Bodor

Edmonton, Alberta, CANADA	6/20-25/93	13th American Peptide Symposium	"Delivery of Peptides into the Central Nervous System by Sequential Metabolism"
Szeged, HUNGARY	7/23-24/93	International Workshop on Molecular Mechanism Regulating the Permeability of the Blood-Brain Barrier	"Strategies for Opening the Gateway to the Brain"
Rockville, MD	7/28-29/93	NIDA Technical Review Meeting on Opiate Pharmacotherapy	"Targeting Drugs to the Brain by Sequential Metabolism"
Bethesda, MD	8/6/93	NIH Drug Discovery Group Meeting	"Discovery of Novel Drugs for Alzheimer's Disease: Project 3--Neuropeptides"
Novi, MI	8/8-10/93	Symposium on Ocular Pharmacology	"The Application of Soft Drug Concepts to the Design of Ophthalmic Drugs"
Chicago,	8/22-27/93	206th ACS National Meeting	"Brain Targeting of Peptides II via Sequential Metabolism"
JAPAN:			
Kyoto	9/2-4/93	International Symposium on Delivery of Protein Drugs - The Next 10 Years	"Peptide Delivery to the Brain by Sequential Metabolism"
Kobe	9/6/93	Senju Pharmaceuticals	
Tokyo	9/7/93	Japan Tobacco Company	
Tsukuba	9/10/93	Upjohn Pharmaceuticals Ltd.	"Soft Drugs Concept"
Bethesda, MD	9/28-29/93	NIDA Technical Review Meeting on Membranes and Barriers: Targeted Drug Delivery	"Retrometabolic Approaches to Drug Targeting"

Curriculum Vitae--Presentations
Nicholas Bodor

Gainesville, FL	10/22, 25, 27/93	Frontiers of Human Knowledge University of Florida	"Drug Design and Discovery Based on Retrometabolism Concepts"
London, ENGLAND	11/22-24/93	IBC Drug Delivery 4	"Site-Specific Drugs by Chemical Trransformations"
Washington,	12/2-3/93	IBC Allergic Disease and Asthma	"Soft Drugs: A DC Retrometabolic Drug Design Concept"
JAPAN:			
Tokyo	4/23/94	Hoshi University Lecture Meeting on Comprehensive Cyclodextrins	"Recent Studies on Cyclo- dextrins and Their Use in Drug Delivery and Targeting"
Tokyo	4/25-28/94	7th International Cyclodextrins Symposium	"Optimization of Drug Targeting by Combinations of Chemical Delivery Systems and Cyclodextrins"
Edmonton, Alberta, CANADA	6/20-25/93	13th American Peptide Symposium	"Delivery of Peptides into the Central Nervous System by Sequential Metabolism"
Rockville, MD	7/28-29/93	NIDA Technical Review Meeting on Opiate Pharmacotherapy	"Targeting Drugs to the Brain by Sequential Metabolism"
Chicago,	8/22-27/93	206th ACS National Meeting	"Brain Targeting of Peptides IL via Sequential Metabolism"
Kyoto, JAPAN	9/2-4/93	International Symposium on Delivery of Protein Drugs - The Next 10 Years	"Peptide Delivery to the Brain by Sequential Metabolism"
Rockville,	9/28-29/93	NIDA Technical Review Meeting on Membranes and Barriers: Targeted Drug Delivery	"Retrometabolic Design MD Approaches to Drug Targeting"

Curriculum Vitae--Presentations
 Nicholas Bodor

Tokyo, JAPAN	4/25-28/94	7th International Cyclodextrins Symposium	"Optimization of Drug Targeting by Combinations of Chemical Delivery Systems and Cyclodextrins"
Washington, DC	8/21-25/94	208th Am. Chem. Soc. National Meeting	"Design of Biologically Safer Chemicals Based on Retrometabolic Concepts"
Buenos Aires, ARGENTINA	11/14-19/94	XV Panamerican Congress of Pharmacy and Biochemistry	"Retrometabolic Drug Design Concepts"
HUNGARY:	12/7-13/94	National Academy	"Retrometabolic Drug Design Concepts"
		Technical University	"Computer-Assisted Drug Design"
		Gedeon Richter Works	"Soft Steroids"
Debrecen		Medical University	"Novel Safe Ophthalmic Drugs"
New Orleans, LA	1/26-29/95	AOPT Annual Meeting	"Sequential Bioactivation of Methoxime Analogs of β -Adrenergic Antagonists in the Eye"
Anaheim,	4/2-7/95	209th Am. Chem. Soc. National Meeting	"Optimization of Drug CA Targeting by Cyclodextrins"
Amelia Island, FL	4/10-13/95	3rd Suncoast Workshop on the Neurobiology of Aging	"The Application of the Molecular Packaging Method to Brain Targeting of TRH Analogs"
San Diego, CA	4/28-30/95	Houghten Pharmaceutical Co.	

Curriculum Vitae--Presentations
Nicholas Bodor

Birmingham, AL	5/5/95	U. of Alabama Vision Research Ctr. Visiting Scholar Program	"Retrometabolic Approaches for the Design of Novel Ophthalmic Drugs"
Thessaloniki, GREECE	5/19-20/95	4th Conference in Advanced Medicinal Chemistry	"Retrometabolic Drug Design Concepts in Drug Targeting"
Hiroshima, JAPAN	7/6-7/95	11th Annual Meeting of Japan Drug Delivery Systems Society Eye"	"Drug Targeting by Chemical and Enzymatic Retrometabolic Approaches to the Brain and Eye"
Heidelberg, GERMANY	7/17/95	BioResearch, BASF Pharma/ Knoll Pharmaceuticals	"Chemical-Enzymatic Targeting of Drugs"
JAPAN:			
Tokyo	9/1-10/31/95	Hoshi University Visiting Professorship	Several Lectures on Drug Design
Tokyo	9/3-8/95	AFMC International Medicinal Chemistry Sym- posium, Plenary Session	"Targeted Drug Delivery to to the Brain Using Chemical Delivery Systems"
Kobe	9/11-13/95	Academy of Pharmaceutical Science and Technology, Plenary Session	"Computer-Assisted Design of Targeted Drugs Based on Retrometabolic Concepts"
Osaka	9/14/95	Fujisawa Pharmaceutical Co., Ltd.	"Optimal Combination of Chemical-Enzymatic and Physical Drug Targeting Approaches"
Osaka	9/20/95	Ono Pharmaceutical Co., Ltd.	"Retrometabolic Drug Design Approaches and Computer Assisted Design of New Drugs on Retrometabolic Concepts"
Osaka	9/22/95	Takeda Chemical Industries, Ltd.	"Retrometabolic Drug Design Approaches"

Curriculum Vitae--Presentations
Nicholas Bodor

SWITZERLAND:

Geneva	9/28-10/01/95	International Symposium on Experimental and Clinical Ocular Pharmacology and Pharmaceutics, Plenary Session	"Retrometabolic Design Concepts in Ophthalmic Drug Discovery"
Milan, ITALY	10/02/95	BioResearch, BASF Pharma/ Knoll Pharmaceutical Co.	"Brain Targeting of Drugs"
SINGAPORE	10/06/95	The National University of Singapore	"Design and Development of Soft Drugs"
Ako, JAPAN	10/12/95	Ostuka Pharmaceutical Co., Ltd.	"Design of Safer Ophthalmic Drugs"
Gainesville, FL	11/01/95	Frontiers Of Science	"Designing Targeted Drugs for the Brain and Eye"
Budapest, HUNGARY	11/14/95	Induction into the Hungarian Academy of Sciences, Plenary Session	"The Chemical and Enzymatic Basis of the Retrometabolic Drug Design Approaches"
Ann Arbor, MI	12/04-05/95	Parke-Davis	"Retrometabolic Drug Design Design Approaches"
Frankfurt, GERMANY	02/09/96	Drug Targeting Symposium, German Chemical Society	"Drug Targeting Based on Retrometabolic Drug Design Approaches"
Budapest, HUNGARY	02/05/96	Gedeon Richter, Ltd.	"Brain Targeting Chemical Works of Gedeon Richter, Ltd."
Budapest, HUNGARY	04/01/96	8th International Cyclodextrin Symposium	"Recent Studies on the Use and Structure of Cyclodextrin Complexes"
Gainesville, FL	04/19/96	Department of Neuroscience University of Florida	"Retrometabolic Approaches to Drug Design and Targeting"

Curriculum Vitae--Presentations
 Nicholas Bodor

SINGAPORE	07/04/96	The National University of Singapore	"Recent Advances In Retrometabolic Drug Design"
Osaka, JAPAN	07/09/96	Senju Pharmaceutical Co.	"Novel Antiglaucoma Drugs"
New York, NY	08/28/96	Forest Laboratories	"Soft Drugs"
Budapest, HUNGARY	09/05-12/96	Institute for Drug Research	"Issues in Drug Development"
Seattle, WA	10/27-31/96	American Association of Pharmaceutical Scientists Annual Meeting & Exposition	"Drug Targeting Based On Retrometabolic Drug Design Approaches"
Gainesville, FL	11/18-20/96	Pharmacy Honors Seminar, "In Search of Magic Bullets"	"Retrometabolism-Based Drug Design"
Ispra, ITALY	01/20-22/97	"Data Management in Computer-Aided Drug Design" Workshop Joint Research Centre	"Computer-Assisted Design of New Drugs Based on Retrometabolic Concepts"
Brussels, BELGIUM	01/23-25/97	Janssen Pharmaceutica	"The Application of Chemical Delivery Systems For Brain Targeting of Drugs"
Gainesville, FL	03/20/97	Univ. of FL Coll of Pharmacy Nat'l. Devel. Advisory Board	"Issues in Drug Discovery and Targeting"
Austin, TX	04/03/97	University of Texas at Austin College of Pharmacy	"Design of Safer Drugs Using Retrometabolic Approaches"
San Francisco, CA	04/13-17/97	National Meeting of the Amer. Chemical Society	"Design of Biologically Safer Chemicals"
Amelia Island, FL	05/06-09/97	"1st Drug Optimization via Retrometabolism Conference" Center for Drug Discovery, University of Florida	"Retrometabolic Drug Design Concepts"

Curriculum Vitae--Presentations
 Nicholas Bodor

St. Petersburg, FL	05/23-24/97	Glaxo Dermatology Advisory Board Meeting	"Overview of the Soft Molecule Concept"
Raleigh, NC	06/17/97	Glaxo Wellcome, Inc.	"Retrometabolic Drug Design Approaches"
Gdansk, POLAND	07/09-12/97	6th Int'l Symp. on Molecular Aspects of Chemotherapy	"Retrometabolic Approaches for Drug Targeting"
Budapest, HUNGARY	9/04/97	Chemical Works of Gedeon Richter	"Design of Soft Drugs"
Frankfurt, GERMANY	9/08/97	ASTA Medica	"Design of Soft Drugs"
Munich, GERMANY	9/11-14/97	2nd Int'l Symp. on Exp. and Clin. Ocular Pharmacol. and Pharmaceutics	"Targeted Drug Delivery to Retina via Systemic Routes"
Chicago, IL	9/27-30/97	Abbott Laboratories, Acceptance of Volwiler Research Achievement Award	"Retrometabolic Drug Design and Targeting Concepts"
Bethesda, MD	10/22-24/97	3rd Annual Mtg. of the Asn. for Ocular Pharmacol. and Ther.	"Targeted Drug Delivery to Retina via Systemic Routes"
Arlington, VA	10/27-28/97	IBC's 7th Annual Conf. on Asthma & Allergy	"Design of Soft Corticosteroids"
Budapest, HUNGARY	11/11/97	Institute for Drug Research	"Drug Development Concepts"
Gainesville, FL	11/17 & 11/19/97	Honors Seminar in Pharm. Research, College of Pharmacy, University of Florida	"Retrometabolism-Based Drug Design: Making MBs Better and Safer"
Osaka, JAPAN	01/14/98	Santen Pharmaceutical Co., Ltd.	"Design of Safer Ophthalmic Drugs by Retrometabolic Approaches"

Curriculum Vitae--Presentations
Nicholas Bodor

Hiroshima, JAPAN	01/16/98	Hiroshima University School of Medicine	"Design of Safer Ophthalmic Drugs Using Retrometabolic Approaches"
Gainesville, FL	01/27/98	University of Florida Dep't. of Neuroscience	"Brain Targeting of Neuro- pharmaceuticals by Chemical Delivery Systems"
Miami, FL	03/02/98	IVAX Corporation	"Retrometabolic Drug Design and Targeting Approaches"
Saskatchewan, CANADA	03/26 & 03/27/98	University of Saskatchewan College of Pharmacy	"Retrometabolic Approaches for Drug Design & Targeting"
Budapest, HUNGARY	4/07-11/98	Institute for Drug Research	"The Past and Future of Drug Discovery Research"
Budapest, HUNGARY	5/06/98	Institute for Drug Research	"Recent Advances In Retrometabolic Drug Design"
Paris, FRANCE	5/25-28/98	2nd World Meeting on Pharmaceutics, Biopharm. and Pharm. Tech.; Inv. Speaker and Session Chair	"Brain Targeting of Basic Amino Acids and Their Redox Analogs Containing Peptides"
Santiago de Compostela, SPAIN	5/31-6/03/98	9th Intl. Symposium on Cyclodextrins; Inv. Speaker and Session Chair	"The Effect of 2- Hydroxypropyl- β Cyclodextrin on the Solubility, Stability and Brain Targeting of Chemical Delivery Systems for Neuropeptides"
Tokyo, JAPAN	6/09-11/98	Challenges for Drug Delivery and Pharmaceutical Technology; Inv. Speaker and Session Chair	"Retrometabolic Drug Design Approaches"
Budapest, HUNGARY	7/16-20/98	Institute for Drug Research, Ltd.	"Neuropeptide Targeting to the Brain"
Reykjavik, ICELAND	7/28-8/3/98	University of Iceland	"Soft Drug Approach in Drug Design"

Curriculum Vitae--Presentations
 Nicholas Bodor

Debrecen, HUNGARY	10/19-23/98	Medical Univ. of Debrecen; Scientific Symposium to Celebrate 80 th Anniversary	"Retrometabolic Concepts for the Design of Safer Drugs"
Gainesville, FL	10/28/98	Honors Seminar in Pharm. Research, College of Pharmacy University of Florida	"Retrometabolism-Based Drug Design: Making MBs Better and Safer"
Budapest, HUNGARY	1/04-31/99	Institute for Drug Research & the Hungarian Academy of Sciences	"Computer Drug Design" & "Computer Assisted Design of Soft Drugs"
Budapest, HUNGARY	3/23-4/02/99	Institute for Drug Research & the Technical University Of Budapest	"Retrometabolism-Based "Drug Design" & "Graduate Education at the University of Florida"
Dresden, GERMANY	4/18-20/99	Technical University of Dresden Invited Speaker	"Chemical Approaches in the Design of Targeted Drugs"
Jerusalem, ISRAEL	4/25-30/99	7 th Euro. Congress of Biopharmaceutics & Pharmacokinetics and 5 th Congress of the Euro. Fed. Of Pharmaceutical Sciences Invited Speaker & Session Co-Chair	"Drug Targeting Using Retrometabolic Approaches"
Amelia Island, FLORIDA	5/11-14/99	2 nd Retrometabolism Based Drug Design and Targeting Conference Founder and Organizer	"Recent Advances in Retrometabolic Drug Design"
Monroe, LOUISIANA	5/20-21/99	AAPS-SRDG 2 nd Annual Meeting Keynote Address	"Drug Targeting Using Retrometabolic Approaches"

Curriculum Vitae--Presentations
 Nicholas Bodor

Groton, CONNECTICUT	5/24/99	Pfizer Central Research Invited Lecturer	"Retrometabolic Drug Design and Targeting" & "Computational Approaches to Retrometabolic Drug Design and Targeting"
New Brunswick, NEW JERSEY	6/2/99	Bristol-Myers Squibb Invited Lecturer	"Computer-Assisted Design of New Drugs Based on Retrometabolic Concepts" & "Recent Advances in Retrometabolic Design Approaches"
Beerse, BELGIUM	9/2-7/99	Janssen Pharmaceuticals Invited Lecturer	"Computational Approaches to Retrometabolic Drug Design And Targeting"
Tampa, FLORIDA	9/21/99	Bausch and Lomb Pharmaceuticals Invited Lecturer	"Novel Soft Steroids for Ophthalmic Use"
Budapest, HUNGARY	9/23-30/99	Institute for Drug Research Invited Lecturer	"Computer Assisted Soft Drug Design"
Gainesville, FLORIDA	10/25 & 27/99	Honors Seminar in Pharm. Research, College of Pharmacy University of Florida	"Retrometabolic Design"
New Orleans, LOUISIANA	11/14-18/99	AAPS Annual Meeting and Exposition Invited Lecturer	"Retrometabolic Approaches for Drug Design and Targeting"
Lisbon, PORTUGAL	2/10-13/00	3 rd Intl. Symposium on Ocular Pharmacology & Pharmaceutics (ISOPP); Invited Lecturer	"The Creation of a Site Active (Soft) Steroid."
London, ENGLAND	2/18/00	Norton Healthcare	"Design of a New Class of Soft Steroids"
Cincinnati, OHIO	4/28/00	Procter & Gamble Pharmaceuticals	"Brain Targeting of Neuropeptides"

Curriculum Vitae--Presentations
Nicholas Bodor

Paris, 7/07/00 FRANCE	27 th Intl. Symp. On Controlled Release of Bioactive Materials	“Cyclodextrins and Brain Delivery”
Philadelphia, 8/29/00 PENNSYLVANIA	Rohm and Haas Co.	“Retrometabolic Drug Design and Targeting”
Gainesville, 10/23 & 25/00 FLORIDA	Honors Seminar, In Search of Magic Bullets”, Coll. of Pharmacy University of Florida	"Retrometabolic Design"
Indianapolis, 11/01/00 INDIANA	AAPS Annual Meeting and Exposition	“Retrometabolic Appr. to Design of Ophth. Drugs”
Budapest, 11/13-16/00 HUNGARY	Semmelweiss Univ. of Medicine	“The Högyes Lecture”
Osaka, 11/22/00 JAPAN	Takeda Chemical Industries, Ltd.	“Recent Results in Retrometabolic Drug Design”
Atlanta, 2/08/01 Georgia	IBC 9 th Annual Conf. On Alzheimer’s	“Brain-Targeting of Drugs and Neuropeptides”
Tempe, 3/31/01 ARIZONA	Muro Asta Medica Investigator Meeting on LE Nasal Spray	“Design of Loteprednol A Soft Corticosterid”
Basel, 3/28/01 SWITZERLAND	Roche Pharm., Ltd. and Novartis Pharma (two presentations)	“Design of Retrometabolism-Based and Specific Receptor Oriented Drugs”
Hawthorne, 4/17/01 NEW YORK	Taro Pharmaceuticals USA, Inc.	“Design of Loteprednol Etabonate, A Novel Soft Steroid”
Amelia Island, 5/14/01 FLORIDA	3 rd Retrometabolism Based Drug Design and Targeting Conf.	“Design of a New Class of Soft Corticosteroids”
Stockholm, 5/31/01 SWEDEN	Stockholm University	“Recent Advances in Retrometabolic Drug Design

Curriculum Vitae--Presentations
Nicholas Bodor

		and Targeting Approaches”
San Francisco, 10/25-28/01 CALIFORNIA	Foundation Fighting Blindness Meeting, “Drug Delivery: Focusing on the Posterior Segment of the Eye”	“Design of Novel Ophthalmic Drugs Using Retrometabolic Principles”
Gainesville, 11/05 & 07/01 FLORIDA	Honors Seminar in Pharm. Research, College of Pharmacy University of Florida	“Retrometabolic Design --- Magic Bullets”
Budapest, 2/13/02 HUNGARY	Institute for Drug Research Scientific Retreat	“Retrometabolic Drug Design”
Ventura, 2/24-3/01 CALIFORNIA	Drug Carriers in Medicine & Biology (Gordon Res. Conf.)	“Brain Drug Delivery via Redox Carriers”
Gainesville, 3/06-08/02 FLORIDA	3 rd Annual Florida Heterocyclic Conference	“The Use of Dihydropyridine Pyridinium Salt Redox System for Development of Brain-Specific Drugs”
Taormina, 4/07-11/02 SICILY	6 th Eilat Conference on New Antiepileptic Drugs	“Talampanel”
Reykjavik, 5/05-08/02 ICELAND	11 th International Cyclodextrin Symposium	“Theoretical Insights into the Formation, Structure, and Energetics of Some Cyclodextrin Complexes”
Gainesville, 10/30 & 11/01/02 FLORIDA	Honors Seminar in Pharm. Research, College of Pharmacy University of Florida	“Retrometabolic Design”
Budapest, 2/20/03 HUNGARY	Institute for Drug Research Annual Scientific Meeting	“Drug Design and Discovery”
Palm Coast, 5/11-14/03 FLORIDA	4 th Retrometabolism Based Drug Design and Targeting Conference	“Soft Corticosteroids: Design Considerations and Recent Advances”

Curriculum Vitae--Presentations
Nicholas Bodor

Tokyo, 2/05-06/04 JAPAN	Metabolism & Membrane Transport in Drug Discovery and Devel. Conf. (MMT3D)	“Retrometabolic Approaches in Drug Design and Targeting”
Osaka, 2/09/04 JAPAN	Takeda Chemical Ind., Ltd. (three lectures)	“Computer Assisted Drug Design” “Novel Approaches to Treat Sepsis” “Use of AMPA Antagonists For Treatment of Neurological Diseases”
Budapest, 2/18/04 HUNGARY	Institute for Drug Research Annual Scientific Meeting (two lectures)	“Design of Novel Soft Steroids” “Recent Advances in Talampanel”
Sardinia, 5/08-13/04 ITALY	Eilat VII Conference on New Antiepileptic Drugs	“Talampanel”
Budapest, 5/17-19/04 HUNGARY	Hungarian Biochemical Society Meeting	“Retrometabolic Drug Design, CDS and Soft Drugs”
Honolulu, 6/12-17/04 HAWAII	Controlled Release Society 31 st Annual Meeting	“Drug Targeting to the Brain by Chemical-Enzymatic Approaches”
Baltimore, 11/07-11/04 MARYLAND	2004 AAPS Annual Meeting	“Insights for Drug Design Based on Metabolic Activity Of the Eye – Soft Drugs and Chemical Delivery Systems”
Budapest, 2/17/05 HUNGARY	Institute for Drug Research Annual Scientific Meeting	“Recent Advances in Soft Drug Design”
Hakone, 5/08-11/05 JAPAN	5 th Retrometabolism Based Drug Design and Targeting Conference	“Overview of and Recent Advances in Retrometabolic Drug Delivery”

Curriculum Vitae--Presentations
Nicholas Bodor

Budapest, 6/21-23/05 HUNGARY	Institute for Drug Research Talampanel Investigator's Meeting	"History of Talampanel – Pre-Clinical & Toxicology
Siófok, 9/26-28/05 HUNGARY	1 st BBBB Conference on Pharmaceutical Sciences	"Etiprednol Dicloacetate: Design and Development of a New Soft Steroid"
Sarasota, 10/23-26/05 FLORIDA	37th Annual Meeting of the Hungarian Medical Assn. Of America	"Antiinflammatory Soft Glucocorticoids. The Design and Development of Two Generations of New, Safer Drugs"
Nashville, 11/05-10/05 TENNESEE	2005 AAPS Annual Meeting and Exposition	"Can Peptides Ever Become Drugs? – Targeted Delivery Of Peptides"
Biberach, 5/02/06 GERMANY	Boehringer Ingelheim Research Institute	"Soft Steroids in Asthma and COPD"
Reykjavík, 9/05/06 ICELAND	University of Iceland	"Design and Activity of Two Classes of Soft Steroids"
San Antonio, 10/29-11/03/06 TEXAS	2006 AAPS Annual Meeting and Exposition Symposium	"Retrometabolic Drug Design as Drugability Strategy: The Design and Development of Two Generations of New, Safer Drugs"
San Antonio, 10/29-11/03/06 TEXAS	2006 AAPS Annual Meeting and Exposition "Targeted Prodrug Design" Session	"Targeted Drug Delivery by Sequential Metabolism"
Göd, 6/04/07 HUNGARY	6 th Retrometabolism Based Drug Design and Targeting Conference	"Transporter Enhanced Soft Corticosteroid Activity"

Curriculum Vitae--Presentations
Nicholas Bodor

Munich, 6/09/07 GERMANY		6 th Global Gator Meeting “Safe Targeted Drugs by Retrometabolic Design: Soft Drugs and Chemical Delivery Systems”
Torino, 8/5-10/07 ITALY	41 st IUPAC Congress	“Recent developments in Retrometabolic Drug Design And Targeting Strategies”
San Diego, 11/10-15/07 CALIFORNIA	2007 AAPS Annual Meeting and Exposition Distinguished Pharmaceutical Scientist Award Special Lecture	“Retrometabolic Drug Design and Targeting Strategies: Chemical Delivery Systems (CDS)”
Orlando, 4/24-26/08 FLORIDA	Keynote Lectures for Bausch & Lomb Symp. Honoring the 10 th Anniversary of Loteprednol Etabonate	“Retrometabolic Drug Design” and “Discovery and Development of LE”
Nutley, 4/22/09 NEW JERSEY	Lecture to scientists of Hoffman-La Roche, Inc.	“Retrometabolic Drug Design”
Orlando, 5/10-13/09 FLORIDA	7 th Retrometabolism Based Drug Design and Targeting Conference	“Recent Advances in Retrometabolic Drug Design (RMDD) and Development”
Primosten, 9/08-11/10 CROATIA	5 th Central European Conf. Chemistry Towards Biology	“Retrometabolic Design: Soft Drugs and Chemical Delivery Systems”
Cambridge, 3/08/11 MASSACHUSETTS	Novartis Institutes for Biomedical Research	“Drug Targeting by Chemical- Enzymatic Delivery Systems”
Sopron, 05/22-25/11 HUNGARY	Hungarian Chemical Society National Conference Plenary Lecture and recipient of Fabinyi Prize	“From Remote Substituent Effects to Retrometabolic Drug Design – 50 Years of Research in Chemistry”

Curriculum Vitae--Presentations
Nicholas Bodor

Graz, 6/02/11
GERMANY

8th Retrometabolism Based
Drug Design and Targeting
Conference

“Recent Advances in
Retrometabolic Design
Concepts”

Tokyo, 01/16-18/12
JAPAN

International Symposium on
Past, Present and Future of
Molecular Pharmacokinetics”

“Transporters in
Retrometabolic Drug Design”

Orlando, 5/12-15/13
FLORIDA

9th Retrometabolism Based
Drug Design and Targeting
Conference

“Recent Advances in
Retrometabolic Drug Design
(RMDD) and Targeting”

NICHOLAS BODOR - PUBLICATIONS

1. N. Bodor, L. Fey, M. Kircz and F. Hodosan, "On Direct Iodination of the 20-Oxopregnanes," *Rev. Roumaine Chim.*, **9**, 147 (1964) (in English).
2. N. Bodor, "Isonitrosation of the Substituted Nitroalkylbenzenes. Application of the Hammet-Taft Equation," Chemistry Thesis, Babes-Bolyai University, Cluj, Romania (1965).
3. N. Bodor and A. Kovendi, "Structure and Reactivity in the Substituted Nitrobenzene Series. I. Kinetics and Mechanism of the Isonitrosation of Nitroalkylbenzenes in Alkaline Solution," *Rev. Roumaine Chim.*, **11**, 393 (1966) (in English).
4. N. Bodor, L. Fey and A. Kovendi, "Structure and Reactivity in the Substituted Nitrobenzene Series. II. The Effects of the Structure of Aliphatic Side-Chain on the Isonitrosation of the Nitroalkylbenzenes and on the Properties of the Corresponding Oximes Resulted from This Reaction," *Rev. Roumaine Chim.*, **11**, 405 (1966) (in English).
5. N. Bodor and A. Kovendi, "Structure and Reactivity in the Substituted Nitrobenzene Series. III. The Effect of p-Substituents on the Isonitrosation of the o-Nitroethylbenzene," *Rev. Roumaine Chim.*, **11**, 413 (1966) (in English).
6. N. Bodor, L. Fey and A. Kovendi, "Structure and Reactivity in the Substituted Nitrobenzene Series. IV. The Effect of p-Substituents on the Dissociation and Polarographic Reduction of the o-Nitroacetophenonoxime," *Rev. Roumaine Chim.*, **11**, 421 (1966) (in English).
7. N. Bodor, "Remote Effects in the Steroid Reactions," *Rev. Chimie (Bucharest)*, **19**(9), (1968) (in Romanian).
8. N. Bodor, "Remote Effects. I. On the Nature of the Effects of Remote Substituents," *Rev. Roumaine Chim.*, **13**, 555 (1968) (in English).
9. N. Bodor and O. Mantsch, "Remote Effects. II. Substituent Effects in Epoxidation of the Steroidic C-4,5 Double Bond " *Rev. Roumaine Chim.*, **13**, 1153 (1968) (in English).
10. N. Bodor, L. Fey and A. Kovendi, "Structure and Reactivity in the Substituted Nitrobenzene Series. V. The Effects of o-Substituents on the Dissociation and Polarographic Reduction of the p-Nitroacetophenonoxime," *Rev. Chimie (Bucharest)*, **19**, 552 (1968) (in Romanian).
11. O. Mantsch, N. Bodor and F. Hodosan, "Kinetische Untersuchungen am System Essigsäurehydrid-Salpetersäure-Essigsäure-Acetylnitrat," *Rev. Roumaine Chim.*, **13**, 1435 (1968) (in German).

12. N. Bodor and M. Dewar, "Ground States of Alpha-Bonded Molecules. VIII: MINDO Calculation for Species Involved in Nitration by Acetylnitrate," *Tetrahedron*, **25**(24), 5777-5784 (1969).
13. L. Fey and N. Bodor, "Electronic Spectra of the Substituted α -Oximinoalkylbenzenes. I. Steric Effects on Electronic Absorption Spectra of the Substituted o-Nitro- α -Oximinoalkylbenzenes," *Rev. Roumaine Chim.*, **14**, 225 (1969) (in English).
14. L. Fey and N. Bodor, "Electronic Spectra of the Substituted Alpha-Oximinoalkylbenzenes. II. MO-Calculations of the Bathochromic Shifts Produced by the Dissociation of Benzaldoxime and p-Nitrobenzaldoxime," *Rev. Roumaine Chim.*, **14**, 319 (1969) (in English).
15. L. Fey and N. Bodor, "Electronic Spectra of the Substituted α -Oximinoalkylbenzenes. III. Steric Effects on Electronic Spectra of the o-Substituted p-Nitro- α -Oximinoalkylbenzenes," *Rev. Roumaine Chim.*, **14**, 481 (1969) (in English).
16. O. Mantsch and N. Bodor, "Kinetik und Mechanismus der Veresterungsreaktion von Steroidalkoholen mit Acetylnitrat," *Rev. Roumaine Chim.*, **14**, 1295 (1969) (in German).
17. N. Bodor, M. Dewar and A. Harget, "Ground States of Conjugated Molecules. XIX. Tautomerism of Heteroaromatic Hydroxy and Amino Derivatives and Nucleotide Bases," *J. Amer. Chem. Soc.*, **92**, 2929 (1970).
18. N. Bodor, M. Dewar, A. Harget and E. Haselbach, "Ground States of Alpha-Bonded Molecules. X. Extension of the MINDO/2 Method to Compounds Containing Nitrogen and/or Oxygen," *J. Amer. Chem. Soc.*, **92**, 3854-3859 (1970).
19. N. Bodor and M. Dewar, "Ground States of α -Bonded Molecules. XI. Conformation Analyses by MINDO/2 Method," *J. Amer. Chem. Soc.*, **92**, 4270-4274 (1970).
20. N. Bodor, M. Dewar and S. Worley, "Photoelectron Spectra of Molecules. III. Ionization Potentials of Some Cyclic Hydrocarbons and Their Derivatives, and Heats of Formation and Ionization Potentials Calculated by the MINDO SCF Method," *J. Amer. Chem. Soc.*, **92**, 19-24 (1970).
21. N. Bodor, M. Dewar, W. Jennings and S. Worley, "Photoelectron Spectra of Molecules. IV. Ionization Potentials and Heats of Formation of Some Hydrazines and Amines," *Tetrahedron*, **26**, 4109-4113 (1970).
22. N. Bodor and N. Trinajstic, "Valence-Shell MO-Calculations for Formamide and Related Compounds," *Rev. Roumaine Chim.*, **15**, 1807 (1970) (in English).

23. N. Bodor and M. Dewar, "Protonation of Cyclopropane" *J. Amer. Chem. Soc.*, **93**, 6685-6686 (1971).
24. N. Bodor, M. Farkas and N. Trinajstic, "SCF MO Calculations for 1,3-Thiazole and 2-Phenyl-1, 3-Thiazole and Rotational Barriers in 2-Phenyl-1, 3-Thiazole and Its Protonated Form," *Croat. Chem. Acta*, **43**, 107-111 (1971) (in English).
25. N. Bodor, E. Pop and N. Trinajstic, "Valence Shell and I-Electron SCF MO Calculations for the Isomerism of 21-Benzylidene 20-Oxopregnane Derivatives," *Rev. Roumaine Chim.*, **16**(9), 1427-1433 (1971) (in English).
26. N. Bodor, I. Schwartz and N. Trinajstic, "SCF MO Study of the Tautomerism of Anilinothiazole and Related Compounds," *Zeitschrift fur Naturforschung*, **26b**, 400-402 (1971) (in English).
27. N. Bodor, M. Dewar and D. Lo, "Ground States of Sigma-Bonded Molecules. XVIII. An Improved Version of MINDO/2 and Its Application to Carbonium Ions and Protonated Cyclopropanes," *J. Amer. Chem. Soc.*, **94**, 5303-5310 (1972).
28. N. Bodor, M. Dewar and J. Wasson, "Ground States of Molecules. XIX. Carbenes and Its Reactions," *J. Amer. Chem. Soc.*, **94**, 9095-9102 (1972).
29. N. Bodor and M. Dewar, "Ground States of Molecules. XX. MINDO/2 Study of Some Carbenes and Their Intramolecular Rearrangements," *J. Amer. Chem. Soc.*, **94**, 9103-9106 (1972).
30. N. Bodor, M. Dewar and Z. Maksic, "Ground States of Molecules. XXIV. MINDO/2 Study of Some Reactions of Cyclopropylidene," *J. Amer. Chem. Soc.*, **95**, 5245-5249 (1973).
31. N. Bodor, B. Chen and S. Worley, "Photoelectron Spectra and SCF MO Calculations for the Dimers of Cyclobutadiene," *J. Elect. Spect. Rel. Phen.*, **4**, 65-71 (1974).
32. N. Bodor, J. Kaminski, S. Worley, R. Colton, T. Lee and J. Rabalais, "Photoelectron Spectra, Hydrolytic Stability, and Antimicrobial Activity of N-Chlorinated Piperidines," *J. Pharm. Sci.*, **63**, 1387-1391 (1974).
33. N. Bodor, E. Shek and T. Higuchi, "Delivery of a Quaternary Pyridinium Salt Across the Blood-Brain Barrier by Its Dihydropyridine Derivative," *Science*, **190**, 155-156 (1975).
34. A. Repta, B. Rawson, R. Shaffer, K. Sloan, N. Bodor and T. Higuchi, "Rational Development of a Soluble Prodrug of Cytotoxic Nucleoside: Preparation and Properties of Arabinosyladenine-5'-Formate," *J. Pharm. Sci.*, **64**, 392-396 (1975).

35. N. Bodor, M. Dewar and Z. Maksic, "A Study of the Interactions Between the Double Bonds in Unsaturated Ketones," *Croat. Chem. Acta*, **48**, 9-15 (1976).
36. N. Bodor, E. Shek and T. Higuchi, "Improved Delivery Through Biological Membranes. I. Synthesis and Properties of 1-Methyl-1,6-dihydropyridine-2-carbaldoxime, a Prodrug of N-Methylpyridinium-2-carbaldoxime Chloride," *J. Med. Chem.*, **19**, 102-107 (1976).
37. J. Kaminski and N. Bodor, "3-Bromo-4, 4-Dimethyl-2-oxazolidinone: Preparation and Investigation of a New Brominating Agent," *Tetrahedron*, **32**(10), 1097-1099 (1976).
38. J. Kaminski, N. Bodor and T. Higuchi, "N-Halo Derivatives III: Stabilization of Nitrogen Chlorine Bond in N-Chloroamino Acid Derivatives," *J. Pharm. Sci.*, **65**, 553-557 (1976).
39. J. Kaminski, N. Bodor and T. Higuchi, "N-Halo Derivatives IV: Synthesis of Low Chlorine Potential Soft N-Chloramine Systems," *J. Pharm. Sci.*, **65**, 1733-1737 (1976).
40. J. Kaminski, M. Huycke, S. Selk, N. Bodor and T. Higuchi, "N-Halo Derivatives V: Comparative Antimicrobial Activity of Soft N-Chloramine Systems," *J. Pharm. Sci.*, **65**, 1737-1742 (1976).
41. M. Kosugi, J. Kaminski, S. Selk, I. Pitman, N. Bodor and T. Higuchi, "N-Halo Derivatives VI: Microbiological and Chemical Evaluations of 3-Chloro-2-oxazolidinones," *J. Pharm. Sci.*, **65**, 1743-1746 (1976).
42. E. Shek, T. Higuchi and N. Bodor, "Improved Delivery Through Biological Membranes. 2. Distribution, Excretion, and Metabolism of N-Methyl-1, 6-dihydropyridine-2-carbaldoxime Hydrochloride, a Pro-Drug of N-Methylpyridinium-2-carbaldoxime Chloride," *J. Med. Chem.*, **19**, 108-112, (1976).
43. E. Shek, T. Higuchi and N. Bodor, "Improved Delivery Through Biological Membranes. 3. Delivery of N-Methylpyridinium-2-carbaldoxime Chloride through the Blood-Brain Barrier in Its Dihydropyridine Pro-Drug Form," *J. Med. Chem.*, **19**, 113-117 (1976).
44. K. Sloan and N. Bodor, "O-Acylation of Acidic Methylene Compounds," *J. Org. Chem.*, **41**, 165-166 (1976).
45. S. Yuan and N. Bodor, "Synthesis and Activity of (R)-(-)-m-Trimethylacetoxy- α [(methylamino)methyl]benzyl Alcohol Hydrochloride: A Prodrug Form of (R)-(-)-Phenylephrine," *J. Pharm. Sci.*, **65**, 929-931 (1976).

46. N. Bodor, "Novel Approaches for the Design of Membrane Transport Properties of Drugs," Chapter 7 in *Design of Bio-Pharmaceutical Properties Through Pro-Drugs and Analogs*, E. B. Roche, Ed., Symposium Proceedings of Academy of Pharm. Sci., 98-135 (1977).
47. N. Bodor, K. Sloan, T. Higuchi and K. Sasahara, "Improved Delivery Through Biological Membranes. 4. Prodrugs of L-Dopa," *J. Med. Chem.*, **20**, 1435-1445, (1977).
48. J. Kaminski, S. Worley and N. Bodor, "N-Halo Derivatives. VII. Mass Spectra of a Series of 3-Halo-2-Oxazolidinones," *Org. Mass Spectrom.*, **12**, 145-149 (1977).
49. K. Sloan, N. Bodor, T. Higuchi, R. Little and M. Wu, "Micellar Acceleration of Phosphorylation of Hydroxamic Acids: Effect of Chain Length and of an Intramolecular Tertiary Amino-group," *J. Chem. Res.(S)*, 290-291 (1977).
50. N. Bodor, J. Kaminski and R. Roller, "Improved Delivery Through Biological Membranes. VI. Potent Sympathomimetic Adrenalone Derivatives," *Int. J. Pharm.*, **1**, 189-196 (1978).
51. N. Bodor and R. Pearlman, "Formation, Stability and Protonation of Dihydropyridines. A MINDO/3 Study," *J. Am. Chem. Soc.*, **100**, 4946-4953 (1978).
52. N. Bodor, R. Roller and S. Selk, "Elimination of a Quaternary Pyridinium Salt Delivered as Its Dihydropyridine Derivative from Brain of Mice," *J. Pharm. Sci.*, **67**, 685-687 (1978).
53. N. Bodor, K. Sloan, N. Kuo and T. Higuchi, "Controlled Delivery of Theophylline: Chemistry of 7-Acyl- and 7,7' Acylditheophylline Derivatives," *J. Pharm. Sci.*, **67**, 1045-1050 (1978).
54. J. Epstein, J. Kaminski, N. Bodor, R. Enever, J. Sowa and T. Higuchi, "Micellar Acceleration of Organophosphate Hydrolysis by Hydroximinomethylpyridinium Type Surfactants," *J. Org. Chem.*, **43**, 2816-2821 (1978).
55. S. Gerson, S. Worley, N. Bodor, J. Kaminski and T. Flechtner, "The Photoelectron Spectra of some Heterocyclic Compounds which contain N, O, Cl and Br," *J. Electr. Spectr. Rel. Phen.*, **13**, 421-434 (1978).
56. S. Gerson, S. Worley, N. Bodor and J. Kaminski, "Electronic Structures of Some Antimicrobial N-Chloramines. Possible Existence of Intramolecular Hydrogen Bonding and Its Effect on Germicidal Efficiency," *J. Med. Chem.*, **21**, 686-688 (1978).
57. J. Kaminski, K. Knutson and N. Bodor, "A Convenient Method of Anion Exchange in Quaternary Salts," *Tetrahedron*, **34**(19), 2857-2859 (1978).

58. K. Sloan, R. Little and N. Bodor, "Acid-Catalyzed Rearrangements of the Dihydroxyacetone Side Chain in Steroids during Ketal Exchange," *J. Org. Chem.*, **43**, 3405-3408 (1978).
59. S. Worley, S. Gerson, N. Bodor and J. Kaminski, "The Electronic Structures of Some Biological Piperazines," *Chem. Phys. Letters*, **60**, 104-107 (1978).
60. S. Worley, S. Gerson, N. Bodor, J. Kaminski and T. Flechtner, "On the Structure of N-Chlorosuccinimide and N-Bromosuccinimide. A Photoelectron Spectroscopic Study," *J. Chem. Phys.*, **68**, 1313-1315 (1978).
61. J. Kaminski and N. Bodor, "Determination of Penicillins and Cephalosporins Using 3-Bromo-4, 4-dimethyl-2-oxazolidinone," *Int. J. Pharm.*, **3**, 151-156 (1979).
62. R. Pearlman and N. Bodor, "Configurational Analysis, Inversion and Reduction of Some Pyridine Carbaldoximes," ACS Symposium Series, No. 112., *Computer-Assisted Drug Design*, E. Olson and R. Christoffersen, Eds., Washington D.C., p. 489-506 (1979).
63. N. Bodor, J. Kaminski and S. Selk, "Soft Drugs 1. Labile Quaternary Ammonium Salts as Soft Antimicrobials," *J. Med. Chem.*, **23**, 469-474 (1980).
64. N. Bodor and J. Kaminski, "Soft Drugs 2. Soft Alkylating Compounds as Potential Antitumor Agents," *J. Med. Chem.*, **23**, 566-569 (1980).
65. N. Bodor, J. Kaminski, S. Worley and S. Gerson, "Quantitative Evaluation of the Reactivity of Alkylating Agents," *Z. Naturforsch.*, **35b**, 758-763 (1980).
66. N. Bodor, K. Knutson and T. Sato, "Resolution of Chiral Phosphamides," *J. Am. Chem. Soc.*, **102**, 3969-3971 (1980).
67. N. Bodor, R. Woods, C. Raper, P. Kearney and J. Kaminski, "Soft Drugs 3. A New Class of Anticholinergic Agents," *J. Med. Chem.*, **23**, 474-480 (1980).
68. N. Bodor, J. Zupan and S. Selk, "Improved Delivery Through Biological Membranes VII. Dermal Delivery of Cromoglycic Acid (Cromolyn) Via its Prodrugs," *Int. J. Pharm.*, **7**, 63-75 (1980).
69. H. Kohl, W. Wheatley, S. Worley and N. Bodor, "Antimicrobial Activity of N-Chloramine Compounds," *J. Pharm. Sci.*, **69**, 1292-1295 (1980).
70. N. Bodor, "Novel Approaches in Prodrug Design," *Drugs of the Future*, **6**(3), 165-182 (1981).

71. N. Bodor, H. Farag and M. Brewster, "Site-Specific, Sustained Release of Drugs to the Brain," *Science*, **214**, 1370-1372 (1981).
72. H. Burkett, J. Faison, H. Kohl, W. Wheatley, S. Worley and N. Bodor, "A Novel Chloramine Compound for Water Disinfection," *Water Res. Bul.*, **17**, 874-879 (1981).
73. T. Loftsson, J. Kaminski and N. Bodor, "Improved Delivery Through Biological Membranes. VIII. Design, Synthesis and In Vivo Testing of True Prodrugs of Aspirin," *J. Pharm. Sci.*, **70**, 743-749 (1981).
74. T. Loftsson and N. Bodor, "Improved Delivery Through Biological Membranes. IX. Kinetics and Mechanism of Hydrolysis of Methylsulfinylmethyl-2-acetoxybenzoate and Related Aspirin Prodrugs," *J. Pharm. Sci.*, **70**, 750-755 (1981).
75. T. Loftsson and N. Bodor, "Improved Delivery Through Biological Membranes. X. Percutaneous Absorption and Metabolism of Methylsulfinylmethyl-2-Acetoxybenzoate and Related Aspirin Prodrugs," *J. Pharm. Sci.*, **70**, 756-758 (1981)
76. K. Sloan, N. Bodor and R. Little, "¹³C NMR Spectroscopy of 4,5- and 5,6-Double Bond Isomers of Spiro-3-Steroidal Ketone Derivatives: The Determination of the Structures of Steroidal Thiazolidines," *Tetrahedron*, **37**(20), 3467-3471 (1981).
77. K. Sloan, N. Bodor and J. Zupan, "Acylation of the 4,5- and 5,6 Double Bond Isomers of 3-Steroidal Thiazolidines," *Tetrahedron*, **37**(20), 3463-3466 (1981).
78. S. Worley, W. Wheatley, H. Kohl, H. Burkett, J. Faison, J. Van Hoose and N. Bodor, "A Novel Bactericidal Agent for Treatment of Water," Chapter 78 in *Water Chlorination Environmental Impact and Health Effects*, Vol. 4., R. Jolley, W. Brungs, J. Cotruvo, R. Cumming, J. Mattice and V. Jacobs, Eds., Proceedings of the Fourth Conference on Water Chlorination, 1105-1113 (1981).
79. N. Bodor, "Designing Safer Drugs Based on the Soft Drug Approach," *Trends in Pharmacological Sciences*, **3**(2), 53-56 (1982).
80. N. Bodor, "Novel Approaches to Prodrug Design," *Optimization of Drug Delivery*, Alfred Benzon Symposium, 17, H. Bundgaard, A. B. Hansen and H. Kofod, Eds., Munksgaard, Copenhagen, 156-177, 1982.
81. N. Bodor, "Soft Drugs: Strategies for Design of Safer Drugs," in *Strategy in Drug Research*, Proceedings of the 2nd IUPAC-IUPHAR Symposium on Research, Noordwijkerhout, J. A. Keversling Buisman, Ed., Elsevier Scientific Publishing Company, Amsterdam, 137-164, 1982.

82. N. Bodor, K. Sloan, R. Little, S. Selk and L. Caldwell, "Soft Drugs 4. 3-Spirothiazolidines of Hydrocortisone and Its Derivatives," *Int. J. Pharm.*, **10**, 307-321 (1982).
83. N. Bodor and K. Sloan, "Soft Drugs V. Thiazolidine-Type Derivatives of Progesterone and Testosterone," *J. Pharm. Sci.*, **71**(5), 514-520 (1982).
84. T. Loftsson and N. Bodor, "Synthesis and Hydrolysis of Some Pivaloyloxymethyl and Pivaloyl Derivatives of Phenolic Compounds," *Arch. Pharm. Chemi. Sci. Ed.*, **10**, 104-110 (1982).
85. E. Mora, H. Kohl, W., Wheatley, S. Worley, J. Faison, H. Burkett and N. Bodor, "Properties of a New Chloramine Disinfectant and Detoxicant," *Poultry Science*, **61**, 1968-1971 (1982).
86. K. Sloan and N. Bodor, "Hydroxymethyl and Acyloxymethyl Prodrugs of Theophylline: Enhanced Delivery of Polar Drugs Through Skin," *Int. J. Pharm.*, **12**, 299-313 (1982).
87. N. Bodor, "Soft Drugs: Strategies for Design of Safer Drugs," *Metab. Concept. Med. Quo Vadis?* [Symp.], 217-251 (1983).
88. N. Bodor and M. Brewster, "Problems of Delivery of Drugs to the Brain," *Pharm. Ther.*, **19**(3), 337-386 (1983).
89. N. Bodor and H. Farag, "Improved Delivery Through Biological Membranes 11. A Redox Chemical Drug-Delivery System and Its Use for Brain Specific Delivery of Phenylethylamine," *J. Med. Chem.*, **26**, 313-318 (1983).
90. N. Bodor and K. Sloan, "Improved Delivery Through Biological Membranes XII. The Effect of the Incorporation of Biphasic Solubilizing Groups Into Prodrugs of Steroids," *Int. J. Pharm.*, **15**, 235-250 (1983).
91. N. Bodor and H. Farag, "Improved Delivery Through Biological Membranes. 13. Brain Specific Delivery of Dopamine with a Dihydropyridine _ Pyridinium Salt Type Redox Delivery System," *J. Med. Chem.*, **26**, 528-534 (1983).
92. N. Bodor and M. Brewster, "Improved Delivery Through Biological Membranes XV. Sustained Brain Delivery of Berberine," *Eur. J. Med. Chem.*, **18**, 235-240 (1983).
93. N. Bodor, A. Harget and E. Phillips, "Structure-Activity Relationships in the Antiinflammatory Steroids: A Pattern Recognition Approach," *J. Med. Chem.*, **26**, 318-328 (1983).

94. N. Bodor, A. Harget and E. Phillips, "Structure-Activity Relationships in the Antiinflammatory Steroids: A Pattern Recognition Approach," *Croat. Chem. Acta*, **56**(2), 175-183 (1983) (in English).
95. N. Bodor and J. Simpkins, "Redox Delivery System for Brain-Specific, Sustained Release of Dopamine," *Science*, **221**(4605), 65-67 (1983).
96. N. Bodor, K. Sloan, J. Kaminski, C. Shih and S. Pogany, "A Convenient Synthesis of (Acyloxy)alkyl α -Ethers of Phenols," *J. Org. Chem.*, **48**, 5280-5284 (1983).
97. M. Brewster and N. Bodor, "Improved Delivery Through Biological Membranes XVI. Enhancement of the Brain Specificity of a Dihydropyridine _ Pyridinium Salt Drug Delivery System by Controlled Infusion," *J. Parenteral Sci. Tech.*, **37**(5), 159-164 (1983).
98. T. Sato, H. Ueda, K. Nakagawa and N. Bodor, "Asymmetric Synthesis of Enantiomeric Cyclophosphamides," *J. Org. Chem.*, **48**, 98-101 (1983).
99. K. Sloan, M. Hashida, J. Alexander, N. Bodor and T. Higuchi, "Prodrugs of 6-Thiopurines: Enhanced Delivery Through the Skin," *J. Pharm. Sci.*, **72**(4), 372-378 (1983).
100. S. Worley, W. Wheatley, H. Kohl, H. Burkett, J. Faison, J. Van Hoose and N. Bodor, *Water Chlorination: Environmental Impact and Health Effects*, **4**, 372-378 (1983).
101. S. Worley, W. Wheatley, H. Kohl, H. Burkett, J. Van Hoose and N. Bodor, "A New Water Disinfectant: A Comparative Study," *Ind. Eng. Chem. Prod. Res. Dev.*, **22**, 716-718 (1983).
102. S. Worley, W. Wheatley, H. Kohl, J. Van Hoose, H. Burkett and N. Bodor, "The Stability in Water of a New Chloramine Disinfectant," *Water Res. Bul.*, **19**, 97-100 (1983).
103. N. Bodor, "Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems," chapter in *Advances in Drug Research*, **13**, 255-331, Academic Press, London, 1984.
104. N. Bodor, "The Soft Drug Approach," *Chemtech*, January, 28-38 (1984).
105. N. Bodor, "Soft Drugs: Principles and Methods for the Design of Safe Drugs," *Med. Res. Reviews*, **3**(4), 449-469 (1984).
106. N. Bodor and H. Farag, "Improved Delivery Through Biological Membranes XIV. Brain Specific, Sustained Delivery of Testosterone Using a Redox Chemical Delivery System," *J. Pharm. Sci.*, **73**(3), 385-389 (March 1984).

107. N. Bodor, Y. Oshiro, T. Loftsson, M. Katovich and W. Caldwell, "Soft Drugs VI. The Application of the Inactive Metabolite Approach for Design of Soft β -Blockers," *Pharm. Res.*, **3**, 120-125, May (1984).
108. N. Bodor and G. Visor, "Formation of Adrenaline in the Iris-Ciliary Body from Adrenalone Diesters," *Exp. Eye Res.*, **38**, 621-626 (1984).
109. N. Bodor and G. Visor, "Improved Delivery Through Biological Membranes. XVII. A Site-Specific Chemical Delivery System as a Short-Acting Mydriatic Agent," *Pharm. Res.*, **4**, 168-173 (1984).
110. M. Katovich, J. Simpkins, I. Song, N. Bodor and R. Tuttle, "A Rapid Quantitative In Vivo Assay for Narcotic Antagonists," *Substance and Alcohol Actions/Misuse*, **5**, 87-95 (1984).
111. T. Loftsson, M. Matsuo, R. Caldwell, N. Gildersleeve and N. Bodor, "Synthesis and Evaluation of Novel Lidocaine Sulfur Analogs," *Int. J. Pharm.*, **22**, 345-355 (1984).
112. N. Bodor, "Novel Approaches to the Design of Safer Drugs by Site-Specific Chemical Delivery Systems," chapter in *Advances in Drug Delivery Systems*, H. P. Tipnis, Ed., MSR Foundation, Bombay, India, 111-127 (1985).
113. N. Bodor, "Prodrugs Vs. Soft Drugs," chapter in *Design of Prodrugs*, H. Bundgaard, Ed., Elsevier Science Publishers B. V., Amsterdam, The Netherlands, 333-354, 1985.
114. N. Bodor, "Targeting of Drugs to the Brain," Chapter in *Methods in Enzymology, Drug & Enzyme Targeting, Part A*, K. J. Widder, Ed., Academic Press, **112**, 381-396, 1985.
115. N. Bodor and M. Abdelalim, "Improved Delivery Through Biological Membranes XIX: Novel Redox Carriers for Brain-Specific Chemical Delivery Systems," *J. Pharm. Sci.*, **74**(3), 241-245 (1985).
116. B. Michniak-Mikolajczak and N. Bodor, "A Study of the Penetration of Five Novel Synthetic Steroids Through Hairless Mouse Skin In Vitro," *Int. J. Cosmetic Sci.*, **7**, 175-179 (1985).
117. J. Simpkins, N. Bodor and A. Enz, "Direct Evidence for Brain Specific Release of Dopamine from a Redox Delivery System," *J. Pharm. Sci.*, **74**(10), 1033-1036 (1985).
118. N. Bodor and M. Abdelalim, "Improved Delivery Through Biological Membranes XX. Nicotinamide _ Dihyronicotinamide Based Ester-linked Redox Carrier Systems," *J. Pharm. Sci.*, **75**(1), 29-35 (1986).

119. N. Bodor and M. Brewster, "A MINDO/3 Study of a Substituted Benzo(b)-isoquinolizinium Salt _ Benzo(b)quinolizine System," *J. Mol. Struct. (THEOCHEM)*, **138**, 261-270 (1986).
120. N. Bodor and M. Brewster, "Problems of Delivery of Drugs to the Brain," chapter in *Methods of Drug Delivery, Int. Enc. of Pharm. & Ther., Section 120*, G. M. Ihler, Ed., Pergamon Press, New York, 153-202 (1986).
121. N. Bodor, M. El-Kommos and C. Nath, "In Vivo Elimination of Dihydropyridine Drug Delivery Carriers from Brain and Blood of Rats," *Bulletin of Pharmaceutical Sciences*, Assiut University, **9**(2), 14-29 (1986).
122. N. Bodor, T. Nakamura and M. Brewster, "Improved Delivery Through Biological Membranes XXIII. Synthesis, Distribution and Neurochemical Effects of a Tryptamine Chemical Delivery System," *Drug Des. & Del.*, **1**, 51-64 (1986).
123. M. Brewster, K. Estes and N. Bodor, "Improved Delivery Through Biological Membranes XXIV. Synthesis, In Vitro Studies, and In Vivo Characterization of Brain-Specific and Sustained Progestin Delivery Systems," *Pharm. Res.*, **3**(5), 278-285 (1986).
124. K. Rand, N. Bodor, A. El-Koussi, I. Raad, A. Miyake, H. Houck and N. Gildersleeve, "Potential Treatment of Herpes Simplex Virus Encephalitis by Brain-Specific Delivery of Trifluorothymidine Using a Dihydropyridine _ Pyridinium Salt Type Redox Delivery System," *J. Med. Virol.*, **20**, 1-8 (1986).
125. J. Simpkins, J. McCornack, K. Estes, M. Brewster, E. Shek and N. Bodor, "Sustained Brain-Specific Delivery of Estradiol Causes Long-Term Suppression of Luteinizing Hormone Secretion," *J. Med. Chem.*, **29**, 1809-1812 (1986).
126. N. Bodor, "Chemical Drug Delivery Systems," Chapter in Theory and Application of Bioreversible Carriers Drug Design, E. B. Roche, Ed., *Symposium Proceedings of Academy of Pharm. Sci.*, Pergamon Press, New York, 95-120 (1987).
127. N. Bodor, "Novel Site-Specific Chemical Drug Delivery Systems," chapter in *Trends in Medicinal Chemistry*, Proceedings of the IXth International Symposium on Medicinal Chemistry," E. Mutschler and E. Winterfeldt, Eds., VCH Verlagsgesellschaft, West Germany, 195-210 (1987).
128. N. Bodor, "Redox Drug Delivery Systems for Targeting Drugs to the Brain," *Biological Approaches to the Controlled Delivery of Drugs*, *Ann. N. Y. Acad. Sci.*, **507**, 289-306 (1987).

129. N. Bodor and J. Kaminski, "Prodrugs and Site-Specific Chemical Delivery Systems," Chapter 30 in *Ann. Reports in Med. Chem.*, **22**, D. Bailey, Ed., Academic Press, 303-313 (1987).
130. N. Bodor and T. Loftsson, "Novel Chemical Approaches for Sustained Drug Delivery," Chapter in *Controlled Drug Delivery*, J. R. Robinson and V. H. L. Lee, Eds., Marcel Dekker, 337-371 (1987).
131. N. Bodor, J. McCornack and M. Brewster, "Improved Delivery Through Biological Membranes XXII. Synthesis and Distribution of Brain-Selective Estrogen Delivery Systems," *Int. J. Pharm.*, **35**, 47-59 (1987).
132. W. Anderson, J. Simpkins, M. Brewster and N. Bodor, "Evidence for the Reestablishment of Copulatory Behavior in Castrated Male Rats with a Brain-Enhanced Estradiol-Chemical Delivery System," *Pharmacol. Biochem. & Behav.*, **27**, 265-271 (1987).
133. W. Anderson, J. Simpkins, M. Brewster and N. Bodor, "Evidence for Suppression of Serum LH Without Elevation in Serum Estradiol or Prolactin with a Brain-Enhanced Redox Delivery System for Estradiol," *Life Sci.*, **42**(16), 1493-1502 (1987).
134. W. Anderson, J. Simpkins, P. Woodard, D. Winwood, W. Stern and N. Bodor, "Anxiolytic Activity of a Brain Delivery System for GABA," *Psychopharmacol.*, **92**(2), 157-163 (1987).
135. M. Brewster, V. Venkatraghavan, E. Shek and N. Bodor, "Facile, One-Step Preparation of Trigonellinate Esters," *Synth. Commun.*, **17**(4), 451-455 (1987).
136. A. El-Koussi and N. Bodor, "Improved Delivery Through Biological Membranes XXV. Enhanced and Sustained Delivery of Trifluorothymidine to the Brain Using a Dihydropyridine _ Pyridinium Salt Type Redox Delivery System," *Drug Des. & Del.*, **1**, 275-283 (1987).
137. K. Estes, M. Brewster and N. Bodor, "Use of a Chemical Redox System for Brain-Enhanced Delivery of Estradiol Decreases Prostate Weight," *Biological Approaches to the Controlled Delivery of Drugs*, *Ann. N. Y. Acad. Sci.*, **507**, 334-336 (1987).
138. K. Estes, M. Brewster, J. Simpkins and N. Bodor, "A Novel Redox System for CNS-Directed Delivery of Estradiol Causes Sustained LH Suppression in Castrate Rats," *Life Sci.*, **40**, 1327-1334 (1987).
139. T. Loftsson, N. Gildersleeve and N. Bodor, "The Effect of Vehicle Additives on the Transdermal Delivery of Nitroglycerin," *Pharm. Res.*, **4**(5), 436-437 (1987).

140. K. Raghavan, E. Shek and N. Bodor, "Improved Delivery Through Biological Membranes XXX. Synthesis and Biological Aspects of a 1,4-Dihydropyridine Based Chemical Delivery System for Brain-Sustained Delivery of Hydroxy CCNU," *Anti-Cancer Drug Des.*, **2**, 25-36 (1987).
141. K. Rand, I. Raad, A. El-Koussi, H. Houck, W. Brey, J. Rocca, T. Loftsson and N. Bodor, "Trifluorothymidine: Potential Non-Invasive Diagnosis of Herpes Simplex Infection Using ¹⁹F Nuclear Magnetic Resonance in a Murine Hepatitis Model," *J. Virol. Methods*, **18**, 257-270 (1987).
142. P. Stacpoole, M. Gonzalez, J. Vlasak, Y. Oshiro and N. Bodor,² "Dichloroacetate Derivatives: Metabolic Effects and Pharmacodynamics in Normal Rats," *Life Sci.*, **41**, 2167-2176 (1987).
143. N. Bodor, "The Application of Soft Drug Approaches to the Design of Safer Corticosteroids," Chapter in *Topical Corticosteroid Therapy: A Novel Approach to Safer Drugs*, E. Christophers et al., Eds., Raven Press, Ltd., New York, 13-25 (1988).
144. N. Bodor, M. Brewster and J. Kaminski, "Theoretical Studies on the Hydride Transfer Between 1-Methyl-1,4-Dihydronicotinamide and Its Corresponding Pyridinium Salt," *Tetrahedron*, **44**(24), 7601-7610 (1988).
145. N. Bodor and A. El-Koussi, "Novel 'Soft' β -Blockers as Potential Safe Antiglaucoma Agents," (Part 8 in Soft Drug Series), *Cur. Eye Res.*, **7**(4), 369-374 (1988).
146. N. Bodor, A. El-Koussi, M. Kano, and M. Khalifa, "Soft Drugs 7. β -Blockers for Systemic and Ophthalmic Use," *J. Med. Chem.*, **31**, 1651-1656 (1988).
147. N. Bodor, A. El-Koussi, M. Kano and T. Nakamura, "Improved Delivery Through Biological Membranes 26. Design, Synthesis, and Pharmacological Activity of a Novel Chemical Delivery System for β -Adrenergic Blocking Agents," *J. Med. Chem.*, **31**, 100-106 (1988).
148. N. Bodor and J. Kaminski, "Reactivity of Biologically Important Reduced Pyridines I. Correlation Between Hydride Transfer and One-Electron Oxidation of Dihydropyridines and Heterocycles," *J. Mol. Struct. (THEOCHEM)*, **163**, 315-330 (1988).
149. W. Anderson, J. Simpkins, M. Brewster and N. Bodor, "Brain-Enhanced Delivery of Testosterone Using a Chemical Delivery System Complexed with 2-Hydroxypropyl- β -Cyclodextrin," *Drug Des. & Del.*, **2**(4), 287-298 (1988).

150. W. Anderson, J. Simpkins, M. Brewster and N. Bodor, "Effects of a Brain-Enhanced Chemical Delivery System for Estradiol on Body Weight and Serum Hormones in Middle-Aged Male Rats," *Endo. Res.*, **14**(2&3), 131-148 (1988).
151. M. Brewster, K. Estes and N. Bodor, "Improved Delivery Through Biological Membranes. XXXII. Synthesis and Biological Activity of Brain-Targeted Delivery Systems for Various Estradiol Derivatives," *J. Med. Chem.*, **31**, 244-249 (1988).
152. M. Brewster, K. Estes and N. Bodor, "Use of a Chemical Redox System for Delivery of Drugs to the Brain: Ethinyl Estradiol," *Ann. N. Y. Acad. Sci.*, **529**, 298-300 (1988).
153. M. Brewster, K. Estes, T. Loftsson, R. Perchalski, H. Derendorf, G. Mullersman and N. Bodor, "Improved Delivery Through Biological Membranes XXXI. Solubilization and Stabilization of an Estradiol Chemical Delivery System by Modified β -Cyclodextrins," *J. Pharm. Sci.*, **77**, 981-985 (1988).
154. M. Brewster, K. Estes, R. Perchalski and N. Bodor, "A Dihydropyridine Conjugate Which Generates High and Sustained Levels of the Corresponding Pyridinium Salt in the Brain Does Not Exhibit Neurotoxicity in Cynomolgus Monkeys," *Neurosci. Letters*, **87**, 277-282 (1988).
155. M. Brewster, J. Kaminski and N. Bodor, "Reactivity of Biologically Important Reduced Pyridines. 2. The Oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). An MNDO Study," *J. Am. Chem. Soc.*, **110**(19), 6337-6341 (1988).
156. M. Brewster, T. Loftsson, K. Estes, G. Mullersman, H. Derendorf and N. Bodor, "Water Soluble Complexes of a Brain-Targeted Drug Delivery System," Proceeding of the Fourth International Symposium on Cyclodextrins, O. Huber and J. Szejtli, Eds., Kluwer Academic Publishers, Dordrecht, 399-405 (1988).
157. K. Estes, M. Brewster and N. Bodor, "A Redox System for Brain Targeted Estrogen Delivery Causes Chronic Body Weight Decrease in Rats," *Life Sci.*, **42**, 1077-1084 (1988).
158. R. Hammer, K. Amin, Z. Gunes, G. Brouillette and N. Bodor, "Novel Soft Anticholinergic Agents," *Drug Des. & Del.*, **2**, 207-219 (1988).
159. G. Mullersman, H. Derendorf, M. Brewster, K. Estes and N. Bodor, "High Performance Liquid Chromatographic Assay of a Central Nervous System-Directed Estradiol Chemical Delivery System and Its Application after Intravenous Administration to Rats," *Pharm. Res.*, **5**, 172-177 (1988).

160. J. Simpkins, W. Anderson, R. Dawson, Jr., A. Seth, M. Brewster, K. Estes and N. Bodor, "Chronic Weight Loss in Lean and Obese Rats with a Brain-Enhanced Chemical Delivery System for Estradiol," *Physiol. & Behav.*, **44**(5), 573-580 (1988).
161. N. Bodor, "Designing Safer Ophthalmic Drugs," chapter in *Proceedings of the Xth International Symposium on Medicinal Chemistry, Trends in Med. Chem. '88*, H. van der Goot, G. Domany, L. Pallos and H. Timmerman, Eds., Elsevier Science Publishers, B.V., Amsterdam, 145-164 (1989).
162. N. Bodor, Z. Gabanyi and C. Wong, "A New Method for the Estimation of Partition Coefficient," *J. Am. Chem. Soc.*, **111**, 3783-3786 (1989).
163. N. Bodor, V. Venkatraghavan, D. Winwood, K. Estes and M. Brewster, "Improved Delivery Through Biological Membranes. XLI. Brain-Enhanced Delivery of Chlorambucil," *Int. J. Pharm.*, **53**, 195-208 (1989).
164. W. Anderson, J. Simpkins, M. Brewster and N. Bodor, "Evidence for Prolonged Suppression of Stress-Induced Release of Adrenocorticotrophic Hormone and Corticosterone with a Brain-Enhanced Dexamethasone Redox Delivery System," *Neuroendocrinol.*, **50**(1), 9-16 (1989).
165. M. Brewster, K. Estes and N. Bodor, "Development of a Non-Surfactant Formulation for Alfaxalone Through the Use of Chemically-Modified Cyclodextrins," *J. Parenteral Sci. & Tech.*, **43**(6), 262-265 (1989).
166. M. Brewster, J. Kaminski, Z. Gabanyi, K. Czako, Agnes Simay and N. Bodor, "Reactivity of Biologically Important Reduced Pyridines V. Relative Importance of Electron Versus Proton Loss in Ferricyanide-Mediated Oxidation of Dihyronicotinamides," *Tetrahedron*, **45**(14), 4395-4402 (1989).
167. M. Brewster, C. Robledo-Luiggi, A. Miyake, E. Pop and N. Bodor, "Improved Delivery Through Biological Membranes 44. Brain-Enhanced Delivery of Anti-Dementia Drugs," Chapter in *Neurobiology of Aging*, E. Meyers, Ed., Plenum, New York, 173-183 (1989).
168. M. Brewster, Agnes Simay, K. Czako, D. Winwood, H. Farag and N. Bodor, "Reactivity of Biologically Important Reduced Pyridines. 4. Effect of Substitution on Ferricyanide-Mediated Oxidation Rates of Various 1,4-Dihydropyridines," *J. Org. Chem.*, **54**, 3721-3726 (1989).
169. M. Brewster, J. Simpkins, M. Hora, W. Stern and N. Bodor, "The Potential Use of Cyclodextrins in Parenteral Formulations," *J. Parenteral Sci. Tech.*, **43**(5), 231-240 (1989).

170. A. El-Koussi and N. Bodor, "Formation of Propranolol in the Iris-Ciliary Body from Its Propranolol Ketoxime Precursor - A Potential Antiglaucoma Drug," *Int. J. Pharm.*, **53**, 189-194 (1989).
171. A. Katritzky, G. Savage, M. Pilarska, N. Bodor and M. Brewster, "The Response to Vapor Challenges of New Microsensor Coatings: Nicotinic Acid Derivatives," *Chemica Scripta*, **29**, 319-323 (1989).
172. T. Loftsson, S. Bjornsdottir, G. Palsdottir and N. Bodor, "The Effects of 2-Hydroxypropyl- β -Cyclodextrin on the Solubility and Stability of Chlorambucil and Melphalan in Aqueous Solution," *Int. J. Pharm.*, **54**, 63-72 (1989).
173. T. Loftsson and N. Bodor, "Effects of 2-Hydroxypropyl- β -Cyclodextrin on the Aqueous Solubility of Drugs and Transdermal Delivery of 17- β -Estradiol," *Acta Pharm. Nordica*, **1**(4), 185-194 (1989).
174. T. Loftsson, N. Gildersleeve, R. Soliman and N. Bodor, "Effect of Oleic Acid on Diffusion of Drugs Through Hairless Mouse Skin," *Acta Pharm. Nordica*, **1**(1), 17-22 (1989).
175. T. Loftsson, G. Somogyi and N. Bodor, "Effect of Choline Esters and Oleic Acid on the Penetration of Acyclovir, Estradiol, Hydrocortisone, Nitroglycerin, Retinoic Acid and Trifluorothymidine Across Hairless Mouse Skin in Vitro," *Acta Pharm. Nordica*, **1**(5), 279-286 (1989).
176. T. Murakami, E. Shek, E. Pop and N. Bodor, "Improved Anticonvulsant Activity of Phenytoin by a Redox Brain Delivery System: Stability in Buffers and Biological Materials," (XXVIII in Improved Delivery Series), *J. Pharm. Sci.*, **78**(9), 732-737 (1989).
177. M. Phelan and N. Bodor, "Improved Delivery Through Biological Membranes XXXVII. Synthesis and Stability of Novel Redox Derivatives of Naproxen and Indomethacin," *Pharm. Res.*, **6**(8), 667-676 (1989).
178. E. Pop, M. Brewster, J. Kaminski and N. Bodor, "Theoretical Aspects of Cephalosporin Isomerism," *Int. J. Quan. Chem., Quantum Biol. Symposium*, **16**, 291-300 (1989).
179. E. Pop, M. Brewster, J. Kaminski and N. Bodor, "Theoretical Study of Some Heterocyclic Amines with Applications to the Chemistry of 9-Amino-1,2,3,4-tetrahydroacridine," *Int. J. Quantum Chem.*, **35**, 315-324 (1989).
180. E. Pop, E. Shek, T. Murakami and N. Bodor, "Improved Anticonvulsant Activity of Phenytoin by a Redox Brain Delivery System I: Synthesis and Some Properties of the Dihydropyridine Derivatives," (XXVII in Improved Delivery Series), *J. Pharm. Sci.*, **78**(8), 609-616 (1989).

181. E. Pop, W. Wu and Nicholas Bodor, "Improved Delivery Through Biological Membranes XL. Chemical Delivery Systems for Some Penicillinase-Resistant Semisynthetic Penicillins," *J. Med. Chem.*, **32**, 1789-1795 (1989).
182. E. Pop, W. Wu, E. Shek and N. Bodor, "Chemical Delivery Systems for Drugs Containing an Amino Group: Synthesis and Properties of Some Pyridine Derivatives of Desipramine," (Improved Delivery Through Biological Membranes. XLII), *Drug Des. & Del.*, **5**, 93-115 (1989).
183. E. Pop, W. Wu, E. Shek and N. Bodor, "Improved Delivery Through Biological Membranes XXXVIII. Brain-Specific Chemical Delivery Systems for β -Lactam Antibiotics. Synthesis and Properties of Some Dihydropyridine and Dihydroisoquinoline Derivatives of Benzylpenicillin," *J. Med. Chem.*, **32**, 1774-1781 (1989).
184. L. Prokai, B. Hsu, H. Farag and N. Bodor, "Desorption Chemical Ionization, Thermospray, and Fast Atom Bombardment Mass Spectrometry of Dihydropyridine _ Pyridinium Salt-Type Redox Systems," *Anal. Chem.*, **61**, 1723-1728 (1989).
185. M. Rahimy, N. Bodor and J. Simpkins, "A Rapid, Sensitive Method for the Simultaneous Quantitation of Estradiol and Estradiol Conjugates in a Variety of Tissues: Assay Development and Evaluation of the Distribution of a Brain-Enhanced Estradiol-Chemical Delivery System," *J. Steroid Biochem.*, **33**, 179-187 (1989).
186. E. Shek, T. Murakami, C. Nath, E. Pop and N. Bodor, "Improved Anticonvulsant Activity of Phenytoin by a Redox Brain Delivery System: Brain Uptake and Pharmacological Effects," (XXIX in Improved Delivery Series), *J. Pharm. Sci.*, **78**(10), 837-843 (1989).
187. A. Simay, L. Prokai and N. Bodor, "Oxidation of Aryloxyaminoalcohols with Activated Dimethylsulfoxide: A Novel C-N Oxidation, Facilitated by Neighboring Group Effect," *Tetrahedron*, **45**(13), 4091-4102 (1989).
188. J. Simpkins, W. Anderson, R. Dawson, Jr., and N. Bodor, "Effects of a Brain-Enhanced Chemical Delivery System for Estradiol on Body Weight and Food Intake in Intact and Ovariectomized Rats," *Pharm. Res.*, **6**(7), 592-600 (1989).
189. J. Simpkins, M. Rahimy, W. Anderson, W. Millard and N. Bodor, "A Brain-Enhanced Delivery System for Gonadal Steroids: Implication for Neurogenerative Diseases," Chapter in *Novel Procedures for the Treatment of Alzheimer's Disease*, E. Meyer, J. Simpkins, Eds., Plenum Press, New York, 197-212 (1989).

190. W. Wu, E. Pop, E. Shek and N. Bodor, "Improved Delivery Through Biological Membranes. 39. Brain-Specific Chemical Delivery Systems for β -Lactam Antibiotics. In Vitro and In Vivo Studies of Some Dihydropyridine and Dihydroisoquinoline Derivatives of Benzylpenicillin in Rats," *J. Med. Chem.*, **32**, 1782-1788 (1989).
191. N. Bodor, M. Brewster and J. Kaminski, "Reactivity of Biologically Important Reduced Pyridines III. Energetics and Mechanism of Hydride Transfer Between 1-Methyl-1,4-Dihydropyridine and the 1-Methylnicotinamide Cation, A Theoretical Study," *J. Mol. Struct. (THEOCHEM)*, **206**, 315-334 (1990).
192. N. Bodor, A. ElKoussi and R. Hammer, "Soft Drug 9. The Ultra-Short Duration of the Muscarinolytic Activity of a New Short-Acting 'Soft' Mydriatic Agent," *J. Pharm. Biopharm. Sci.*, **1**(3), 215-223 (1990).
193. N. Bodor and T. Loftsson, "The Effect of Phosphine Oxides on Transdermal Delivery," *Acta Pharm. Nordica*, 123-126 (1990).
194. N. Bodor and L. Prokai, "Site- and Stereospecific Ocular Drug Delivery by Sequential Enzymatic Bioactivation," *Pharm. Res.*, **7**(7), 723-725 (1990).
195. N. Bodor and M. Varga, "Effect of a Novel Soft Steroid on the Wound Healing of Rabbit Cornea," *Exp. Eye Res.*, **50**(2), 183-187 (1990).
196. M. Brewster, M. Deyrup, K. Czako and N. Bodor, "Extension of a Redox-Based Delivery System to α,β -Unsaturated Ketones," (Improved Delivery Series XXXVI), *J. Med. Chem.*, **33**, 2063-2065 (1990).
197. M. Brewster, K. Estes and N. Bodor, "An Intravenous Toxicity Study of 2-Hydroxypropyl- β -Cyclodextrin (A Useful Drug Solubilizer) in Rats and Monkeys," *Int. J. Pharm.*, **59**, 231-243 (1990).
198. M. Brewster, J. Kaminski, Z. Gabanyi, K. Czako, Agnes Simay and N. Bodor, "Reactivity of Biologically Important Reduced Pyridines VI. Lack of Through-Resonance Stabilization in the Ferricyanide-Mediated Oxidation of Substituted 1-Phenyl-1,4-Dihydropyridines," *Tetrahedron*, **46**(2), 319-324 (1990).
199. M. Brewster, J. Kaminski, M. Huang and N. Bodor, "Reactivity of Biologically Important Reduced Pyridines 7. Energetics and Effect of Substitution on Hydride Versus Electron Transfer in Dihydropyridines, Dihydroquinolines and Dihydroisoquinolines," *J. Org. Chem.*, **33**, 2361-2366 (1990).
200. M. Brewster, J. Simpkins and N. Bodor, "Brain-Targeted Delivery of Estrogens," *Reviews in the Neurosciences*, **2**(4), 241-285 (1990).

201. K. Dietzel, K. Estes, M. Brewster, N. Bodor and H. Derendorf, "The Use of Hydroxypropyl- β -Cyclodextrin as a Vehicle for Intravenous Administration of Dexamethasone in Dogs," *Int. J. Pharm.*, **59**, 225-230 (1990).
202. K. Dietzel, V. Keuth, K. Estes, M. Brewster, R. Clemmons, Richard Vistelle, N. Bodor and H. Derendorf, "A Redox-Based System That Enhances Delivery of Estradiol to the Brain: Pharmacokinetic Evaluation in the Dog," *Pharm. Res.*, **7**(8), 879-883 (1990).
203. P. Druzgala and N. Bodor, "Selective 17α -Alkylation of Cortinenic Acid Derivatives in a Solid-Liquid Biphasic System," *Synth. Com.*, **20**(8), 1133-1141 (1990).
204. K. Estes, M. Brewster, A. Webb and N. Bodor, "A Non-Surfactant Formulation for Alfaxalone Based on an Amorphous Cyclodextrin: Activity Studies in Rats and Dogs," *Int. J. Pharm.*, **65**, 101-107 (1990).
205. J. Kaminski and N. Bodor, "Chemical Approaches for Site-Specific Drug Delivery," Chapter in *Modern Drug Discoveries Technologies*, C. Clark and W. Moos, Eds. Horwood Publishers, Spring/Summer (1990).
206. R. Little, D. Bailey, M. Brewster, K. Estes, R. Clemmons, A. Saab and N. Bodor, "Improved Delivery Through Biological Membranes XXXIII. Brain Enhanced Delivery of Azidothymidine (AZT)," *J. Biopharm. Sci.*, **1**(1), 001-018 (1990).
207. W. Millard, T. Romano, N. Bodor and J. Simpkins, "GH Secretory Dynamics in Animals Administered Gonadal Steroids Utilizing a Chemical Delivery System," *Pharm. Res.*, **7**(10), 1011-1018 (1990).
208. E. Pop, W. Anderson, K. Prokai-Tatrai, M. Brewster, M. Fregly and N. Bodor, "Antihypertensive Activity of Redox Derivatives of Tryptophan," (Improved Delivery Through Biological Membranes. 50), *J. Med. Chem.*, **33**, 2216-2221 (1990).
209. E. Pop, M. Brewster and N. Bodor, "Central Nervous System-Enhanced Delivery of β -Lactam Antibiotics," *Drugs of the Future*, **15**(5) 473-492 (1990).
210. E. Pop, T. Loftsson and N. Bodor, "Novel Central Nervous System Targeted Semisynthetic Penicillins," (Improved Delivery Through Biological Membranes XLIII), *Drug Des. & Del.*, **5**, 221-237 (1990).
211. E. Pop, K. Prokai-Tatrai, W. Anderson, J. Lin, M. Brewster and N. Bodor, "Application of a Brain-Specific Chemical Delivery System Approach to Tranylecypromine," *Eur. J. Pharmacol.*, **183**, 1909 (1990).

212. E. Pop, K. Prokai-Tatrai, J. Scott, M. Brewster and N. Bodor, "Improved Delivery Through Biological Membranes. 49. Application of a Brain-Targeting Chemical Delivery System to 9-Amino-1,2,3,4-Tetrahydroacridine," *Pharm. Res.*, **7**(6) 658-664 (1990).
213. B. Radhakrishnan, D. Winwood and N. Bodor, "A Convenient Preparation of Phosphate Diester Monoanions," *Synth. Com.*, **20**(17), 2654-2658 (1990).
214. M. Rahimy, J. Simpkins and N. Bodor, "Dose and Time-Course Evaluation of a Redox-Based Estradiol-Chemical Delivery System for the Brain. I. Tissue Distribution," *Pharm. Res.*, **7**, 1061-1067 (1990).
215. M. Rahimy, J. Simpkins and N. Bodor, "Dose and Time-Course Evaluation of a Redox-Based Estradiol-Chemical Delivery System for the Brain. II. Pharmacodynamic Responses," *Pharm. Res.*, 1107-1112 (1990).
216. M. Rahimy, J. Simpkins and N. Bodor, "Tissue Distribution of a Brain-Enhanced Chemical Delivery System for Estradiol," *Drug Des. & Del.*, **6**, 29-40 (1990).
217. P. Woodard, D. Winwood, M. Brewster, K. Estes and N. Bodor, "Improved Delivery Through Biological Membranes XXI. Brain-Targeted Anticonvulsive Agents," *Drug Des. & Del.*, **6**, 15-28 (1990).
218. N. Bodor, "Soft Drugs," in *Enc. of Human Biol.*, **7**, Academic Press, Harcourt Brace Jovanovich, Publishers, San Diego, 101-117 (1991).
219. N. Bodor and M. Brewster, "Chemical Delivery Systems," chapter 7 in *Handbook of Experimental Pharmacology*, **100**, Targeted Drug Delivery, R. Juliano Ed., Springer-Verlag, Berlin Heidelberg, 231-284 (1991).
220. N. Bodor, S. Buris and L. Buris, "Novel Soft Steroids: Effects on Cell Growth In Vitro and on Wound Healing in the Mouse," *Steroids*, **56**, 434-439 (1991).
221. N. Bodor and P. Chikhale, "Improved Delivery of Acyclovir to the Skin Using a Dihydrotrigonelline _ Trigonelline Redox Carrier," (XLVII in Improved Delivery Series), *J. Pharm. Sci.*, **80**(4), 402-403 (1991).
222. N. Bodor and A. ElKoussi, "Improved Delivery Through Biological Membranes LVI. Pharmacological Evaluation of Alprenoxime - A New Potential Antiglaucoma Agent," *Pharm. Res.*, **8**(11), 1389-1395 (1991).
223. N. Bodor, A. Harget and M. Huang, "Neural Network Studies. 1. Estimation of the Aqueous Solubility of Organic Compounds," *J. Amer. Chem. Soc.*, **113**, 9480-9483 (1991).

224. N. Bodor and M. Huang, "Predicting Partition Coefficients for Isomeric Diastereoisomers of Some Tripeptide Analogs," *J. Comp. Chem.*, **12**(9), 1182-1186 (1991).
225. M. Alberth, W. Wu, D. Winwood and N. Bodor, "Lipophilicity, Solubility and Permeability of Loteprednol Etabonate: Novel Soft Anti-inflammatory Corticosteroid," *J. Biopharm. Sci.*, **2**(2), 115-125 (1991).
226. W. Anderson, E. Pop, S. Lee, M. Bhagrath, N. Bodor and M. Brewster, "Brain-Targeting Chemical Delivery Systems for Adenosine Depresses Locomotor Behavior in Rats," *Med. Chem. Res.*, **1**, 74-79 (1991).
227. W. Anderson, M. Rahimy, M. Brewster, N. Bodor and J. Simpkins, "The Effects of a Brain-Enhanced Estradiol Delivery System on Androgen and Androgen-Dependent Tissues. II. Assessment of the Testosterone Role," *Endocrinol.*, **129**(2), 726-733 (1991).
228. M. Bhagrath, R. Sidwell, K. Czako, K. Seyda, W. Anderson, N. Bodor and M. Brewster, "Improved Delivery Through Biological Membranes 54. Synthesis, Characterization and Antiviral Activity of a Series of Ribavirin Chemical Delivery Systems: 5' and Carboxamide Derivatives," *Antiviral Chem. & Chemo.*, **2**(5), 265-286 (1991).
229. M. Brewster, W. Anderson and N. Bodor, "Brain, Blood and Cerebrospinal Fluid Distribution of an Azidothymidine Chemical Delivery System in Rabbits," (Improved Delivery Through Biological Membranes. 52), *Pharm. Res.*, **80**(9) 843-846 (1991).
230. M. Brewster, W. Anderson, K. Estes and N. Bodor, "Development of Aqueous Parenteral Formulations for Carbamazepine Through the Use of Modified Cyclodextrins," *J. Pharm. Sci.*, **80**, 380-383 (1991).
231. M. Brewster, W. Anderson, K. Estes and N. Bodor, "Simple Reduced Nicotinamide Derivatives Exert Potent Anticonvulsant Activity," *Med. Chem. Res.*, **1**, 80-85 (1991).
232. M. Brewster, M. Deyrup, K. Seyda and N. Bodor, "Synthesis, Characterization and In Vitro Evaluation of Various Sulfonamide Chemical Delivery Systems," (Improved Delivery Through Biological Membranes. 46), *Int. J. Pharm.*, **68**, 215-229 (1991).
233. M. Brewster, D. Doerge, M. Huang, J. Kaminski, E. Pop and N. Bodor, "Application of Semiempirical Molecular Orbital Techniques to the Study of Peroxidase-Mediated Oxidation of Phenols, Anilines, Sulfides and Thiobenzamides," *Tetrahedron*, **47**(36), 7525-7536 (1991).
234. M. Brewster, M. Hora, J. Simpkins and N. Bodor, "Use of 2-Hydroxypropyl- β -cyclodextrin as a Solubilizing and Stabilizing Excipient for Protein Drugs," *Pharm. Res.*, **8**(6), 792-795 (1991).

235. M. Brewster, M. Huang and N. Bodor, "Reactivity of Biologically Important Reduced Pyridines IX. Effects of Substitution on Rotational Barriers in 1-Phenyl-1,4-dihydropyridine and the 1-Phenylpyridinium Cation and Related Systems," *J. Mol. Struct. (THEOCHEM)*, **257**, 49-56 (1991).
236. M. Brewster, M. Huang, J. Kaminski, E. Pop and N. Bodor, "Reactivity of Biologically Important Reduced Pyridines VIII. Use of Semiempirical Parameters to Probe Oxidative Conversion in a Series of 3-Substituted 1-Methyl-1,4 Dihydropyridines," *J. Comp. Chem.*, **12**, 1278-1282 (1991).
237. M. Brewster, M. Huang, J. Kaminski, E. Pop and N. Bodor, "Use of Semiempirical Molecular Orbital Parameters to Probe Dihydropyridine Stability - Implications to Brain-Targeting Chemical Delivery Systems," *Rev. Roumaine Chim.*, **36**, 647-656 (1991).
238. M. Brewster, T. Loftsson, J. Baldvinsdottir and N. Bodor, "Stabilization of Aspartame by Cyclodextrins," *J. Int. Pharm.*, **75**, R5-R8 (1991).
239. M. Deyrup, R. Sidwell, R. Little, P. Druzgala, N. Bodor and M. Brewster, "Improved Delivery Through Biological Membranes [55]. Synthesis and Antiviral Activity of a Series of Ribavirin Chemical Delivery Systems: 2' and 3' Derivatives," *Antiviral Chem. & Chemo.*, **2**(6), 337-355 (1991).
240. P. Druzgala and N. Bodor, "Regioselective Alkylation of Cortienic Acid and Synthesis of a New Class of Glucocorticoids Containing A 17 α -Alkoxy, A 17 α -(1'-Alkoxyethyloxy), A 17, α -Alkoxy-methyloxy, or A 17 α -Methylthiomethyloxy Function," *Steroids*, **56**, 490-494 (1991).
241. P. Druzgala, G. Hochhaus and N. Bodor, "Soft Drugs--10. Blanching Activity and Receptor Binding Affinity of a New Type of Glucocorticoid: Loteprednol Etabonate," *J. Steroid Biochem. Molec. Biol.*, **38**(2), 149-154 (1991).
242. P. Druzgala, W. Wu and N. Bodor, "Ocular Absorption and Distribution of Loteprednol Etabonate, A Soft Steroid in Rabbit Eyes," *Cur. Eye Res.*, **10**(10), 933-937 (1991).
243. K. Estes, P. Dewland, M. Brewster, H. Derendorf and N. Bodor, "A Redox-Based Chemical Delivery System (CDS) Applied to Estradiol," *Pharm. Zeit. Wissen.*, 153-158 (1991).
244. K. Estes, V. Keuth, K. Dietzel, M. Brewster, N. Bodor and H. Derendorf, "A Redox-Based Chemical Delivery System That Enhances Estradiol to the Brain: Disposition Studies in the Rat," *Pharm. Res.*, **8**(9), 1180-1185 (1991).

245. R. Hammer, W. Wu J. Sastry and N. Bodor, "Short Acting Mydriatics," *Cur. Eye Res.*, **10**(6), 565-570 (1991).
246. G. Hochhaus, P. Druzgala, R. Hochhaus, J. Huang and N Bodor, "Glucocorticoid Activity and Structure Activity Relationships in a Series of Some Novel 17- α -Ether-Substituted Steroids: Influence of 17- α Substituents," *Drug Des. & Del.*, **8**, 117-125 (1991).
247. T. Loftsson, M. Brewster, H. Derendorf and N. Bodor, "2-Hydroxypropyl- β -cyclodextrin: Properties and Usage in Pharmaceutical Formulations," *Pharm. Zeitung*, **1**, 5-10 (1991).
248. T. Loftsson, B. Olafsdottir and N. Bodor, "The Effects of Cyclodextrins on Transdermal Delivery of Drugs," *Eur. J. Pharm. Biopharm.*, **37**(1), 30-33 (1991).
249. S. Nishitani and N. Bodor, "Polymer Supported 1-Benzyl-1,2-Dihydroisonicotinamides as Reducing Agents," *Rev. Roumaine Chim.*, **36**, 635-645 (1991).
250. P. Polgar and N. Bodor, "Cardiac Electrophysiologic Effects of Adaprolol Maleate, a New β -Blocker, in Closed Chest Dogs," (Soft Drugs 11), *Life Sci.*, **48**(16), 1519-1528 (1991).
251. E. Pop, W. Anderson, M. Brewster and N. Bodor, "Enhanced Monamine Oxidase Inhibitor Activity of Tranlylcypromine," *Med. Chem. Res.*, **1**, 230-234 (1991).
252. E. Pop, W. Anderson, K. Prokai-Tatrai, M. Brewster and N. Bodor, "Redox Analogs of Centrally Acting Amines: Design, Synthesis and Properties of a Tranlylcypromine Derivative with a Potentially Enhanced Therapeutic Index," (Improved Delivery Through Biological Membranes. 53), *J. Biopharm. Sci.*, **2**(1), 11-23 (1991).
253. E. Pop, M. Brewster and N. Bodor, "Improved Central Nervous System Delivery and Activity of Antiepileptic Drugs," *Drugs of the Future*, **16**(3), 221-248 (1991).
254. E. Pop, M. Brewster and N. Bodor, "Site Specific Delivery of the Central Nervous System Acting Amines," *Drugs of the Future*, **16**(10), 919-944 (1991).
255. E. Pop, M. Huang, N. Bodor, S. Bercovici and S. Shatzmiller, "Ionic and Radical Intermediates of 3-Substituted 5,6-Dihydro-1,4,2-Dioxazines; A Theoretical (AM1) Study," *J. Mol. Struct. (THEOCHEM)*, **235**, 343-353 (1991).
256. E. Pop, M. Huang, S. Matei, M. Brewster and N. Bodor, "Electrophilic Substitution in the Benzofuran Series: A Theoretical (AM1) Study," *Int. J. Quant. Chem.: Quant. Chem. Symp.*, **25**, 325-333 (1991).

257. E. Pop, T. Loftsson and N. Bodor, "Solubilization and Stabilization of a Benzylpenicillin Chemical Delivery System by 2-Hydroxypropyl- β -Cyclodextrin," *Pharm. Res.*, **8**(8) 1044-1049 (1991).
258. K. Prokai-Tatrai, E. Pop, W. Anderson, J. Lin, M. Brewster and N. Bodor, "Redox Derivatives of Tranylcypromine: Syntheses, Properties and Monoamine Oxidase Inhibitor Activity of Some Chemical Delivery Systems and Novel Analogs," (Improved Delivery Through Biological Membranes. 51), *J. Pharm. Sci.*, **80**(3), 255-261 (1991).
259. K. Prokai-Tatrai, E. Pop, W. Anderson, J. Lin, M. Brewster and N. Bodor, "Redox Derivatives of Tranylcypromine: Syntheses, Properties and Monoamine Oxidase Inhibitor Activity of Some Chemical Delivery Systems and Novel Analogs," (Improved Delivery Through Biological Membranes. 51), selected to be published in recognition of excellence in *Clinical Digest Series* (1991).
260. L. Prokai and N. Bodor, "Reversed-Phase High-Performance Liquid Chromatography - Thermospray Mass Spectrometry of Alprenolol and Its Ketoxime Analogues," *J. Chromatog.*, **541**, 474-479 (1991).
261. L. Prokai, A. Simay and N. Bodor, "Reversed-Phase High-Performance Liquid Chromatography and Liquid Chromatography of Ketoxime Analogues of β -Adrenergic Blockers," *J. of Chromatog.*, **541**, 469-473 (1991).
262. M. Rahimy, W. Anderson, M. Brewster, N. Bodor and J. Simpkins, "The Effects of Brain-Enhanced Estradiol Delivery System on Androgen and Androgen-Dependent Tissues. I. Dose-Response and Time-Course Evaluation," *Endocrinol.*, **129**(2), 717-725 (1991).
263. M. Rahimy, N. Bodor and J. Simpkins, "Effects of a Brain-Enhanced Estrogen Delivery System on Tail-Skin Temperature of the Rat: Implications for Menopausal Hot Flush," *Maturitas*, **13**, 51-63 (1991).
264. W. Wu, E. Pop, E. Shek, R. Clemmons and N. Bodor, "Brain and CSF Specific Chemical Delivery Systems for β -Lactam Antibiotics. In Vitro and In Vivo Studies of Dihydropyridine Derivatives of Benzylpenicillin in Rabbits and Dogs," (Improved Drug Delivery Series 48), *Drug Des. & Del.*, **7**, 33-43 (1991).
265. N. Bodor, "New Methods of Drug Targeting," chapter in *Trends in Medicinal Chemistry '90*, S. Sarel, R. Mechoulam and I. Agranat, Eds., Blackwell Scientific Publications, 35-44 (1992).
266. N. Bodor, Nicole Bodor and W. Wu, "A Comparison of Intraocular Pressure Elevating Activity of Loteprednol Etabonate and Dexamethasone in Rabbits," *Cur. Eye Res.*, **11**(6), 525-530 (1992).

267. N. Bodor and A. ElKoussi, "A New Ocular Site-Specific Chemical Delivery System for Antiglaucoma Drugs," *S.T.P Pharma Sciences*, **2**(1), 61-67 (1992).
268. N. Bodor and M. Huang, "An Extended Version of a Novel Method for the Estimation of Partition Coefficients," *J. Pharm. Sci.*, **81**(3), 272-281 (1992).
269. N. Bodor and M. Huang, "Intermolecular Interactions of Methyl Acetate, β -Propiolactone, Ethyl Acetate and γ -Butyrolactone: An AM1 Study," *Int. J. Quantum Chem.*, **44**, 81-89 (1992).
270. N. Bodor and M. Huang, "A New Method for the Estimation of the Aqueous Solubility of Organic Compounds," *J. Pharm. Sci.*, **81**(9), 954-960 (1992).
271. N. Bodor and M. Huang, "Optimized Structures and Relative Stabilities of the Isomers of $(\text{CO}_2)_{2n-1}$ ($1 \leq n \leq 6$) from AM1 Calculations," *Chem. Physics Letters*, **192**(4), 386-389 (1992).
272. N. Bodor, M. Huang and A. Harget, "Neural Network Studies. 4. An Extended Study of the Aqueous Solubility of Organic Compounds," *Int. J. Quan. Chem.: Quant Chem. Symp.*, **26**, 853-867 (1992).
273. N. Bodor, M. Huang, C. Szantay and C. Szantay, Jr., "On the Reactivity of $\text{CF}_n\text{H}_{3-n}\text{CH}_2\text{X}$ ($n = 0, 1, 2$, and 3 , and $\text{X} = \text{H}$ or Halogen Atom)," *Tetrahedron*, **48**(28), 5823-5830 (1992).
274. N. Bodor, E. Koltai and L. Prokai, "Borohydride Reduction of Imidazolidino[1,2-d]dithiazepines+," *Tetrahedron*, **48**(23), 4767-4772 (1992).
275. N. Bodor, T. Loftsson and W. Wu, "The Metabolism, Distribution and Transdermal Permeation of a Soft Corticosteroid, Loteprednol Etabonate," *Pharm. Res.*, **9**(10), 1275-1278 (1992).
276. N. Bodor and L. Prokai, "Intermediates of the Borane Reduction of Some Imidazolidines: An AM1 Study," *Int. J. Quantum Chem.*, **44**, 795-805 (1992).
277. N. Bodor, L. Prokai, W. Wu, H. Farag, S. Jonnalagadda, M. Kawamura and J. Simpkins, "A Strategy for Delivering Peptides into the Central Nervous System by Sequential Metabolism," *Science*, **257**, 1698-1700 (1992).
278. D. Bailey, R. Perchalski, M. Bhagrath, E. Shek, D. Winwood and N. Bodor, "Synthesis of Pyridinium Salt Derivatives of 1,1'-[[1-{Aminomethyl}-1,2-Ethandediyl]Diimino]Bis[2-Met hyl-2 -Propanethiol]: Potential Brain Specific Ligands Tc-99m Complexes," *J. Biopharm. Sci.*, **2**(3), 205-218 (1992).

279. M. Brewster, W. Anderson and N. Bodor, "Enhanced Brain Delivery of Amino Acids and Peptides Through the Use of Redox Targeting Systems," in *Treatment of Dementias: A New Generation of Progress*, E. Meyer, J. Simpkins and J. Yamamoto, Eds., Plenum Press, New York, 301-316 (1992).
280. M. Brewster and N. Bodor, "Parenteral Safety and Applications of 2-Hydroxypropyl- β -Cyclodextrin," In *Proceedings of the Fifth International Symposium on Cyclodextrins*, D. Duchene, Ed., Editions de Sante Publishers, Paris, 315-350 (1992).
281. M. Brewster and N. Bodor, "Redox Approaches to Drug Delivery to the Central Nervous System," *NIDA Research Monograph Series, Bioavailability of Drugs to the Brain and the Blood-Brain Barrier*, J. Frankenheim and R. Brown, Eds., **120**, 169-201 (1992).
282. M. Brewster, M. Huang, A. Harget and N. Bodor, "Neural Network Studies 2. Use of a Neural Net to Estimate Oxidation Energies for Substituted Dihydropyridines and Related Heterocycles," *Tetrahedron*, **48**(17), 3463-3472 (1992).
283. N. Brewster, T. Loftsson, K. Estes, J. Lin and N. Bodor, "Effect of Various Cyclodextrins on Solution Stability and Dissolution Rate of Doxorubicin Hydrochloride," *Int. J. Pharm.*, **79**(2-3), 289-299 (1992).
284. P. Druzgala, D. Winwood, M. Drewniak-Deyrup, S. Smith, N. Bodor and J. Kaminski, "New Water Soluble Pilocarpine Derivatives with Enhanced and Sustained Muscarinic Activity," *Pharm. Res.*, **9**(3), 372-377 (1992).
285. A. Harget and N. Bodor, "Computer-Aided Drug Design: A Neural Network Approach," *Pers. Comps. & Intel. Sys.*, F. Vogt, Ed., Elsevier Science Publishers, North Holland, 252-258 (1992).
286. G. Hochhaus, L. Chen, A. Ratka, P. Druzgala, J. Howes, N. Bodor and H. Derendorf, "Pharmacokinetic Characterization and Tissue Distribution of the New Glucocorticoid Soft Drug Loteprednol Etabonate in Rats and Dogs," *J. Pharm. Sci.*, **81**, 1210-1215 (1992).
287. M. Huang and N. Bodor, "Structure Studies of Bitetrahedryl Molecule C₈H₆, Coupled Tricyclo[3.1.0.0]Hexyl Molecule C₁₂H₁₄, and Coupled Bicyclo[1.1.0]Butane Derivatives," *Chem. Physics Letters*, **190**(1,2), 25-28 (1992).
288. E. Pop, W. Anderson, K. Prokai-Tatrai, J. Vlasak, M. Brewster and N. Bodor, "Syntheses and Preliminary Pharmacological Evaluation of Some Chemical Delivery Systems of 2,6-Diisopropylphenol (Propofol)," *Med. Chem. Res.*, **2**, 16-21 (1992).

289. E. Pop, W. Anderson, J. Vlasak, M. Brewster and N. Bodor, "Enhanced Brain Delivery of 2'-Fluoro-5-Methylarabinosyluracil," (Improved Delivery Through Biological Membranes. LVII.), *Int. J. Pharm.*, **84**, 39-48 (1992).
290. E. Pop and N. Bodor, "Chemical Systems for Delivery of Antiepileptic Drugs to the Central Nervous System," *Epilepsy Res.*, **13**, 1-16 (1992).
291. E. Pop, M. Brewster, W. Anderson and N. Bodor, "Biodistribution of Azidothymidine Mediated by a Highly Lipophilic Chemical Delivery System," *Med. Chem. Res.*, **2**, 457-466 (1992).
292. E. Pop, M. Huang, M. Brewster and N. Bodor, "A Theoretical Study of the Hydrolysis of Some Sterically Hindered Phenolic Esters," *Int. J. Quant. Chem.: Quant. Biol. Symp.*, **19**, 77-85 (1992).
293. K. Raghavan, T. Loftsson and N. Bodor, "Improved Delivery Through Biological Membranes XLV: Synthesis, Physical-Chemical Evaluation, and Brain Uptake Studies of 2-Chloroethyl Nitrosourea Delivery Systems," *Pharm. Res.*, **9**(6), 743-749 (1992).
294. M. Rahimy, N. Bodor and J. Simpkins, "Evaluation of a Novel Redox-Based Estrogen Chemical Delivery System for the Brain," *Trends in Medicinal Chemistry '90*, S. Sarel, R. Mechoulam and Agranat, Eds., Blackwell Scientific Publications, 369-376 (1992).
295. A. Simay and N. Bodor, "Site- and Stereospecific Drug Delivery to the Eye," *Trends in Medicinal Chemistry '90*, S. Sarel, R. Mechoulam and I. Agranat, Eds., Blackwell Scientific Publications, 361-368 (1992).
296. J. Simpkins and N. Bodor, "Brain-Enhanced Drug Delivery Systems for the Treatment of Dementia," Chapter 4 in *Alzheimer's Disease*, Z. Khachaturian and J. Blass, Eds., Marcel Dekker, Inc., New York, 37-55 (1992).
297. J. Simpkins and N. Bodor, "Brain Targeted Delivery of Neurotransmitters: Use of a Redox Based Chemical Delivery System," chapter in *The Treatment of Dementias, A New Generation of Progress*, E. Meyer, J. Simpkins, F. Crews and J. Yamamoto, Eds., Plenum Press, New York, 317-331 (1992).
298. J. Simpkins, M. Rahimy and N. Bodor, "Enhanced Brain Delivery of Steroids and Neurotransmitters," Proc. of 18th Intl. Symp. of Controlled Release of Bioactive Materials, (1992).
299. N. Bodor, "Design of Novel Soft Corticosteroids," in *Topical Glucocorticoids with Increased Benefit-Risk Ratio*, Vol. 21 of *Cur. Probl. Dermatol.*, H. Korting, Ed., 11-19 (1993).

300. N. Bodor, "Soft Drugs," *Hungarian Chem. Journal*, **2**, 45-58 (1993).
301. N. Bodor and M. Brewster, "Chemical Approaches to Brain-Targeting of Biologically Active Compounds," chapter in *Organic Chemistry for the Neurosciences*, A. Kozikowski, Ed., Raven Press, 435-467 (1993).
302. N. Bodor, M. Huang and J. Kaminski, "A Theoretical Study of Prednisolone, 6 α -Flouroprednisolone, 9 α -Flouroprednisolone, 6 α ,9 α -Difluoroprednisolone and Related Compounds," *J. Mol. Struct. (THEOCHEM)*, **279**, 59-69 (1993).
303. C. Betlach, M. Gonzalez, B. McKiernan, C. Neff-Davis and N. Bodor, "The Oral Pharmacokinetics of Carbamazepine in Dogs from Commercial Tablets and a Cyclodextrin Complex," *J. Pharm. Sci.*, **82**(10), 1058-1060 (1993).
304. M. Brewster, M. Huang, E. Pop and N. Bodor, "Hydroxyl Stretching in Substituted Phenols: An AM1 Study," *Int. J. Quant. Chem.: Quant Biol. Symp.*, **20**, 7-15 (1993).
305. M. Brewster, M. Huang, E. Pop, J. Pitha, M. Dewar, J. Kaminski and N. Bodor, "An AM1 Molecular Orbital Study of α -D-Glucopyranose and β -Maltose: Evaluation and Implications," *Carbohydrate Res.*, **242**, 53-67 (1993).
306. M. Brewster, E. Pop and N. Bodor, "Chemical Approaches to Brain-Targeting of Biologically Active Compounds," chapter 16 in *Drug Des. for Neuroscience*, A. Kozikowski, Ed., Raven Press, Ltd., New York, 435-467 (1993).
307. M. Brewster, E. Pop, A. Braunstein, A. Pop, P. Druzgala, W. Anderson, A. ElKoussi and N. Bodor, "The Effect of Dihyronicotinate N-Substitution on the Brain-Targeting Efficacy of a Zidovudine Chemical Delivery System," *Pharm. Res.*, **10**(9), 1356-1362 (1993).
308. R. Hammer, E. Gunes, G. Kumar, W. Wu, V. Srinivasan and N. Bodor, "Soft Drugs--XIV. Synthesis and Anticholinergic Activity of Soft Phenylsuccinic Analogs of Atropine," *Bioorg. & Med. Chem.*, **1**(3), 183-187 (1993).
309. G. Kumar, R. Hammer and N. Bodor, "Soft Drugs 12. Design, Syntheses, Stability and Evaluation of Soft Anticholinergics," *Drug Des. & Discov.*, **10**, 11-21 (1993).
310. G. Kumar, R. Hammer and N. Bodor, "Soft Drugs 13: Design and Evaluation of Phenylsuccinic Analogs of Scopolamine as Soft Anticholinergics," *Drug Des. & Discov.*, **10**, 1-9 (1993).

311. G. Kumar, R. Hammer, W. Wu and N. Bodor, "Soft Drugs 15. Mydriatic Activity of Phenylsuccinic Analogs of Methscopolamine and Transcorneal Penetration of Short Acting Mydriatics," *Cur. Eye Res.*, **12**(6), 501-506 (1993).
312. G. Kumar, R. Hammer and N. Bodor, "Soft Drugs 16. Design, Evaluation and Transdermal Penetration of Novel Soft Anticholinergics Based on Methatropine," *Bioorg. & Med. Chem.*, **1**(5), 327-332 (1993).
313. E. Pop, M. Brewster, M. Huang and N. Bodor, "Dihydropyridine Isomerisms in the Chemical Delivery System Series," *Croat. Chem. Acta*, **66**(3-4), 531-537 (1993).
314. E. Pop, M. Brewster, M. Huang and N. Bodor, "Dithionite Reduction of Pyridinium Salts: An AM1 Study," *J. Mol. Struct. (THEOCHEM)*, **283**, 27-32 (1993).
315. E. Pop, M. Brewster, M. Huang and N. Bodor, "A Theoretical Study of Dithionite Reduction of Pyridinium Salts," *Int. J. Quant. Chem.: Quant. Chem. Symp.* **20**, 17-24 (1993).
316. E. Pop, Z. Liu, J. Vlasak, W. Anderson, M. Brewster and N. Bodor, "A Dihydroisoquinoline Targetor-Based Acid Resistant Chemical Delivery System of Azidothymidine (AZT)," *Drug Del.*, **1**, 143-149 (1993).
317. L. Prokai, K. Prokai-Tatrai, E. Pop, N. Bodor, J. Lango and J. Roboz, "Fast Atom Bombardment and Tandem Mass Spectrometry of Quaternary Pyridinium Salt-Type Tryptophan Derivatives," *Org. Mass Spectrom.*, **28**, 707-715 (1993).
318. M. Rahimy, N. Bodor and J. Simpkins, "Suppression of Plasma Testosterone and Prostate Carcinoma Size by a Redox-Based, Brain-Targeted Estrogen Delivery System in the Rat," *The Prostate*, **23**, 79-90 (1993).
319. I. Reddy and N. Bodor, "Chemical Approaches to Design Ophthalmic Drugs," *Ind. J. Pharm. Sci.*, **55**(5), 163-167 (1993).
320. S. Yoon, N. Bodor and J. Simpkins, "Synthesis and In Vitro Dopaminergic Activity of (2'Aminoethyl)-1-Hydroxy-2-Pyridone Type Dopamine Analogs," *Drug Des. & Discov.*, **10**, 35-44 (1993).
321. N. Bodor, "Designing Safer Ophthalmic Drugs by Soft Drug Approaches," *J. Ocular Pharmacol.*, **10**(1), 3-15 (1994).
322. N. Bodor, "Drug Targeting and Retrometabolic Drug Design Approaches," *Adv. Drug Del. Revs.*, **14**, 157-166 (1994).

323. N. Bodor, "Optimizing Drug Targeting by Combination of Delivery Systems and Cyclodextrins," *Proceedings of the 7th International Cyclodextrins Symposium*, April 25-29, 1994, Tokyo, Japan, 3-12 (1994).
324. N. Bodor, A. Harget and M. Huang, "Neural Network Studies. Part 3. Prediction of Partition Coefficients," *J. Mol. Struct. (Theochem)*, **309**, 259-266 (1994).
325. N. Bodor and L. Prokai, "Delivery of Peptides into the Central Nervous System by Sequential Metabolism," in *Peptides: Chemistry, Structure and Biology*, (Proceedings of the Thirteenth American Peptide Symposium, Edmonton, Alberta, Canada, June 20-25, 1993), ESCOM Science, Leiden, The Netherlands, R.S. Hodges and J.A. Smith, Eds., 830-833 (1994).
326. W. Anderson, M. Brewster, E. Pop, K. Estes and N. Bodor, "Improvement of Parenteral Formulations for Traditional Antiepileptics," *J. Parenteral Sci. Technol.*, **48**(6), 333-335 (1994).
327. M. Brewster and N. Bodor, "Improved Brain Delivery of Antiviral Agents Through the Use of Redox Targeting," *Adv. Drug Del. Revs.*, **14**, 177-197 (1994).
328. M. Brewster, A. Braunstein, M. Bartruff, E. Pop and N. Bodor, "Solubilization and Electrochemical Stabilization of Substituted Phenols Through the Use of 2-Hydroxypropyl- β -cyclodextrin," *Supramolecular Chem.*, **4**, 69-76 (1994).
329. M. Brewster, C. Kibbey, M. Huang, E. Pop and N. Bodor, "Interaction of Substituted Phenols and 2-Hydroxypropyl- β -Cyclodextrin," *Proceedings of the 7th International Cyclodextrins Symposium*, April 25-28, 1994, Tokyo, Japan, 250-253 (1994).
330. M. Brewster, E. Pop, M. Huang and N. Bodor, "Contributions of Molecular Orbital Techniques to the Study of Dihydropyridines," *Heterocycles*, **37**(2), 1373-1415 (1994).
331. M. Brewster, E. Pop, M. Huang and N. Bodor, "Rotational Barriers in Phenol and Sterically Congested Phenol Derivatives, an AM1 Study," *J. Mol. Struct. (Theochem)*, **303**, 25-38 (1994).
332. M. Brewster, V. Raghavan, E. Pop and N. Bodor, "Enhanced Delivery of Ganciclovir to the Brain through Use of Redox Targeting," *Antimicrob. Agts. and Chemo.*, **38**(4) 817-823 (1994).
333. M. Brewster, M. Scott, M. Bartruff, W. Anderson, P. Druzgala, N. Bodor and E. Pop, "Effect of Molecular Manipulation on the Estrogenic Activity of a Brain-Targeted Estradiol Chemical Delivery System," *J. Med. Chem.*, **37**, 4237-4244 (1994).

334. P. Chikhale, E. Marvanyos and N. Bodor, "Improved Delivery Through Biological Membranes LXI: Design, Synthesis, and Evaluation of a Lipolol-Based Intradermal Drug Targeting System for 5-Flourouracil," *Cancer Biother.*, **9**(3), 245-252 (1994).
335. K. Estes, M. Brewster and N. Bodor, "Evaluation of an Estradiol Chemical Delivery System (CDS) Designed to Provide Enhanced and Sustained Hormone Levels in the Brain," in *Adv. Drug Del. Revs.*, **14**, 167-175 (1994).
336. M. Huang and N. Bodor, "Quantitative Structure-Inhibitory Activity Relationships of Substituted Phenols on Bacillus Subtilis Spore Germination," *Int. J. Quant. Chem.: Quant. Biol. Symp.* **21**, 181-185 (1994).
337. G. Kumar, M. Huang, R. Hammer and N. Bodor, "Soft Drugs 17: Quantitative Structure-Activity Relationships of Soft Anticholinergics Based on Methatropine and Methscopolamine," *J. Pharm. Sci.*, **83**(1), 117-118 (1994).
338. T. Loftsson and N. Bodor, "The Pharmacokinetics and Transdermal Delivery of Loteprednol Etabonate and Related Soft Steroids," *Adv. Drug Del. Revs.*, **14**, 293-299 (1994).
339. A. Miyake and N. Bodor, "Improved Delivery Through Biological Membranes XXXV. Synthesis of Novel Bioreversible Redox Derivatives of Trifluorothymidine," *Pharm. Sci. Comms.*, **4**(4), 231-237 (1994).
340. F. Omar, H. Farag and N. Bodor, "Synthesis and Evaluation of a Redox Chemical Delivery System for Brain-Enhanced Dopamine Containing an Activated Carbamate-Type Ester," *J. Drug Targeting*, **2**, 309-316 (1994).
341. E. Pop, M. Brewster, A. Dinculescu, M. Huang and N. Bodor, "Isomerism of Cephalosporin Esters; Theoretical and Practical Aspects," *Heterocycles*, **37**(1), 477-486 (1994).
342. E. Pop, M. Brewster, K. Prokai-Tatrai and N. Bodor, "Novel Redox Derivatives of Tryptophan," *Heterocycles*, **38**, 2051-2064 (1994).
343. E. Pop, M. Brewster, K. Prokai-Tatrai and N. Bodor, "Preparation of Redox Derivatives of 3 α -Hydroxy-5 α -Pregnane-11,20-Dione," *OPPI Briefs*, **26**(3), 379-382 (1994).
344. E. Pop, M. Huang, M. Brewster and N. Bodor, "On the Mechanism of Cephalosporin Isomerization," *J. Mol. Struct. (THEOCHEM)*, **315**, 1-7 (1994).
345. E. Pop, M. Huang, M. Brewster and N. Bodor, "Stability of the 1,3-Substituted 1,4-Dihydropyridines; Substituent Effects on the Acid Catalyzed Hydration and Oxidation Reactions," *Int. J. Quant. Chem.: Quant. Biol. Symp.* **21**, 173-180 (1994).

346. E. Pop, K. Prokai-Tatrai, M. Brewster and N. Bodor, "Analogues of Tryptophan," *OPPI Briefs*, **26**(6), 687-690 (1994).
347. L. Prokai, X. Ouyang, W. Wu and N. Bodor, "Chemical Delivery System to Transport a Pyroglutamyl Peptide Amide to the Central Nervous System," *J. Am. Chem. Soc.*, **116**(6), 2643-2644 (1994).
348. I. Reddy and N. Bodor, "In Vitro Evaluation of a Controlled-Release, Site-Specific Diisovaleryl tert-Butalonyl Chemical Delivery System for the Eye," *J. Pharm. Sci.*, **83**(3), 450-453 (1994).
349. I. Reddy and N. Bodor, "Novel Approaches to Design and Deliver Safe and Effective Anti-glaucoma Agents to the Eye," *Adv. Drug Del. Revs.*, **14**, 251-267 (1994).
350. J. Simpkins and N. Bodor, "Enhanced Delivery of Steroids to the Brain Using a Redox-Based Chemical Delivery System," in *Methods in Neurosciences*, **22**, R. de Kloet and W. Sutanto, Eds., 23-35 (1994).
351. J. Simpkins and N. Bodor, "The Brain-Targeted Delivery of Dopamine Using a Redox Based Chemical Delivery System," *Adv. Drug Del. Revs.*, **14**, 243-249 (1994).
352. J. Simpkins, X. Ouyang, L. Prokai and N. Bodor, "Delivery of Peptides into the Central Nervous System by Molecular Packaging and Sequential Metabolism as a Method to Alter Neuropeptide Activity During Aging," *Neuroprotocols*, **4**, 225-234 (1994).
353. N. Bodor, "Design of Biologically Safer Chemicals," *Chemtech*, October, 22-32 (1995).
354. N. Bodor, "Retrometabolic Approaches to Drug Targeting," in *NIDA Research Monograph Series, Membranes and Barriers: Targeted Drug Delivery*, R. Rapaka, Ed., **154**, 1-27 (1995).
355. N. Bodor, "Retrometabolic Drug Design Concepts in Ophthalmic Target-Specific Drug Delivery," *Adv. Drug Del. Revs.*, **16**, 21-38 (1995).
356. N. Bodor, "Targeted Drug Delivery to the Brain Using Chemical Delivery Systems," *Medicinal Chemistry: Today and Tomorrow; Proceedings of the AFMC International Medicinal Chemistry Symposium (AIMECS '95) Tokyo (Japan): 3-8 September 1995*, Blackwell Science, Oxford, 183-190 (1995).
357. N. Bodor, "Targeting Drugs to the Brain by Sequential Metabolism," *NIDA Research Monograph Series, Discovery of Novel Opioid Medications*, R. Rapaka and H. Sorer, Eds., **147**, 1-32 (1995).

358. N. Bodor, H. Farag and F. Omar, "Preparation, Preliminary Characterization and Complexation of a Crystalline Redox-Based Chemical Delivery System for Dopamine," *Pharm. Sci.*, **1**, 301-306 (1995).
359. N. Bodor and M. Huang, "Computer-Aided Design of New Drugs Based on Retrometabolic Concepts," chapter 7 in *Computer Aided Molecular Design*, ACS Symposium Series 589, C. Reynolds, M. Holloway and H. Cox, Eds., 98-113 (1995).
360. N. Bodor, M. Huang and J. Watts, "Theoretical Studies on the Structures of Natural and Alkylated Cyclodextrins," *J. Pharm. Sci.*, **84**(3), 330-336 (1995).
361. N. Bodor, T. Murakami, and W. Wu, "Soft Drugs 18. Oral and Rectal Delivery of Loteprednol Etabonate, a Novel Soft Corticosteroid, in Rats - For Safer Treatment of Gastrointestinal Inflammation," *Pharm. Res.*, **12**(6), 869-874 (1995).
362. N. Bodor, T. Murakami, W. Wu, and S. Engel, "Soft Drugs 19. Pharmacokinetics, Metabolism and Excretion of a Novel Soft Corticosteroid, Loteprednol Etabonate, in Rats," *Pharm. Res.*, **12**(6), 875-879 (1995).
363. N. Bodor and L. Prokai, "Molecular Packaging: Peptide Delivery to the Central Nervous System by Sequential Metabolism," chapter 14 in *Peptide-Based Drug Design: Controlling Transport and Metabolism*, M. Taylor and G. Amidon, Eds., ACS Professional Reference Book, 317-337 (1995).
364. N. Bodor, L. Prokai, W. Wu, G. Somogyi and H. Farag, "Sequential Bioactivation of Methoxime Analogs of β -Adrenergic Antagonists in the Eye," Proceedings of the annual Meeting of the Association for Ocular Pharmacology and Therapeutics in *J. Ocular Pharmacol. & Ther.*, **11**(3), 305-318 (1995).
365. S. Anselem, D. Friedman, A. Yogev, W. Anderson, D. Helton, N. Bodor, E. Pop and M. Brewster, "Formulation Development for a Zidovudine Chemical Delivery System: Towards Oral and Non-Parenteral Dosage Forms," *Int. J. Pharm.*, **125**, 31-43 (1995).
366. M. Brewster, W. Anderson, K. Estes, N. Bodor, E. Pop and J. Panetta, "Tissue Distribution of LY231617, An Antioxidant with Neuroprotectant Activity, in the Rat," *J. Pharm. Sci.*, **84**(7), 791-793 (1995).
367. M. Brewster, W. Anderson, D. Helton, N. Bodor and E. Pop, "Dose-Dependent Brain Delivery of Zidovudine Through the Use of a Zidovudine Chemical Delivery System," *Pharm. Res.*, **12**(5), 796-798 (1995).

368. M. Brewster, W. Anderson, T. Loftsson, N. Bodor and E. Pop, "Preparation, Characterization and Anesthetic Properties of 2-Hydroxypropyl- β -cyclodextrin Complexes of Pregnanolone and Pregnenolone in Rat and Mouse," *J. Pharm. Sci.*, **84**, 1154-1159 (1995).
369. M. Brewster and N. Bodor, "Passive and Facilitative Transport of Nucleobases, Nucleosides, and Oligonucleotides - Application to Antiviral and Other Therapies," *NIDA Research Monograph Series, Membranes and Barriers: Targeted Drug Delivery*, R. Rapaka, Ed., **154**, 61-85 (1995).
370. M. Brewster, P. Druzgala, W. Anderson, M. Huang, N. Bodor and E. Pop, "Efficacy of a 3-Substituted versus 17-Substituted Chemical Delivery System for Estradiol Brain Targeting," *J. Pharm. Sci.*, **84**(1), 38-43 (1995).
371. M. Brewster, M. Huang, C. Browne, N. Bodor and E. Pop, "Relative Reactivity of 1,4- and 1,6-Dihydronicotinic Acid Derivatives to Radically Mediated Oxidation - A Theoretical and Experimental Evaluation," *Int. J. Quant. Chem.: Quant. Biol. Symp.*, **22**:161-170 (1995).
372. M. Brewster, M. Huang, E. Pop and N. Bodor, "Isomeric Interconversions in Tamoxifen and Related Compounds, An AM1 Study," *Int. J. Quant. Chem.*, **53**, 343-352 (1995).
373. M. Huang, D. Doerge, N. Bodor, E. Pop and M. Brewster, "Nitrogen Radical Cations as Intermediates in Enzymatically Mediated Oxidative Deaminations - Application of Molecular Parametric Models," *Int. J. Quant. Chem.: Quant. Biol. Symp.*, **22**:171-179 (1995).
374. A. Kourounakis, M. Badawi, N. Bodor and J. Simpkins, "Synthesis of Two Isomers of 4-Methylcatechol and Evaluation of Their NGF-Inducing Effect," *Pharm. Sci.*, **1**, 407-410 (1995).
375. A. Kourounakis and N. Bodor, "Quantitative Structure Activity Relationships of Catechol Derivatives on Nerve Growth Factor Secretion in L-M Cells," *Pharm. Res.*, **12**(8), 1199-1204 (1995).
376. T. Loftsson and N. Bodor, "The Effect of Cyclodextrins on Percutaneous Transport of Drugs," chapter 13.1 in *Percutaneous Penetration Enhancers*, E. Smith and H. Maibach, Eds., CRC Press, Inc., Boca Raton, 335-342 (1995).
377. P. Polgar and N. Bodor, "Minimal Cardiac Electrophysiological Activity of Alprenoxime, A Site-Activated Ocular β -Blocker, in Dogs," *Life Sci.*, **56**(14), 1207-1213 (1995).
378. E. Pop, M. Brewster, M. Huang and N. Bodor, "Substituent Effects on the Stability of 1,4-Dihydropyridines," *J. Mol. Struct. (THEOCHEM)*, **337**, 49-55 (1995).

379. E. Pop, M. Huang, N. Bodor and M. Brewster, "Hydrolytic Stability of Allylic and Phenolic Esters of Some Synthetic Cannabinoids; A Theoretical (AM1) Study," *Int. J. Quant. Chem.: Quant. Biol. Symp.* **22.**, John Wiley & Sons, 137-143 (1995).
380. E. Pop, Z. Liu, J. Vlasak, W. Anderson, M. Brewster and N. Bodor, "Synthesis and Evaluation of a Novel Chemical Delivery System of Zidovudine with Increased Stability at Low pH," *Pharm. Sci.*, **1**, 265-269 (1995).
381. L. Prokai, W. Wu, G. Somogyi and N. Bodor, "Ocular Delivery of β -Adrenergic Antagonist Alprenolol by Sequential Bioactivation of Its Methoxime Analog," *J. Med. Chem.*, **38**(11), 2018-2020 (1995).
382. S. Anselem, D. Friedman, A. Yogev, W. Anderson, D. Helton, N. Bodor, E. Pop and M. Brewster, "Formulation Development for a Zidovudine Chemical Delivery System: Parenteral dosage forms," *Int. J. Pharm.*, **125**, 17-30 (1995).
383. H. Yang, W. Wu and N. Bodor, "Soft Drugs 20. Design, Synthesis and Evaluation of Ultra-Short Acting Beta-Blockers," *Pharm. Res.*, **12**(3), 329-336 (1995).
384. N. Bodor, "Design of Biologically Safer Chemicals Based on Retrometabolic Concepts," chapter 5 in *Designing Safer Chemicals*, **III**, ACS Books, R. Garrett and S. DeVito, Eds., ACS Symposium Series, 84-115 (1996).
385. N. Bodor, "The Use of Retrometabolic Drug Design Concepts in Ophthalmic Drug Discovery," in *Ocular Therapeutics and Drug Delivery*, I. Reddy, Ed., Technomic Publishing Company, Inc., Lancaster, PA, chapter 11, 335-361 (1996).
386. N. Bodor, A. ElKoussi, K. Zuobi and P. Kovacs, "Synthesis and Pharmacological Activity of Adaprolol Enantiomers: A New Soft Drug for Treating Glaucoma," *J. Ocular Pharmacol. & Ther.*, **12**(2), 115-122 (1996).
387. N. Bodor and M. Huang, "Computational Approaches to the Design of Safer Drugs and Their Molecular Properties," chapter 7 in *Computational Chemistry: Reviews of Current Trends*, Volume 1, J. Leszczynski Ed., World Scientific, Singapore, 219-266 (1996).
388. N. Bodor, M. Huang and J. Watts, "Theoretical AM1 Studies of Inclusion Complexes of α - and β -Cyclodextrins With Methylated Benzoic Acids and Phenol, and γ -Cyclodextrin With Buckminsterfullerene," *Proceedings of the Eighth International Symposium on Cyclodextrins Symposium, Budapest (Hungary): 3-30 to 4-02, 1996*, and *Journ. Incl. Phenomena and Mol. Recog. In Chem.*, **25**(1-3), 97-102 (1996).

389. M. E. Brewster, W. R. Anderson, T. Loftsson, N. Bodor and E. Pop, "Effect of 2-Hydroxypropyl- β -Cyclodextrin Complexes of the Neurosteroids, Alfaxalone, Pregnanolone And Pregnenolone, On Various Convulsant Stimuli In The Mouse," *Proceedings of the 8th International Cyclodextrin Symposium, Budapest (Hungary): 3-30 to 4-02, 1996*, Editions de Sante, Paris (1996).
390. M. E. Brewster, W. R. Anderson, A. Webb, N. Bodor and E. Pop, "Anesthetic Activity and Pharmacokinetics of the Neurosteroid Alfaxalone Formulated in 2-Hydroxypropyl- β -Cyclodextrin in the Rat," *Proceedings of the 8th International Cyclodextrin Symposium, Budapest (Hungary): 3-30 to 4-02, 1996*, Editions de Sante, Paris, (1996).
391. M. E. Brewster, J. Howes, W. Griffith, N. Garty, N. Bodor, W. R. Anderson and E. Pop, "Intravenous and Buccal 2-Hydroxypropyl- β -Cyclodextrin Formulations of E2-CDS - Phase I Clinical Trials," *Proceedings of the 8th International Cyclodextrin Symposium, Budapest (Hungary): 3-30 to 4-02, 1996*, Editions de Sante, Paris, (1996).
392. M. Brewster, M. Huang, N. Bodor and E. Pop, "AM1-Based Model System for Estimation of Brain/Blood Concentration Ratios," *Int. J. Quantum Chem.*, **60**, 51-63 (1996).
393. M. E. Brewster, T. Murakami, W. R. Anderson, N. Bodor and E. Pop, "Improved Bioavailability of the Brain-Targeting Estrogen, E2-CDS, Through the Use of Carboxymethylethyl- β -Cyclodextrin," *Proceedings of the 8th International Cyclodextrin Symposium, Budapest (Hungary): 3-30 to 4-02, 1996*, Editions de Sante, Paris, (1996).
394. G. Brouillette, M. Kawamura, G. Kumar and N. Bodor, "Soft Drugs 21. Design and Evaluation of Soft Analogs of Propantheline," *J. Pharm Sci.*, **85**(6), 619-623 (1996).
395. P. Chikhale, V. Venkatraghavan and N. Bodor, "Improved Delivery Through Biological Membranes LX: Intradermal Targeting of Acyclovir Using Redox-Based Chemical Delivery System," *Drug Del.*, **3**, 17-26 (1996).
396. A.Kourounakis, N. Bodor and J. Simpkins, "Synthesis and Evaluation of Brain-Targeted Catechol Derivative as a Potential NGF-Inducer," *Int. J. Pharm.*, **141** 239-250 (1996).
397. G. Kumar and N. Bodor, "Soft Anticholinergics," *Cur. Med. Chem.*, **3**, 23-36 (1996).
398. E. Pop, F. Soti, W. Anderson, J. Panetta, K. Estes, N. Bodor and M. Brewster, "Redox Targeting of LY231617, An Antioxidant with Potential Use in the Treatment of Brain Damage," *Int. J. Pharm.*, **140**, 33-44 (1996).
399. K. Prokai-Tatrai, L. Prokai and N. Bodor, "Brain-Targeted Delivery of a Leu-Enkephalin Analogue by Retrometabolic Design," *J. Med. Chem.*, **39**, 4775-4782(1996).

400. I. Reddy, M. Khan, W. Wu and N. Bodor, "Permeability of a Soft Steroid, Loteprednol Etabonate Through An Excised Rabbit Cornea," *J. Ocular Pharmacol. & Ther.*, **12**(2), 159-167 (1996).
401. M. Saah, W. Wu, K. Eberst, E. Marvanyos and N. Bodor, "Design, Synthesis and Pharmacokinetic Evaluation of a Chemical Delivery System for Drug Targeting to Lung Tissue," *J. Pharm. Sci.*, **85**(5), 496-504 (1996).
402. N. Bodor, "Brain Targeting of Drugs and Neuropeptides by Retrometabolic Design Approaches," *s.t.p. pharma sciences Editions De Sante*, **1**, 43-55 (1997).
403. N. Bodor, "Drug Discovery in Universities," *Farumashia*, **33**(10) 1116-118 (1997) (in Japanese).
404. N. Bodor, "Retrometabolic Approaches for Drug Design and Targeting," *Pharmazie*, **52**(7), 491-494 (1997).
405. N. Bodor and P. Buchwald, "A Molecular Size Based Approach to Estimate Partition Properties for Organic Solutes," *J. Phys. Chem. B*, **101**, 3404-3412 (1997).
406. N. Bodor and P. Buchwald, "Drug Targeting via Retrometabolic Approaches," *Proceedings of the 6th Int'l Symposium on Molecular Aspects of Chemotherapy, Gdansk (Poland): 7/9-12, 1997; Pharm. and Ther.*, **76**(103), 1-27 (1997).
407. N. Bodor, H. Farag, G. Somogyi, W. Wu, D. Barros and L. Prokai, "Ocular-Specific Delivery of Timolol by Sequential Bioactivation of its Oxime and Methoxime Analogs," *J. Ocular Pharmacol. & Ther.*, **13**(5), 389-403 (1997).
408. N. Bodor and M. Huang, "Theoretical Study of the Stereoisomers of Tetrahydrocannabinols," *Int. J. Quant. Chem.*, **61**, 127-135 (1997).
409. M. Brewster, W. Anderson, D. Meinsma, D. Moreno, A. Webb, L. Pablo, K. Estes, H. Derendorf, N. Bodor, R. Sawchuk, B. Cheung and E. Pop, "Intravenous and Oral Pharmacokinetic Evaluation of a 2-Hydroxypropyl- β -cyclodextrin-Based Formulation of Carbamazepine in the Dog: Comparison with Commercially Available Tablets and Suspensions," *J. Pharm. Sci.*, **86**(3), 335-339 (1997).
410. M. Brewster, W. Anderson, A. Webb, L. Pablo, D. Meinsma, D. Moreno, H. Derendorf, N. Bodor and E. Pop, "Evaluation of a Brain-Targeting Zidovudine Chemical Delivery System in Dogs," *Antimicrobial Agents and Chemotherapy*, **41**(1), 122-128 (1997).

411. H. Farag, W. Wu, D. Barros, G. Somogyi, L. Prokai and N. Bodor, "Ocular-Specific Chemical Delivery Systems of Betaxolol for Safe Local Treatment of Glaucoma," *Drug Design and Discovery*, **15**, 117-130 (1997).
412. M. Huang, J. Watts and N. Bodor, "Theoretical Studies of Inclusion Complexes of α - and β -Cyclodextrin with Benzoic Acid and Phenol," *Int'l. J. Quant. Chem.*, for the *Proceedings of the 1997 Sanibel Symposium*, **65**, 1135-1152 (1997).
413. M. Huang, J. Watts and N. Bodor, "Theoretical Studies of Inclusion Complexes of β -Cyclodextrin with Methylated Benzoic Acids," *Int. J. Quant. Chem.*, **64**, 711-719 (1997).
414. A. Kourounakis, N. Bodor and J. Simpkins, "Synthesis and Evaluation of Brain-Targeted Chemical Delivery Systems for the Neurotrophomodulator 4-Methylcatechol," *J. Pharm. & Pharmacol.*, **49**, 1-9 (1997).
415. L. Prokai, K. Prokai-Tatrai, W. Wu, J. Wu, X. Ouyang, H. Kim, A. Zharikova, J. Simpkins and N. Bodor, "Brain delivery and targeting of thyrotropin-releasing hormone analogs by covalent packaging and sequential metabolism," in *Peptides: Chemistry, Structure and Biology* (J. P. Tam and P. T. P. Kauyama, Eds.) Kluwer Academic Publ., Dordrecht, 834-836 (1997).
416. O. Rabbani, K. Panickar, G. Rajakumar, M. King, N. Bodor, E. Meyer and J. Simpkins, "17 β -Estradiol Attenuates Fimbrial Lesion-Induced Decline of ChAT-Immunoreactive Neurons in the Rat Medial Septum," *Experimental Neurology*, **146**, 179-186 (1997).
417. J. Simpkins, G. Rajakumar, Y. Zhang, C. Simpkins, D. Greenwald, C. Yu, N. Bodor and A. Day, "Estrogens Reduce Mortality and Ischemic Damage Induced by Middle Cerebral Artery Occlusion in the Female Rat," *J. Neurosurgery*, **87**, 724-730 (1997).
418. N. Bodor and P. Buchwald, "All in the Mind," *Chemistry in Britain*, January, 36-40 (1998).
419. N. Bodor, P. Buchwald and M. Huang, "Computer-Assisted Design of New Drugs Based on Retrometabolic Concepts, *Proceedings of the Data Management in Computer-Aided Drug Design Workshop*, Ispra (Italy): 1/20 to 22, 1997, *SAR and QSAR in Envir. Research*, **8**, 41-92 (1998).
420. N. Bodor, P. Chen, W-M. Wu and L. Prokai, "Brain Targeting of Basic Amino Acids and Their Redox Analogs Containing Peptides," *Proceedings of the 2nd World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology*, Paris, France, May 25-28 (1998).

421. N. Bodor, K. Prokai-Tatrai, E. Koltai and L. Prokai, "Preparation of O-(3,3,8,10,10-pentamethyl-1,2-dithia-5,8-diaza-cyclodecan-5-yl)ethyl-O-pivaloyloxymethylene-P-phenyl phosphonate,' *OPPI Briefs*, **30**(4), 485-488, (1998).
422. P. Buchwald and N. Bodor, "Molecular Size-Based Model to Describe Simple Organic Liquids," *J. Phys. Chem.*, **102**(29), 5715-5726 (1998).
423. P. Buchwald and N. Bodor, "Octanol-Water Partition Coefficient for Non-Zwitterionic Peptides: Predictive Power of a Molecular Size Based Model," *Proteins Structure, Function, and Genetics*, **30**, 86-99 (1998).
424. P. Buchwald and N. Bodor, "Octanol-water partition: Searching for predictive models," *Curr. Med. Chem.*, **5**(5), 353-380 (1998).
425. L. Buris, Jr., N. Bodor and L. Buris, "Loteprednol etabonate, a new soft steroid is effective in a rabbit acute experimental model for arthritis," *Pharmazie*, **53**(12), 1-6 (1998).
426. P. Chen, N. Bodor, W. Wu and L. Prokai, "Strategies to Target Kyotorphin Analogs to the Brain," *J. Med. Chem.*, **41**(20), 3773-3781 (1998).
427. A. Juhasz, F. Huang, F. Ji, P. Buchwald, W. M. Wu and N. Bodor, "Design and Evaluation of New Soft Anticholinergic Agents," *Drug Devel. Res.*, **43**, 117-127 (1998).
428. L. Prokai, X. Ouyang, K. Prokai-Tatrai, J. Simpkins, N. Bodor, "Synthesis and behavioral evaluation of a chemical brain-targeting system for a thyrotropin-releasing hormone analogue," *Eur. J. Med. Chem.*, **33**, 879-886 (1998).
429. G. Somogyi, P. Buchwald, D. Nomi, L. Prokai and N. Bodor, "Targeted Drug Delivery to the Brain via Phosphonate Derivatives II. Anionic Chemical Delivery System for Zidovudine (AZT)," *Int. J. Pharm.*, **166**, 27-35 (1998).
430. G. Somogyi, S. Nishitani, D. Nomi, P. Buchwald, L. Prokai and N. Bodor, "Targeted Drug Delivery to the Brain via Phosphonate Derivatives I. Design, Synthesis, and Evaluation of an Anionic Chemical Delivery System for Testosterone," *Int. J. Pharm.*, **166**, 15-26, (1998)
431. N. Bodor, "Recent Advances in Retrometabolic Design Approaches," *Proceedings of the Conference on Challenges for Drug Delivery and Pharmaceutical Technology, in honor of Professor Tsuneji Nagai's 65th Birthday, Waseda University, Tokyo, Japan, June 9-11, 1998*, special issue, *Journal of Controlled Release*, **62**, 209-222 (1999).
432. N. Bodor, "Retrometabolic Concepts for the Design of Safer Drugs," *Proceedings of the 80th Anniversary of the Debrecen University Medical School, Debrecen, Hungary, October*

- 17-25, 1998, G. Barabas, L. Fesus, and M. Gyorffi, Eds., Trends in Biomedical Sciences at the turn of the Millenium, Hungary, 3-26 (1999).
433. N. Bodor and P. Buchwald, "Recent Advances in the Brain Targeting of Neuropharmaceuticals by Chemical Delivery Systems," chapter in *Adv. Drug Del. Reviews*, **36**, 229-254 (1999).
434. N. Bodor and P. Buchwald, "Retrometabolic Drug Design: Principles, Examples, and Computational Techniques, *Magyar Kemiai Folyoirat*, **105**, 337-362 (1999).
435. N. Bodor and P. Buchwald, "Soft Drugs: Designing Safer Drugs by Simplifying Drug Metabolism," Chapter in *IUPAC Monograph: Drug Metabolism Databases and High-Throughput Testing During Drug Design and Development*, 223-235 (1999).
436. N. Bodor, P. Buchwald and M. Huang, "The role of computational techniques in retrometabolic drug design strategies," chapter 15 in *Theoretical and Computational Chemistry, Computational Molecular Biology*, J. Leszczynski, Ed., Elsevier Science B.V., Vol. 8, 569-618 (1999).
437. N. Bodor and J. Kaminski, "Chemical Approaches to Drug Delivery," *Encyclopedia of Controlled Drug Delivery*, 1, 285-298 (1999).
438. N. Bodor, W-M. Wu and J. Wu, "The Effect of 2-Hydroxypropyl- β -Cyclodextrin on the Solubility, Stability and Brain Targeting of Chemical Delivery Systems for Neuropeptides," *Proceedings of the 9th International Symposium on Cyclodextrins, Santiago de Compostela, Spain: 05/31-06/03/98*, Kluwer Academic Publishers, 251-256 (1999).
439. P. Buchwald and N. Bodor, "Quantitative Structure-Metabolism Relationships: Steric and Other Effects in the Enzymatic Hydrolysis of Non-Congener Carboxylic Esters," *Journal of Medicinal Chemistry*, **42**, 5160-5168 (1999).
440. V. Goskonda, M. Khan, N. Bodor and I. Reddy, "Chemical Delivery Systems: Evaluation of Physicochemical Properties and Enzymatic Stability of Phenylephrone Derivatives," *Prod. Dev. Tech.*, **4**(2), 189-198 (1999).
441. R.J. Little, N. Bodor and T. Loftsson, "Soft Drugs Based on Hydrocortisone. The Inactive Metabolite Approach and its Application to Steroidal Antiinflammatory Agents," *Pharmaceutical Research*, **16**(6), 961-967 (1999).
442. L. Prokai, K. Prokai-Tatrai, X. Ouyang, H. Kim, W. Wu, A. Zharikova and N. Bodor, "Metabolism-Based Brain-Targeting System for a Thyrotropin-Releasing Hormone Analogue," *J. Med. Chem.*, **42**(22), 4563-4571 (1999).

443. N. Bodor, "Recent advances in retrometabolic drug design and targeting approaches," *Pharmazie*, **55**(3), 163-166 (2000).
444. N. Bodor and P. Buchwald, "Extended Covalent Polymeric Form of Carbon Dioxide: A Possible Structure," *Chemical Physics Letters*, **319**, 645-649 (2000).
445. N. Bodor and P. Buchwald, "Soft Drug Design: General Principles and Recent Applications," *Medicinal Research Reviews*, **20**, 58-101 (2000).
446. N. Bodor, J. Drustrup and W.-M. Wu, "Effect of cyclodextrins on the solubility and stability of a novel soft corticosteroid, loteprednol etabonate," *Pharmazie*, **55**(3), (2000).
447. N. Bodor, S. C. Moon and L. Bruno-Blanch, "Synthesis and pharmacological evaluation of prodrugs of valproic acid," *Pharmazie*, **55**(3), 184-186 (2000).
448. A. Buchwald, C. E. Browne, W.-M. Wu, F. Ji and N. Bodor, "Soft cannabinoid analogues as potential anti-glaucoma agents," *Pharmazie*, **55**(3), 196-201, (2000).
449. P. Buchwald and N. Bodor, "Structure-based estimation of enzymatic hydrolysis rates and its application in computer-aided retrometabolic drug design," *Pharmazie*, **55**(3), 210-217 (2000).
450. P. Buchwald and N. Bodor, "Simple Model for Non-associative Organic Liquids and Water," *J. Amer. Chem. Soc.*, **122**(43), 10671-10679, (2000).
451. F. Ji, F. Huang, A. Juhász, W. Wu and N. Bodor, "Design, synthesis, and pharmacological evaluation of soft glycopyrrolate and its analog," *Pharmazie*, **55**(3), 187-191 (2000).
452. S-K Hwang, A. Juhasz, S-H Yoon and N. Bodor, "Soft Drugs XII; Design, Synthesis and Evaluation of Soft Bufuralol Analogues," *Journal of Medicinal Chemistry*, **43**(8), 1525-1532 (2000).
453. A Juhász and N. Bodor, "Cardiovascular studies on different classes of soft drugs," *Pharmazie*, **55**(3), 228-238 (2000).
454. L. Prokai, K. Prokai-Tatrai and N. Bodor, "Targeting Drugs to the Brain by Redox Chemical Delivery Systems," *Medicinal Research Reviews*, **20**(5), 367-416 (2000).
455. S-H Yoon, J. Wu, W-M Wu, L. Prokai and N. Bodor, "Brain-Targeted Chemical Delivery of [Leu², Pip³]-TRH: Synthesis and Biological Evaluation", *Bioorganic & Medicinal Chemistry*, **8**, 1059-1063 (2000).

456. N. Bodor, "Retrometabolic Drug Design – Novel Aspects, Future Directions," *Pharmazie*, **56**, Suppl. 1, S67-S74 (2001).
457. N. Bodor and P. Buchwald, "Design and Development of a Soft Corticosteroid, Loteprednol Etabonate," chapter in *Inhaled Steroids in Asthma: Optimizing Effects in the Airways*, Eds. R. Scheimer, P. O'Byrne, S. Szeffler and R. Brattsand; Marcel Dekker, Inc., 541-564 (2001).
458. N. Bodor and P. Buchwald, "Drug Targeting by Retrometabolic Design: Soft Drugs and Chemical Delivery Systems," *Journal of Receptor and Signal Transduction Research*, **21** (2-3), 287-310 (2001).
459. N. Bodor and P. Buchwald, "Drug Targeting by Retrometabolic Design: Soft Drugs and Chemical Delivery Systems," chapter 6 in book, *Drug Targeting Technology: Physical · Chemical · Biological Methods*, Marcel Dekker, Inc., **115**, 163-187 (2001).
460. Bodor, H. Farag, and P. Polgar, "A tryptamine analog with high affinity to the heart tissues is a potential antiarrhythmic agent," *Journal of Pharmacy and Pharmacology*, **53**(6), 889-894 (2001).
461. P. Buchwald and N. Bodor, "A Simple, Predictive, Structure-Based Skin Permeability Model," *J. Pharm. & Pharmacol.*, **53**(8), 1087-1098 (2001).
462. F. Huang, P. Buchwald, C. E. Browne, H. H. Farag, W.-M. Wu, F. Ji, G. Hochhaus and N. Bodor, "Receptor Binding Studies of Soft Anticholinergic Agents," *AAPS PharmSci.*, **3**(4), 1-13 (2001).
463. Reddy, S. R. Vaithiyalingam, M. Khan and N. Bodor, "Design, *In Vitro* Stability and Ocular Hypotensive Activity of t-Butalone Chemical Delivery Systems," *J. Pharm. Sci.*, **90**(8), 1026-1033 (2001).
464. N. Bodor and P. Buchwald, "Designing Safer (Soft) Drugs by Avoiding the Formation of Toxic and Oxidative Metabolites," chapter 32 in book, *Oxidative Stress Biomarkers and Antioxidant Protocols*, Humana Press, Ed. D. Armstrong, **186**, 301-312 (2002).
465. N. Bodor and P. Buchwald, "Barriers to Remember: Brain-Targeting Chemical Delivery Systems and Alzheimer's Disease," *Drug Discovery Today*, **7**(14), 766-774 (2002).
466. N. Bodor and P. Buchwald, "Theoretical Insights into the Formation, Structure, and Energetics of Some Cyclodextrin Complexes," *Journal of Inclusion Phenomena and Macrocyclic Chemistry*; proceedings of the 11th International Cyclodextrin Symposium, May 5-8, 2002, Reykjavik, Iceland, **44**(1-4), 9-14 (2002).

467. N. Bodor, H. H. Farag, M. D. C. Barros, W.-M. Wu and P. Buchwald, "In Vitro and In Vivo Evaluations of Dihydroquinoline- and Dihydroisoquinoline-Based Targetor Moieties for Brain-Specific Chemical Delivery Systems," *Journal of Drug Targeting*, **10**(1), 63-71 (2002).
468. Buchwald, H. Derendorf, F. Ji, N. Nelamangala, W.-M. Wu and N. Bodor, "Soft cannabinoid analogues as potential anti-glaucoma agents," Proceedings of the 3rd *Retrometabolism Based Drug Design and Targeting Conference*, held May 13-16, 2001, Amelia Island, Florida; *Pharmazie*, **57**, 108-114 (2002).
469. P. Buchwald and N. Bodor, "Physicochemical Aspects of the Enzymatic Hydrolysis of Carboxylic Esters," Proceedings of the 3rd *Retrometabolism Based Drug Design and Targeting Conference*, held May 13-16, 2001, Amelia Island, Florida; *Pharmazie*, **57**, 87-93 (2002).
470. P. Buchwald and N. Bodor, "Computer-aided drug design: the role of quantitative structure-property, structure-activity, and structure-metabolism relationships, (QSPR, QSAR, QSMR)," *Drugs of the Future*, **27**(6), 577-588 (2002).
471. F. Huang, W.-M. Wu, F. Ji, A. Juhász and N. Bodor, "Design, pharmacokinetic, and pharmacodynamic evaluation of soft anticholinergics based on tropyl - phenylcyclopentylacetate," Proceedings of the 3rd *Retrometabolism Based Drug Design and Targeting Conference*, held May 13-16, 2001, Amelia Island, Florida; *Pharmazie*, **57**, 115-121 (2002).
472. F. Ji, W.-M. Wu and N. Bodor, "Studies on a soft glycopyrrolate analog, SG-1," Proceedings of the 3rd *Retrometabolism Based Drug Design and Targeting Conference*, held May 13-16, 2001, Amelia Island, Florida; *Pharmazie*, **57**, 138-141 (2002).
473. A. Miklós, Z. Magyar, É. Kiss, I. Novák, M. Grósz, M. Nyitray, I. Dereszlay, E. Czégeni, A. Druga, J. Howes and N. Bodor, "28-Day oral toxicity study with soft corticosteroid BNP-166 in rats and dogs, followed by a 14-day recovery period," Proceedings of the 3rd *Retrometabolism Based Drug Design and Targeting Conference*, held May 13-16, 2001, Amelia Island, Florida; *Pharmazie*, **57**, 142-146 (2002).
474. G. Somogyi, P. Buchwald and N. Bodor, "Targeted drug delivery to the central nervous system via phosphonate derivatives (anionic delivery system for testosterone)," Proceedings of the 3rd *Retrometabolism Based Drug Design and Targeting Conference*, held May 13-16, 2001, Amelia Island, Florida; *Pharmazie*, **57**, 135-137 (2002).

475. W.-M. Wu, J. Wu and N. Bodor, "Effect of 2-hydroxypropyl- β -cyclodextrin on the solubility, stability, and pharmacological activity of the chemical delivery system of TRH analogs," Proceedings of the 3rd Retrometabolism Based Drug Design and Targeting Conference, held May 13-16, 2001, Amelia Island, Florida; *Pharmazie*, **57**, 130-134 (2002).
476. J. Wu, S.-H. Yoon, W.-M. Wu and N. Bodor, "Synthesis and Biological Evaluations of Brain Targeted Chemical Delivery Systems of [Nva²]-TRH," *Journal of Pharmacy and Pharmacology*, **54**(7), 945-950 (2002).
477. S.-H. Yoon and N. Bodor, "Synthesis and Brain Targeted Chemical Delivery of [Nva², Pip 3]-TRH," *Bulletin of the Korean Chemical Society*, **23**(5), 761-764 (2002).
478. N. Bodor and P. Buchwald, "Retrometabolism-Based Drug Design and Targeting," In *Burger's Medicinal Chemistry, Vol. 2: Drug Discovery and Development*, 6th Edition, John Wiley & Sons: New York, Ed. D. Abraham, **2**(15), 533-608 (2003).
479. N. Bodor and P. Buchwald, "Brain-Targeted Drug Delivery: Experiences to Date," *Am. J. Drug Deliv.*, **1**(1), 13-26 (2003).
480. F. Huang, C. E. Browne, W.-M. Wu, At. Juhász, F. Ji and N. Bodor, "Design Pharmacokinetic, and Pharmacodynamic Evaluation of a New Class of Soft Anticholinergics," *Pharmaceutical Research*, **20**(10), 1681-1689 (2003).
481. A. Juhász, J. Howes, L. Mantelle, A. Halabi and N. Bodor, "Evaluation of a Buccal Delivery Formulation of E₂CDS in Postmenopausal Women," *Proceedings of the North American Menopause Society 14th Annual Meeting*, Sept. 17-19, 2003 (poster presentation).
482. I. Kurucz, S. Tóth, K. Németh, K. Török, V. Csillik-Perczel, Á. Pataki, C. Salamon, Z. Nagy, J. Székely, K. Horváth and N. Bodor, "Potency and specificity of the pharmacological action of a new, anti-asthmatic, topically administered soft steroid, etiprednol dicloacetate (BNP-166), *J. Pharm. & Exp. Ther.*, **307**(1), 83-92 (2003). Also published online July 31, 2003 as DOI:10.1124/jpet.103.053652.
483. N. Bodor, "Talampanel," included in "Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII), by M. Bialer, et. al., *Epilepsy Research*, **61**, 17-19 (2004).
484. N. Bodor and P. Buchwald, "Designing Safer (Soft) Drugs by Avoiding the Formation of Toxic and Oxidative Metabolites," *Molecular Biotechnology*, **26**(2), 123-132 (2004).
485. M. Brewster, T. Loftsson and N. Bodor, "Applications of chemically-modified cyclodextrins: use of hydroxypropyl- β -cyclodextrin as an enabling excipient for brain

- targeting, redox-based derivatives of estradiol – A review of preclinical and clinical findings,” *J. Drug Del. Sci. Tech.*, **14**(1), 21-34 (2004).
486. P. Buchwald and N. Bodor, “Soft Glucocorticoid Design: Structural Elements and Physicochemical Parameters Determining Receptor-Binding Affinity,” Proceedings of the 4th Retrometabolism Based Drug Design and Targeting Conference, held May 11-14, 2003, Palm Coast, Florida; *Pharmazie*, **5**, 396-404 (2004).
487. Á. Csanádi Gy. Horváth, t. Szekeres, T. Haskó, L. ila, J. Ivanics, M. Patthy, J. Salát, G. Seres, I. Pallagi, G. Tóth, F. Szederkényi, A. Kónya, A. Tegdes, N. Bodor and Z. Zubovics, “Etiprednol Dicloacetate, a New Soft Glucocorticoid Drug Candidate. Development of Chemistry,” Proceedings of the 4th Retrometabolism Based Drug Design and Targeting Conference, held May 11-14, 2003, Palm Coast, Florida; *Pharmazie*, **5**, 349-359 (2004).
488. I. Kurucz, K. Németh, S. Mészáros, K. Török, Z. Nagy, Z. Zubovics, K. Horváth and N. Bodor, “Anti-inflammatory Effect and Soft Properties of Etiprednol Dicloacetate (BNP-166), a New, Anti-Asthmatic Steroid,” Proceedings of the 4th Retrometabolism Based Drug Design and Targeting Conference, held May 11-14, 2003, Palm Coast, Florida; *Pharmazie*, **5**, 412 - 416 (2004).
489. M. Patthy, G. Seres, Á. Csanádi, T. Szekeres, Z. Zubovics and N. Bodor, “HPLC Separation of Related Impurities in Etiprednol Dicloacetate, a Novel Soft Corticosteroid,” Proceedings of the 4th Retrometabolism Based Drug Design and Targeting Conference, held May 11-14, 2003, Palm Coast, Florida; *Pharmazie*, **5**, 382-386 (2004).
490. G. Somogyi, P. Buchwald and N. Bodor, “Metabolic Properties of Phosphonate Esters,” Proceedings of the 4th Retrometabolism Based Drug Design and Targeting Conference, held May 11-14, 2003, Palm Coast, Florida; *Pharmazie*, **5**, 378-381 (2004).
491. M. Tapfer, L. Sebestyén, I. Kurucz, K. Horváth, I. Szelenyi and N. Bodor, “New evidence for the selective, long-lasting central effects of the brain-targeted estradiol, Estredox,” *Pharmacol. Biochem. Behav.*, **77**, 423-429 (2004).
492. N. Bodor and P. Buchwald, “Ophthalmic Drug Design Based on the Metabolic Activity of the Eye: Soft Drugs and Chemical Delivery Systems,” *AAPS Journal*, **7**, article 79, E820-E833 (2005).
493. P. Buchwald, B. Einstein and N. Bodor, “QSAR Study of 2,3-Benzodiazepin-4(thi)one- and 1,2-Phthalazine-Related Negative Allosteric Modulators of the AMPA Receptor: A Structural Descriptors-Based Reassessment,” *QSAR & Combinatorial Science*, **24**, 325-331 (2005).

494. P. Buchwald, A. Juhász, C. Bell, M. Pátfalusi, J. Howes and N. Bodor, "Unified Pharmacogenetics-Based Parent-Metabolite Pharmacokinetic Model Incorporating Acetylation Polymorphism for Talampanel in Humans," *Journal of Pharmacokinetics and Pharmacodynamics*, **32**, 377-400 (2005).
495. F. Ji, W.-M. Wu, X. Dai, N. Mori, J. Wu, P. Buchwald and N. Bodor, "Synthesis and Pharmacological Effects of New, N-Substituted Soft Anticholinergics Based on Glycopyrrolate," *Journal of Pharmacy and Pharmacology*, **57**(11), 1427-1436(10) (2005).
496. W.-M. Wu, P. Buchwald, N. Mori, F. Ji, J. Wu and N. Bodor, "Pharmacokinetic and Pharmacodynamic Evaluations of the Zwitterionic Metabolite of a New Series of N-Substituted Soft Anticholinergics," *Pharm. Res.*, **22**(12), 2035-2044 (2005).
497. N. Bodor and P. Buchwald, "Corticosteroid Design for the Treatment of Asthma: Structural Insights and the Therapeutic Potential of Soft Corticosteroids," *Curr. Pharm. Design*, **12**, 3241-3260 (2006).
498. N. Bodor and P. Buchwald, "Targeting of Neuropharmaceuticals by Chemical Delivery Systems," chapter in book, *Blood-Brain Interfaces – From Ontogeny to Artificial Barriers*, Dermietzel, Spray, Nedergaard, Eds., Wiley Press, 463-500 (2006).
499. N. Bodor and P. Buchwald, "Brain-targeted Delivery of Peptides," *Am. Pharm. Rev.*, **9**(1), 100-104 (2006).
500. N. Bodor and P. Buchwald, "Brain-targeted Delivery of Estradiol: Therapeutic Potential and Results Obtained with a Chemical Delivery System Approach," *Am. J. Drug Deliv.*, **4**(3), 161-175 (2006).
501. P. Buchwald and N. Bodor, "Soft Quaternary Anticholinergics: Comprehensive Quantitative Structure-Activity Relationship (QSAR) with a Linearized Biexponential (LinBiExp) Model," *J. Med. Chem.*, **49**, 883-891 (2006).
502. P. Buchwald, A. Juhász, C. Bell, M. Pátfalusi, P. Kovács, G. Hochhaus and N. Bodor, "The Influence of the N-Acetylation Polymorphism on the Metabolism of Talampanel: An Investigation in Fasted and Fed Subjects Genotyped for NAT2 Variants," Proceedings of the 5th Retrometabolism Based Drug Design and Targeting Conference, May 8-11, 2005, Hakone, Japan, *Pharmazie*, **61**(2), 125-134 (2006).
503. N. Mori, P. Buchwald, W.-M. Wu, F. Ji, G. Hochhaus and N. Bodor, "Pharmacological Effects of Some Newly Developed Soft Anticholinergics," Proceedings of the 5th

- Retrometabolism Based Drug Design and Targeting Conference, May 8-11, 2005, Hakone, Japan, *Pharmazie*, **61**(2), 148-153, (2006).
504. Sziráki, K. Horváth, and N. Bodor, "Comparative Evaluation of Estredox, a Brain-Targeted Estradiol Delivery System Versus Traditional Estrogen Replacement Therapy," Proceedings of the 5th Retrometabolism Based Drug Design and Targeting Conference, May 8-11, 2005, Hakone, Japan, *Pharmazie*, **61**(2), 140-143 (2006).
505. É. Tóth-Sarudy, G. Tóth, I. Pallagi, G. Seres, B. Vitális, M. Tapfer, V. Perczel, I. Kurucz, N. Bodor and Z. Zubovics, "Preparation and biological effects of pure stereoisomeric novel soft anticholinergics," Proceedings of the 5th Retrometabolism Based Drug Design and Targeting Conference, May 8-11, 2005, Hakone, Japan, *Pharmazie*, **61**(2), 90-96 (2006).
506. N. Bodor, É. Tóth-Sarudy, T. Holm, I. Pallagi, E. Vass, P. Buchwald and Ü. Langel, "Novel Cell-Penetrating Molecular Transporters with Flexible Backbones and Permanently Charged Side Chains," *Journal of Pharmacy and Pharmacology*, **59**(8), 1065-1076 (2007).
507. N. Bodor and P. Buchwald, "Retrometabolic drug design: Principles and recent developments," *Pure and Applied Chemistry*, IUPAC, **80**(8), 1669-1682 (2008).
508. N. Bocca, A. Pileggi, R.D. Molano, S. Marzorati, W. Wu, N. Bodor, C. Ricordi, and P. Buchwald, "Soft Corticosteroid of Local Immunosuppression: Exploring the Possibility for the Use of Loteprednol Etabonate for Islet Transplantation," Proceedings of the 6th Retrometabolism Based Drug Design and Targeting Conference, June 3-6, 2007, Göd, Hungary, *Pharmazie*, **63**(3), 226-232 (2008).
509. Park, H.-J., Shin, Y.G., Park, S.H., Wu, J., Bodor, N. and Yoon, S.-H., "Selective reduction of trigonellyl group to the corresponding dihydropyridine in the presence of disulfide group," *Bulletin of the Korean Chemical Society*, **29**(2), 479-482 (2008).
510. M. Patthy, G. Seres, É. Tóth-Sarudy, I. Hazai, I. Pallagi, A. Simay, and N. Bodor, "Determination of Estredox, a compound with sustained estradiol function, and its impurity profile by HPLC," Proceedings of the 6th Retrometabolism Based Drug Design and Targeting Conference, June 3-6, 2007, Göd, Hungary, *Pharmazie*, **63**(3), 210-216 (2008).
511. W. Wu, F. Huang, Y. Lee, P. Buchwald, and N. Bodor, "Pharmacokinetics of the Sequential Metabolites of Loteprednol Etabonate in Rats," *Journal of Pharmacy and Pharmacology*, **60**, 291-297 (2008).
512. W. Wu, J. Wu, N. Mori, P. Buchwald, and N. Bodor, "Stereoisomers of N-Substituted Soft Anticholinergics and Their Zwitterionic Metabolite Based on Glycopyrrolate – Syntheses and Pharmacological Evaluations," Proceedings of the 6th Retrometabolism Based Drug

- Design and Targeting Conference, June 3-6, 2007, Göd, Hungary, *Pharmazie*, **63**(3), 200-219 (2008).
513. N. Bodor and P. Buchwald, "Retrometabolism-Based Drug Design and Targeting," In *Burger's Medicinal Chemistry, Drug Discovery and Development*, Vol. 2: *Discovering Lead Molecules*, 7th ed. (D.J. Abraham, Ed.) Wiley: New York, (2010), chapter 3.
514. N. Bodor and P. Buchwald, "Recent advances in retrometabolic drug design (RMDD) and development," Proceedings of the 7th Retrometabolism Based Drug Design and Targeting Conference, May 10-13, 2009, Orlando FL, *Pharmazie*, **65**(6), 395-403 (2010).
515. P. Buchwald, N. Bocca, S. Marzorati, G. Hochhaus, N. Bodor, C. Stabler, N. S. Kenyon, L. Inberardi, R. D. Molano, C. Ricordi and A. Pileggi, "Feasibility of localized immunosuppression: 1. Exploratory studies with glucocorticoids in a biohybrid device designed for cell transplantation," Proceedings of the 7th Retrometabolism Based Drug Design and Targeting Conference, May 10-13, 2009, Orlando FL, *Pharmazie*, **65**(6), 421-428 (2010).
516. E. Pinto, B. Zhang, S. Song, N. Bodor, P. Buchwald and G. Hochhaus, "Feasibility of localized immunosuppression: 2. PLA microspheres for the sustained local delivery of a soft immunosuppressant," Proceedings of the 7th Retrometabolism Based Drug Design and Targeting Conference, May 10-13, 2009, Orlando FL, *Pharmazie*, **65**(6), 429-435 (2010).
517. W.-M. Wu, Y. Tang, P. Buchwald and N. Bodor, "Pharmacokinetics and ¹-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats," Proceedings of the 7th Retrometabolism Based Drug Design and Targeting Conference, May 10-13, 2009, Orlando FL, *Pharmazie*, **65**(6), 412-416 (2010).
518. N. Bodor and P. Buchwald, "Retrometabolic Drug Design and Targeting," book, John Wiley & Sons, 405 pp. (2012).
519. W.-M. Wu, E. T. Bodor, J. Howes and N Bodor, "The effects of ¹-cortienic acid on skin blanching, pharmacokinetics and stability of loteprednol etabonate," Proceedings of the 8th Retrometabolism Based Drug Design and Targeting Conference, June 2-4, 2011, Graz, Austria, *Pharmazie*, **67**(5), 406-410 (2012).
520. P. Buchwald and N. Bodor, "Recent advances in the design and development of soft drugs," Proceedings of the 9th Retrometabolism Based Drug Design and Trgeting Conference, May 12-15, 2013, Orlando, FL, *Pharmazie*, **69**(6), 403-413 (2014).